The Enzymes VOLUME XVII
CONTROL BY PHOSPHORYLATION Part A General Features Specific Enzymes (I) Third Edition
This P...
44 downloads
825 Views
32MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
The Enzymes VOLUME XVII
CONTROL BY PHOSPHORYLATION Part A General Features Specific Enzymes (I) Third Edition
This Page Intentionally Left Blank
THE ENZYMES Edited by Edwin G. Krebs Paul D. Boyer Department of Chemistry and Biochemistry and Molecular Biology Insiitute university of California Los Angeles. California
Howard Hughes Medical Insiiiute and Department of Pharmacology University of Washington Seattle, Washington
Volume XVII CONTROL BY PHOSPHORYLATION Part A General Features Specific Enzymes (I) THIRD EDITION
1986
ACADEMIC PRESS, INC. Harcourt Brace Jovanovich, Publishers
Orlando San Diego New York Austin Boston London Sydney Tokyo Toronto
BY ACADEMIC PRESS. INC. ALL RIGHTS RESERVED. NO PART O F THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS. ELECTRONIC OR MECHANICAL. INCLUDING PHOTOCOPY. RECORDING. OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM. WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.
COPYRIGHT 0 1986
ACADEMIC PRESS, INC. Orlando. Florida 32887
United Kingdom Edition published by
ACADEMIC PRESS INC.
(LONDON) 24-28 Oval Road. London NWI 7DX
LTD.
Library of Congress Cataloging in Publication Data (Revised for vol.: 17, pt. A) The Enzymes. Includes bibliographical references. 1. Enzymes-Collected works. 1. Boyer, Paul D., ed. [DNLM: 1. Enzymes. Q U 135 B791el QP601.ES23 574.19’25 75-1 17107 ISBN 0-12-122717-0
PRINTED IN THE UNITED STATES OF AMERICA
86 87 88 89
9 8 7 6 5 4 3 2 1
Contents Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ix
Section 1. Enzymology of Control by Phosphorylation
1. The Enzymology of Control by Phosphorylation EDWING . KREES I. 11. 111. IV.
Historical Aspects of Protein Phosphorylation . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . Protein Phosphorylation-Dephosphorylation Reactions ....................... Classification of Protein Kinases and Phosphoprotein Phosphatases . . . . . . . . . . . . . Protein Phosphorylation and the Regulation of Biological Processes . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 4 10 15 18
2. Cyclic Cascades and Metabolic Regulation EMILYSHACTER, P. BOON CHOCK,SUEGoo RHEE, AND EARLR. STADTMAN I. Perspectives . . . .................................. . . . . . 11. Features of Cyclic Cascade Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111. Experimental Verification of the Cyclic Cascade Model ...................... IV. Energy Consumption ....................... V. Covalent Interconversion versus Simple Allosteric .................... VI. Concluding Remarks .................................. References ......................... ................
21 21
33 36 31 31
3. Cyclic Nucleotide-Dependent Protein Kinases STEPHEN J. BEEBEAND JACKIE D. CORBIN I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
........................................................... 111. Characterization and Physical Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Mechanism of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. Purification
V
44 46 49 64
vi
CONTENTS V. Biological Role of Protein Kinases ........................................ References ...........................................................
69 100
.
4 Calmodulin-Dependent Protein Kinases JAMES T . STULL.MARYH . NUNNALLY. AND CAROLYN H . MICHNOFF I . Introduction ..........................................................
I1. Myosin Light Chain Kinases ............................................. 111. Multifunctional Calmodulin-DependentProtein Kinases ....................... References ...........................................................
114 118 142 159
.
5 Protein Kinase C USHIOKIKKAWAAND YASUTOMINISHIZUKA I. I1. I11. IV . V. VI . VII . VIII . IX . X. XI .
Introduction .......................................................... Properties .................................. .................. Biochemical Activation ................................................. Physiological Activation ................................................ Action of Tumor Promoters ..................... ........... Inhibitors .................. ........... Synergistic ............................ Growth Response and Down ................ Target Proteins and Catalytic .............. Relation to Other Receptors .............. Conclusion ................................................. ..... References . ....................................................
167 168 169 171 173 174 175 177 179 181 183 183
.
6 Viral Oncogenes and Tyrosine Phosphorylation TONYHUNTERAND JONATHAN A . COOPER I. I1. I11. IV . V. VI .
Introduction and Historical Perspective .................................... Individual Viral Protein-Tyrosine Kinases and Their Cellular Homologues . . . . . . . Other Transformation-Related Tyrosine Phosphorylation Systems ............... General Properties of Protein-Tyrosine Kinases ............................. Cellular Substrates for Protein-Tyrosine Kinases ............................. Conclusions .......................................................... References ...........................................................
192 193
214 219 228 235 237
.
7 The Insulin Receptor and Tyrosine Phosphorylation MORRISF . WHITEAND C . RONALDKAHN I . Introduction and Scope ................................................. I1. Structure of the Insulin Receptor and Its Relation to Other Tyrosine-Specific Protein Kinases ....................................................... I11. Properties of Tyrosine-Specific Protein Kinases .............................
248 249 264
vii
CONTENTS 1V. Tyrosine Phosphorylation of Insulin Receptors and Other Proteins in the Intact Cell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Regulation of Hormone Receptors by Multisite Phosphorylation . . . . . . . . . . . . . . . . VI. Evidence That Tyrosine Phosphorylation Is Physiologically Important . . . . . . . . . . . VII. Conclusions .......................................................... References ...........................................................
285 296 299 302 302
8. Phosphoprotein Phosphatases LISAM. BALLOUAND EDMONDH. FISCHER 1. Introduction and Historical Overview: The “PR Enzyme” .................... 11. Classification of Protein Phosphatases ..................... Ill. Phosphatase Type 1 (Phosphorylase Phosphatase) . . . . . . . . . . . . IV. Phosphatase Type 2A ........... . . . . . . . . . . . . . . . . . . . . . . . V. Phosphatase Type 2B (Calcineurin) ..................... VI. Phosphatase Type 2C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII. Phosphotyrosyl-Protein Phosphatases . . . . ...................
References . . .................................... . . . . .
312
331 339 346 349 355
Section II. Control of Specific Enzymes
9. Glycogen Phosphorylase NEILB. MADSEN ................................... cs of Phosphorylase . . . . . . . 111. Molecular Structure
IV. V. VI. VII.
.........................
Substrate-Directed Control of Phosphorylation and Structural Consequences of Serine-14 Phosphorylation ........................ Functional Results of the Phosphorylation of Serine-14 . . . . . . . . . . . . . . . Concluding Remarks . . .................................... References ......................... .............................
377 384 389 390
10. Phosphorylase Kinase CHERYL A. PICKETT-GIES AND DONALA. WALSH .................................. 1. Introduction . . . . . . ................ 11. Physicochemical Properties . . . . . . . . . . . . 111.
396 398
1v.
409
.................................. Catalytic Properties V. VI . Proteolytic Activation of Phosphorylase Kinase . . . . . . . . . . . . . VII . VIII. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CONTENTS
1 1. Muscle Glycogen Synthase PHILIPCOHEN I. 11. 111. IV. V. VI. VII. VIII.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Structure of Glycogen Synthase from Mammalian Skeletal Muscle . . . . . . . . . . . . . . Glycogen Synthase Kinases in Mammalian Skeletal Muscle . . . . . . . . . . . . . . . . . . . Effect of Phosphorylation on the Activity of Skeletal-Muscle Glycogen Synthase . . Synergism between Glycogen Synthase Kinase-3 and Glycogen Synthase Kinase-5 The Glycogen Synthase Phosphatases in Skeletal Muscle . . . . . . . . . . . . . . . . . . . . . Phosphorylation State of Skeletal-Muscle Glycogen Synthase in Vivo . . . . . . . . . . . Interpretation of in Vivo Phosphorylation Experiments . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . , . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
462 462 464 469 47 1 472 478 486 493
12. Liver Glycogen Synthase
PETERJ. ROACH .... . . . . . . . . . . . . . ... . . . . ... . . . . . . . ... . ... . . . . . . . . . . 111. Converting Enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I. Introduction
500
11. Liver Glycog
501 507
IV. Phosphorylation of Liver Glycogen Synthase V. Comparative Enzymology of Glycogen Syntha YI. Control of Hepatic Glycogen Synthase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII. Conclusion References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
521 533 534
Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
54 1
. . . . . . . . . . . . . . . .. . . ... . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .. . . .
602
Subject index
Preface Over the past two decades there has been a remarkable increase in the recognition of the salient importance and the wondrous complexity of the control of enzyme catalysis. The modulation of enzymic and other protein-dependent processes by protein phosphorylation or dephosphorylation has emerged as the most widespread and important control achieved by covalent modification. So much information has emerged that adequate coverage in two volumes (XVII and XVIII) was a challenging task. The editors are gratified that the contributing authors have commendably met this challenge. The first portion of Volumes XVII and XVIII concerns the “machinery” of control by protein phosphorylation and dephosphorylation and includes coverage of the major types of protein kinases and of phosphoprotein phosphatases. The central core of the volumes presents chapters on the control of specific enzymes. This is followed by a substantial final section on the control of biological processes. The selection of authors for various chapters was a rewarding experience, but made somewhat difficult because for most topics there was more than one wellqualified potential author. The quality of the volumes was assured by the welcome acceptance of the invitation to participate by nearly all of the invited authors. The reversible covalent modification of enzymes and of proteins with other functions is now known to occur in all types of cells and in virtually all cellular compartments and organelles. Enzymes as a group constitute those proteins whose function and control are best understood in molecular terms. The treatment of enzymes gains additional importance because their regulation provides prototypic examples to guide investigators studying less well defined and often less abundant proteins. The versatility of protein control by phosphorylation finds expression in ion channels, hormone receptors, protein synthesis, contractile processes, and brain function. Chapters in these areas point the way for future exciting developments. Although the breadth of coverage is in general regarded as satisfying, there are other topics or areas that may have warranted inclusion. These include the ix
X
PREFACE
developing knowledge of the control by phosphorylation of histones of the nucleus and the messenger-independent casein kinases, whose role is not as clear as that of the major protein kinases that respond to regulatory agents. The quality of the volumes has been crucially dependent on the editorial assistance of Lyda Boyer and the fine cooperation provided by the staff of Academic Press. We record our thanks here. As readers of this Preface have likely discerned, it is a pleasure for the editors to have volumes of high quality to present to the profession. Paul D. Boyer Edwin G. Krebs
Section I
Enzymology of Control by Phosphorylation
This Page Intentionally Left Blank
The Enzymology of Control by Phosphorylation EDWIN G . KREBS Howard Hughes Medical Institute and Department of Pharmacology University of Washington Seattle, Washington 98195
1. Historical Aspects of Protein Phosphorylation ......................... II. Protein Phosphorylation-Dephosphorylation Reactions A. General Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
B. Specificity for Phosphoryl Donors in Protein Kinase Reactions C. Protein Substrate Specificity of Protein Kinases and Phosphoprotein Phosphatases .................... ... D. The Reversibility of Protein K E. Autophosphorylation Reactions ................................. 111. Classification of Protein Kinases and Phosphoprotein Phosphatases . . . . . . . A. Protein Kinases ........................................ B . Phosphoprotein Phosphatases ................................... IV. Protein Phosphorylation and the Regulation of Biological Processes . . . . . . . A. Phosphorylation-Dephosphorylation versus Other Control Mechanisms ................... B. Diversity of Phosphorylatio Control Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References ........................................
1.
3 4 5
6 6 8 9 10
LO 14 15
15 17 18
Historical Aspects of Protein Phosphorylation
Of the many types of posttranslational modification of proteins that occur in cells relatively few are readily reversible. Those that are include acetylation, 3 THE ENZYMES, Vol. XVlI Copyright 0 1986 by Academic Press. Inc. All rights of repduction in any form reserved.
4
EDWIN G . KREBS
methylation, adenylylation, uridylylation, phosphorylation, and possibly one or two others such as ADP ribosylation. By all odds the most common type of reversible protein modification is phosphorylation, the process with which this volume is concerned. As has become abundantly clear nature has chosen phosphorylation-dephosphorylation as an almost universal mechanism for regulating the function of proteins, not only those that display enzymic activity but also proteins involved in many other biological processes. General recognition that protein phosphorylation has a major role in regulating protein function developed over a protracted period of time rather than being appreciated immediately as happened for allosteric regulation after the revelations by Monod et af. (1) in the mid-1960s. The first dynamic protein phosphorylation-dephosphorylation system to be elucidated was that involving glycogen phosphorylase, an enzyme that had been known to exist in two interconvertible forms, phosphorylases b and a (2, 3). In the mid-1950s these forms were shown to be nonphosphorylated and phosphorylated species of the eyzyme, which could be interconverted through the action of a protein kinase and a phosphoprotein phosphatase (4, 5 ) . In 1959 evidence was obtained that the kinase involved in this process, phosphorylase kinase, was itself regulated by phosphoxylation-dephosphorylation (6). A few years later it was determined that glycogen synthase also exists in interconvertible phosphorylated and nonphosphorylated forms (7). The fact that the first three phosphorylatable enzymes to be discovered all involved glycogen metabolism suggested to some that the process might be restricted to this area, but this idea was soon abandoned as further reports began to appear implicating enzymes that act in other pathways (8, 9). In particular, the studies by Lester Reed and his associates (10, 11)showing that pyruvate dehydrogenase is regulated by phosphorylation-dephosphorylation served to broaden people’s perspective regarding the scope of the process. At about this same time evidence was obtained that the enzyme that catalyzed the phosphorylation and activation of phosphorylase kinase was a cyclic AMP-dependent protein kinase that could catalyze the phosphorylation of other proteins, thus making it a probable mediator of the diverse actions of cyclic AMP (12, 13). These events served to stimulate general interest in the process of protein phosphorylation, and during the next fifteen years numerous enzymes were found to be regulated in this manner. In addition, many important functional proteins other than enzymes were shown to undergo reversible phosphorylation and to be controlled by this process. More detailed accounts of early work on protein phosphorylation have been reviewed elsewhere (14, 15).
II. Protein Phosphorylation-Dephosphorylation Reactions Phosphoproteins are formed in cells through the action of protein kinases, and they also occur as transient intermediates formed as part of the mechanism of
I.
5
ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
action of certain enzymes and transport proteins [reviewed in Ref. (16)]. It is with the former type of protein phosphorylation that the various chapters in this volume are concerned. A.
GENERALPROPERTIES
The reactions of protein phosphorylation-dephosphorylation involving protein kinases and phosphoprotein phosphatases are shown in Eqs. (1) and (2). Protein
+ nNTP-
Protein kinase
Protein-P,
+ nNDP
Phonphoprolein phosphalase
Protein-P,
+ nHzO
Protein
+ nPi
(1) (2)
As is implied in Eq. ( l ) , a given protein kinase often catalyzes the transfer of phosphate to more than a single site in its protein substrate. In this sense, glycogen phosphorylase, the first enzyme shown to undergo phosphorylationdephosphorylation and the prototype for many studies in this field, is unusual inasmuch as it is phosphorylated at a single site. In protein phosphorylation reactions it is common for a single protein to serve as the substrate for more than one kinase. In some instances different kinases catalyze the phosphorylation of identical sites in the protein substrate, but more commonly each kinase has its own site “preference” since, as discussed in Section II,C,2, protein kinases exhibit a moderately high degree of specificity for particular amino acid sequences surrounding phosphorylatable amino acid residues. The phosphorylation of an identical site by two or more protein kinases probably occurs due to a high degree of exposure of that site combined with the fact that protein kinases do not exhibit absolute specificities. The most intensively studied set of protein kinase reactions involving a single substrate are those that occur with glycogen synthase, which can be phosphorylated in vitro by no less than ten different protein kinases. It should be noted, however, that all of the kinases capable of phosphorylating glycogen synthase in virro may not function in this manner physiologically (see Chapters 11 and 12 in this volume). As with essentially all phosphotransferase reactions, protein kinase reactions require divalent metal ions, Mg2 probably serving as the physiologically significant cation in all instances, although manganous ions are nearly always effective in vifro. The actual substrate for the reaction depicted in Eq. (1) is the NTP-Me2+ complex. In some instances, however, a role for divalent ions in addition to forming the metal-nucleotide complex has been noted. This is seen, for example, with the cyclic AMP-dependent protein kinase, which binds free metal ions at a separate site (17, 18). The protein kinases constitute a very diverse set of enzymes, the total number of which is only now beginning to be appreciated. These enzymes are commonly regulated through their interaction with “second messengers” generated within cells in response to hormones and other extracellular agents (see below). The +
6
EDWIN G. KREBS
reactions catalyzed by the kinases are also regulated through the interaction of metabolites with their substrates, that is, through “substrate level” control (see, for example, Chapter 9, this volume and Chapter 2, Volume XVIII). The phosphoprotein phosphatases appear to be smaller in total number than the protein kinases, and they probably exhibit broader specificities. This in itself implies that these enzymes may not be as actively involved in regulating phosphorylation-dephosphorylation cycles as are the kinases, since the broader the specificity the greater the number of pathways that would be affected simultaneously by the regulation of a given enzyme. A more passive regulatory role for the phosphatases as compared to the kinases is also suggested by the fact that investigators have not discovered as many diverse forms of regulation for this set of enzymes. With respect to the last point, however, it is possible that the phosphatases have simply been more difficult to characterize than the kinases, and additional regulatory mechanisms may be found in the future. These matters are considered more fully in Chapter 8. B.
SPECIFICITY FOR PHOSPHORYL DONORS IN PROTEIN KINASEREACTIONS
The protein kinase reaction (Eq. 1) is written as being dependent on a nucleoside triphosphate, The physiologically significant donor in nearly all instances is probably ATP (19), although several protein kinases can also use GTP effectively in vitro. The last category includes casein kinase I1 [reviewed in Ref. (20)],a histone H1 kinase from tumor cells (21) and pp6CPrc (22). An unusual protein kinase from rabbit skeletal muscle, which utilizes phosphoenolpyruvate as a phosphate donor was reported by Khandelwal et al. (23). The kinase studied by this group was found to be activated by CTP (24). Phosphoenolpyruvate has long been known to serve as the phosphoryl donor in the phosphorylation of the enzyme involved in the first step of sugar transport in bacteria [reviewed in Ref. (25)],but this process belongs in a category set apart from typical protein kinase reactions as previously indicated. C.
PROTEINSUBSTRATE SPECIFICITY OF PROTEIN KINASES AND PHOSPHOPROTEIN PHOSPHATASES
1. Amino Acid Residues That Serve as Acceptors
of Phosphoryl Groups
Most of the acid-stable protein-bound phosphate found in cells is present as phosphoserine and phosphothreonine and is formed as a result of the action of protein serine and threonine kinases. A much smaller fraction, usually less than 0.2% of the total, is present as phosphotyrosine and arises as a result of the action of protein tyrosine kinases [reviewed in Ref. ( 2 6 ) ] .The possible existence of a
1 . ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
7
hydroxylysine kinase has also been indicated (27). In addition to protein kinases that catalyze the previously mentioned phosphorylations, there are indications that protein kinases exist that can catalyze the formation of acid-labile phosphohistidine and phospholysine in proteins (28-30). No work has been done on phosphatases that reverse the action of this last set of kinases, so it is not known whether such phosphorylations represent reversible protein modifications.
2 . Structural Determinants of Specificity The phosphorylation site sequences in various protein substrates for a number of different protein kinases have been determined and investigators using synthetic peptides as substrates have also elucidated a number of the structural requirements for substrate specificity of protein kinases. It has become clear that although the primary structure of a phosphorylation site sequence does not tell the whole story, it is usually possible to distinguish differences between the site specificities of the various kinases. For the CAMP-dependent protein kinase, for example, it can be predicted that if a given protein has an exposed -Arg-Arg-XSer-X- sequence, it will be phosphorylated by this enzyme. Similarly, casein kinase I1 phosphorylates exposed serine (or threonine) residues followed by one or more glutamic acids residues one position removed from the serine (e.g., -X-X-Ser-X-Glu-). The entire specificity pattern of a protein kinase is not revealed, however, simply by knowledge of its preferred primary amino acid sequence. Higher orders of protein structure also play a part in determining whether a given protein can be phosphorylated at an appreciable rate by a given kinase. These considerations are discussed in chapters that refer to specific kinases. The specificity of the phosphoprotein phosphatases is not as well understood as that of the kinases. One of the problems in studying this set of enzymes has been that earlier investigators were never certain whether their preparations contained more than one enzyme, and conclusions regarding specificity were obviously difficult to reach. Later studies, however, and particularly in the laboratory of Dr. Philip Cohen, made considerable headway in defining and classifying these enzymes. The relative activities of different phosphatases toward a number of different phosphoprotein substrates have been determined. Several general observations can be made: First, there is probably more overlapping of specificity among the phosphatases than is seen for the kinases. Second, it is evident that the pattern of specificity is not one in which a given phosphatase is “designed” to dephosphorylate a set of proteins phosphorylated by a given kinase. Thus, although the kinases recognize specific amino acid sequences in their substrates, this is not so readily apparent for the phosphatases. This suggests that higher orders of protein structure may be more important in governing substrate specificity for the phosphatases than for the kinases. If this is so, then one might anticipate that regulation of phosphatase activity might commonly
8
EDWIN G. KREBS
occur at the “substrate level” (i.e., through the interaction of metabolites with the phosphoproteins involved). Through such interactions and the ensuing conformational changes phosphatase activities could be regulated in a highly specific manner. Finally, it is apparent that some phosphatases exist that may attack lowmolecular-weight substrates as well as proteins under physiological conditions. Synthetic phosphopeptides have been employed only rarely in studies on phosphoprotein phosphatases. A pioneering effort in this regard was the work of Titanji et al. (31).
D. THEREVERSIBILITY OF PROTEIN KINASEREACTIONS The phosphorylation reactions that result in the formation of phosphoserine and phosphotyrosine in proteins, and presumably those that result in phosphothreonine, can all be demonstrated to be reversible albeit not under physiological conditions. Rabinowitz and Lipmann (32) were the first to describe the reversibility of protein phosphorylation. Using phosphorylated phosvitin as a phosphate donor, they demonstrated the formation of ATP from ADP in the presence of phosvitin kinase (probably casein kinase 11) from yeast or brain and postulated that runs of adjacent phosphoserines in phosvitin may have accounted for the apparent high free energy of hydrolysis of the bound phosphate in this protein. That such structural relationships are not essential for reversibility of protein kinase reactions was brought out by the work of Shizuta et al. (33), using the cyclic AMP-dependent protein kinase as enzyme and substrates in which no adjacent phosphoserines are present. These workers determined the equilibrium position in a well-defined protein kinase reaction and calculated that the free energy of hydrolysis of serine phosphate in this substrate (32P-labeled reduced carboxymethylated maleylated lysozyme) was -6.5 kcal mol- l . The reversibility of a number of other protein serine kinase reactions has been reported (34-37). Fukami and Lipmann (38) described reversibility of Rous sarcomaspecific immunoglobulin phosphorylation catalyzed by the src gene kinase and reported a free energy of hydrolysis of -9.48 kcal mol-I for protein-bound tyrosine phosphate, appreciably higher than the value of -6.5 kcal reported for protein serine phosphate by Shizuta et al. (33). However, the latter workers assumed a different AGO’ for hydrolysis of ATP (-8.4 kcal mol-l) than that used by Fukami and Lipmann (- 10 kcal mol- I ) . When the same value is used, a free energy of hydrolysis of -8.1 kcal mo1-I is obtained for protein serine phosphate (i.e., only slightly lower than that for tyrosine phosphate). A standard free energy of hydrolysis for serine phosphate in pyruvate kinase was found to be -6.6 kcal mol-I by El-Maghrabi et al. (37). These workers used -8.4 kcal mol-I for the free energy of hydrolysis of ATP. Very little has been made of the possible physiological significance of the reversal of protein kinase reactions, but it is possible that under some circumstances the process could be important. The fact that protein-bound serine phos-
1. ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
9
phate and tyrosine phosphate is relatively “energy rich” would indicate that a significant rate of turnover of this phosphate could occur in the absence of protein phosphatase activity. Potentially, the phosphate could be transferred to receptors other than proteins. In connection with the possible physiological significance of the reversal of protein kinase reactions, it is of interest that reversal of the phosphorylase kinase reaction required the presence of glucose or glycogen demonstrating that the reaction might be subject to regulation (36).
E. AUTOPHOSPHORYLATION REACTIONS Almost all protein kinases catalyze autophosphorylation reactions (i .e., reactions in which the kinase serves as its own substrate). Flockhart and Corbin (19) published a comprehensive list of the kinases that had been shown by the time of their review (1982) to exhibit this property. Their list could now be extended to include glycogen synthase kinase 3 (39), protein kinase C (40), the insulin receptor [reviewed in Ref. (41)] and a number of other oncogene-encoded protein tyrosine kinases (26). Autophosphorylation reactions can be intramolecular or intermolecular. This aspect was first examined with respect to the autophosphorylation of phosphorylase kinase, in which case the latter mechanism was shown to prevail (42). The autophosphorylation reaction involving type I1 cyclic AMP-dependent protein kinase, however, was found to occur by an intramolecular process (43).An intramolecular reaction was also found to be involved in autophosphorylationof the cyclic GMP-dependent protein kinase (44) and the insulin receptor (see Chapter 11). The significance of autophosphorylationreactions of protein kinases is readily apparent in some instances but not in all. With phosphorylase kinase autophosphorylation causes marked enhancement of activity, although there is no evidence that this is the physiologically significant process (see Chapter 10). Autophosphorylation of type II cyclic AMP-dependent protein kinase affects cyclic AMP binding and the dissociation-reassociation reactions of the enzyme in the presence of cyclic AMP [Ref. (45) and Chapter 31, an effect that may be of physiological significance, although again this has not been demonstrated. Of great interest is the fact that autophosphorylation of the insulin receptor renders this protein kinase independent of insulin (46). In some instances, particularly with those protein kinases in which autophosphorylation occurs by an intermolecular process and in which no functional change occurs in the activity of the kinase as a result of autophosphorylation, the reaction may simply be an expression of the lack of absolute specificity of protein kinases. In looking for autophosphorylation investigators often employ high concentrations of a kinase, and under these conditions autophosphorylation is observed even though the enzyme is actually an extremely poor substrate for itself. A possible unifying concept with respect to the significance of the auto-
10
EDWIN G. KREBS
phosphorylation reactions of protein kinase is that many of these enzymes may be kept in an inactive or inhibited state as a result of interaction between their autophosphorylation sites and their protein substrate binding sites. This phenomenon was first observed with type I1 cyclic AMP-dependent protein kinase. Here the autophosphorylation site on the regulation subunit (RI,), which possesses an amino acid sequence closely resembling a typical substrate sequence, is believed to interact with the active center of the catalytic subunit (see Chapter 3). Autophosphorylation of R,, renders it less potent as an inhibitor of R,, and facilitates activation by cyclic AMP. The latter activator, however, is capable of fully activating the enzyme with or without autophosphorylation. A similar, albeit not identical, situation appears to exist with the insulin receptor in which activation occurs as a result of an autophosphorylationreaction involving a site whose binding to the active center may well render the enzyme inactive in its dephospho form. The role of autophosphorylation in other protein tyrosine kinases is discussed in Chapters 6 and 7. For some protein kinases a functional autophosphorylation site may not exist (e.g., type I cyclic AMP-dependent protein kinase); instead, pseudoautophosphorylation sites are present. In these instances sites homologous to protein substrate phosphorylation sites are present but the sites lack phosphorylatable amino acid residues. For such enzymes activation is dependent on activators that alter conformation of the kinases and cause displacement of the pseudosubstrate sites from the active centers of these enzymes. Skeletal muscle myosin light chain kinase may be a second example of a protein kinase that is kept in its inactive form as a result of interaction of a pseudosubstrate site with the active center. This enzyme possesses what appears to be a site that shows strong homology to the phosphorylation site in myosin light chains. Interestingly, this site is close to or a part of the calmodulin binding site in this enzyme (47, 48).
111. Classification of Protein Kinases and Phosphoprotein Phosphatases
A. PROTEIN KINASES How many different protein kinases are there and how are they classified and named? The latter presents a difficult problem for a number of reasons. Classically, enzymes are grouped in accordance with the kind of chemical reaction that they catalyze and individual enzymes are then delineated and named on the basis of the specific substrate on which they act. This system breaks down for the protein kinases for several reasons. First, as previously indicated, a given protein kinase usually catalyzes the phosphorylation of a number of different proteins, so the selection of one particular substrate loses its meaning. Second, more often
I.
ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
11
than not one protein can serve as a substrate for more than one kinase. At times, even the same phosphorylation site is involved with two or more kinases. Because of these complications, no systematic approach for naming this set of enzymes has been developed. In practice, it appears that protein kinases can be divided initially into broad classes based on whether the amino acid acceptor of the phosphoryl residue is (1) a protein alcohol group (i.e., the protein serine and protein threonine kinases), (2) a protein phenolic group (i.e., the protein tyrosine kinases), or (3) a protein nitrogen-containing group (i.e., the protein, histidine and lysine kinases). The existence of this last class of protein kinases is strongly suggested by the work of Roberts Smith and his collaborators (28, 29) and the report by Huebner and Mathews (30). Within each of the main classes of kinases individual groups of enzymes or subclasses exist, which more often than not can be delineated on the basis of the regulation of their activities. Table I presents a possible classification and nomenclature scheme for the protein serine and threonine kinases and Table I1 a scheme for the protein tyrosine kinases. Some of the groups or subclasses of protein serine and threonine kinases have only one known member at this time, but this situation may change. With respect to the grouping of the protein serine and threonine kinases shown in Table I, Group 6 consists of the so-called “independent” protein kinases (i.e., those that are not definitely known to be regulated through the interaction of a messenger(s) directly with the kinase). Some of the kinases in Group 6 are regulated as a result of the interaction of metabolites with their substrates. The individual protein serine and threonine kinases of Table I are not discussed here. The most intensively studied groups are the cyclic nucleotidedependent and calcium-calmodulin-dependent enzymes. Each of these groups is the subject of a separate chapter in this volume (see Chapters 3 and 4). The protein kinase that is regulated by diacylglycerol in the presence of calcium ions and phospholipid, protein kinase C, is also discussed in a separate chapter (see Chapter 5). One of the calcium-calmodulin (CaM)-dependent protein kinases, phosphorylase kinase, is itself an enzyme subject to regulation and is treated in the set of specific enzymes regulated by phosphorylation-dephosphorylation (see Chapter 10). Many of the protein serine and threonine kinases of Table I are discussed in chapters concerned with specific regulatory systems in which they function. For example, the double-stranded RNA-dependent and the hemininhibited protein kinases are handled in the chapter on the regulation of protein synthesis. Pyruvate dehydrogenase kinase and branched-chain ketoacid dehydrogenase kinase are discussed in Volume XVIII, Chapters 3 and 4 on the regulation of pyruvate dehydrogenase and branched chain keto acid dehydrogenase, respectively. The last set of enzymes (i.e., the two mitochondria1 dehydrogenases) are arbitrarily listed in Table I as independent kinases. They are both subject to regulation by metabolites that most logically would be thought to act by combin-
12
EDWW G. KREBS TABLE I
CLASSIFICATION AND NOMENCLATURE OF PROTEIN KINASESTHATCATALYZE THE TRANSFER OF PHOSPHATE TO PROTEIN ALCOHOL GROUPS(PROTEIN SERINE AND THREONINE KINASES) Group
Regulatory agent(s)
1
Cyclic nucleotides
2
Ca2+ and calmodulin
3
Diacylglycerol (Ca2+ and phospholipid) Double-stranded RNA Hemin Independent of regulation except at substrate level
4 5 6
Specific enzyme Type I cyclic AMP-dependent protein kinases Type I1 (H) cyclic AMP-dependent protein kinase“ Type I1 (B) cyclic AMP-dependent protein kinasea Cyclic GMP-dependent protein kinase Phosphorylase kinase (GSK 2)b Skeletal muscle myosin light chain kinase Smooth muscle myosin light chain kinase Multifunctional Ca2 + -calmodulin-dependent protein kinase Protein kinase C Double-stranded RNA-dependent protein kinase Hemin-inhibited protein kinase Fyruvate dehydrogenase kinase Branched-chain ketoacid dehydrogenase kinase Casein kinase I Casein kinase I1 GSK 3 (Factor FA)c GSK 4 Rhodopsin kinase HMG-CoA reductase kinase HMG-CoA reductase kinase kinase Histone HI kinase Histone kinase I1 H4-specific protease-activated protein kinase, Protease-activated kinase I1
“H” and “B” signify heart and brain isozymes. GSK stands for glycogen synthase kinase (see Chapter 11). Factor FA, name applied to a phosphoproteinphosphatase-activatingfactor that was later found to be a glycogen synthase kinase (49).
ing with their respective protein substrates. It should be noted, however, that acetyl-CoA, NADH, ADP, and pyruvate have all been reported to affect the activity of pyruvate dehydrogenase kinase when it is acting on a small synthetic peptide substrate, suggesting that the kinase itself interacts with these metabolites (see Volume XVIII,Chapter 3). Thus, it is possible that pyruvate dehydrogenase should be handled differently than shown in Table I (49). Some protein serine and threonine kinases have not been included in Table I because they have not been studied sufficiently to be certain of their status and relationship to other kinases. In this category the double-stranded DNA-depen-
1.
ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
13
TABLE I1 CLASSIFICATION AND NOMENCLATURE OF PROTEIN KINASES THATCATALYZE THE TRANSFER OF PHOSPHATE TO PROTEIN PHENOLIC GROUPS(PROTEINTYROSINE KINASES) Group 1
2
Regulatory agent(s)
Specific enzymes
Polypeptide hormones EGF receptor and growth factors PDGF receptor Insulin receptor IGF-I receptor Unknown v-src and c-src-Encoded protein kinases v-yes and c-yes-Encoded protein kinases v-abl and c-abl-Encoded protein kinases v-fgr and c-fgr-Encoded protein kinases v-fps and c-fps-Encoded protein kinases v-fes and c-fes-Encoded protein kinases v-ros and c-ros-Encoded protein kinases
dent protein kinase (50) and the polypeptide-dependentprotein kinase (51) could be mentioned as examples. These and many new independent kinases will probably be implicated as having specific regulatory roles in the future. The protein tyrosine kinases have arbitrarily been divided into the two groups shown in Table I1 (i.e., the hormone or growth factor-dependent enzymes (see Chapter 7) and the independent kinases for which no regulatory agents are known (see Chapter 6). The latter set of kinases are encoded by certain retroviral oncogenes and their closely related cellular counterparts. Other independent protein tyrosine kinases not listed in Table II consist of the LSTRA kinase (52),a possibly related kinase from spleen (53),and TPK-75 from liver (54). The intriguing possibility that protein tyrosine kinases are regulated by intracellular second messengers is raised by reports suggesting that calcium-CaM and polyamines can stimulate tyrosine phosphorylation (55). The protein serine and tyrosine kinases all contain homologous catalytic domains indicating that they are members of a single family. This homology is shown in Fig. 1 in which the sequence of a portion (residues 49-253) of the catalytic subunit of beef cyclic AMP-dependent protein kinase (56) is used as a basis for calculating alignment scores (57) for comparing this sequence with the catalytic domains of other protein kinases. Comparisons are made with beef lung cyclic GMP-dependent protein kinase (58), the y-subunit of rabbit skeletal muscle phosphorylase kinase (59), rabbit skeletal muscle myosin light chain kinase (60),P 9 0 g a g - r u f (61), ppW" (62), the EGF receptor (63), and the insulin receptor (64).As can be seen there is a highly significant degree of homology for the catalytic domains in all of these protein kinases. As might be expected the
14
EDWIN G. KREBS
cAK cat subunit cGK
1
49
253
350
1
I
I
574
670
I
1
365 L
25
Phos K. Y subunit MLCK
pp6OSrc
I
302 I
20.0
386 I
17.0
I
273 I
12.0
510
603
I
A
480
526
I
718
Insulin Receptor Precursor
1017
/-
246
I
EGF Receptor
I
31.8
I
10.3
I
932 I
9.0
1242 I
1210 f P 1370 I
FIG. 1. Amino acid sequence homology between the catalytic domains of representative protein kinases. Each protein is represented by a horizontal bar, the length of which is proportional to the molecular weight of the protein as determined by its amino acid sequence (except for a portion of p90naS-raf). The small numbers indicate residue numbers. The large numbers indicate BarkerDayhoff alignment scores (57)of the catalytic domains to the various protein kinases compared to the segment between residues 49 and 253 in the catalytic subunit of the cyclic AMP-dependent protein kinase (cAK cat. subunit). cGK = cyclic GMP-dependent protein kinase; Phos. K = phosphorylase = chimeric protein containing raf oncogenekinase; MLCK = myosin light chain kinase; p9OnOg-..f encoded sequence and the gag sequence; pp6orrc = src-encoded protein tyrosine kinase.
degree of homology between the catalytic subunit of the cyclic AMP-dependent protein kinase and other protein serine and threonine kinases is higher than it is with the protein tyrosine kinase, except that this is not seen with respect to the oncogene-encoded protein p9ogng- ,f‘r which is thought to be a protein serine kinase (see Chapter 6). Phosphotransferases other than protein kinases have not been found to contain catalytic domains homologous to the catalytic subunit of the cyclic AMP-dependent protein kinase.
B. PHOSPHOPROTEIN PHOSPHATASES Early work on the phosphoprotein phosphatases was insufficient to make it feasible to classify or name them in a systematic manner. Impure preparations were often characterized and treated as single entities, when in fact more than one enzyme was present. What were thought of as different phosphatases often turned out to be dissociation products of more complex holoenzymes. In some instances “new” phosphatases were later recognized to be proteolytic artifacts.
1.
ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
15
Fortunately, these enzymes that have been so recalcitrant to experimentation in the past are beginning to reveal their secrets. They are treated as a group in Chapter 8 and no attempt is made to classify them here.
IV. Protein Phosphorylation and the Regulation of Biological Processes A.
PHOSPHORYLATION-DEPHOSPHORYLATION VERSUS OTHERCONTROL MECHANISMS
Given the many different mechanisms that are available for regulating biological functions what is special about protein phosphorylation? Does this process have a unique role that cannot be carried out by other mechanisms? The last question is particularly pertinent when one considers the enormous potential for regulation through allosteric control involving the reversible binding of ligands to proteins. In fact, examination of the mechanisms for regulation of many of the specific enzymes described in this volume reveals that the kinetic parameters that are altered by ligand binding are usually the same as those changed by phosphorylation. Why attach a ligand (phosphate) covalently, when the reversible binding of metabolite can apparently accomplish the same purpose? (See Chapter 2, however, for a discussion of signal amplification by means of allosteric control versus cyclic covalent modification casades.) Reference to the role of protein phosphorylation in the regulation of glycogen phosphorylase may help to provide an answer to this question. In Chapter 9 Neil Madsen notes that conversion of phosphorylase b to phosphorylase a allows phosphorylase “to escape from the allosteric controls” to which it is subject when present in its b form; that is, after phosphorylation phosphorylase becomes fully active in the absence of 5‘-AMP and is no longer subject to inhibition by ATP or glucose 6-P. The implication is that there may be an advantage in having a system in which under certain circumstances an enzyme can be “frozen” in its active (or inactive) configuration regardless of what happens to metabolite levels. The same line of thinking may also apply to the purpose of a third form of regulation in which the amount of a given enzyme is altered through changes in its rate of biosynthesis or destruction. Dramatic changes in the concentration of an enzyme provides a means of superceding control by phosphorylation-dephosphorylation as well as allosteric control. Implicit in this form of reasoning is the often-voiced idea that allosteric control provides an immediate or almost instantaneous response to a given situation, control by protein phosphorylation provides an intermediate form of response on a time scale, and control through changes in the levels of particular proteins provides a slow but enduring response.
16
EDWN G . KREBS
IPROTEIN
PHOSPHORYLATION-DEPHOSPHORYLATION
1
FIG. 2. Protein phosphorylation and the transduction of hormonal signals.
Regardless of these considerations, although not entirely unrelated, is the fact that protein phosphorylation as a process is geared to the handling of signals that have an extracellular origin (hormones, growth factors, etc.), whereas allosteric control is utilized primarily for the handling of signals that arise intracellularly. The major pathways involving protein phosphorylation as a mechanism for relaying hormonal signals are shown in Fig. 2. One group of hormones, arbitrarily designated as Group 1, act through their receptors to raise or lower cyclic nucleotide levels in cells and thus affect the state of phosphorylation of cyclic nucleotide-dependent protein kinase substrates. A second large group of hormones and other extracellular agents (Group 2) trigger the breakdown of phosphatidylinositol diphosphate generating diacylglycerol and inositol triphosphate, the latter causing elevated intracellular calcium ion levels. The increase in calcium ions causes activation of a set of Ca2 -CaM-dependent protein kinases and one phosphoprotein phosphatase, leading to the modulation in the state of phosphorylation of protein substrates for these enzymes. The diacylglycerol formed as a result of the action of this group of hormones causes activation of protein kinase C, which again leads to protein phosphorylation. Finally, the third set of hormones (Group 3) act through receptors that possess protein kinase activity (i.e., protein tyrosine kinase activity). Although the nature of the protein substrates for this set of enzymes have not been fully elucidated (see Chapters 6 and 7) there appears to be little doubt that they constitute important phosphorylatable proteins involved in the action of these hormones. The same pro+
1 . ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
17
teins affected by the transmembrane signaling mechanism portrayed in Fig. 2, are also often targets for allosteric control through their interactions with metabolites generated within the cell. The concept that protein phosphorylation functions primarily to handle extracellular signals whereas allosteric control is utilized to handle intracellular signals is in keeping with the finding that eukaryotic cells contain much more phosphoprotein than is found in the prokaryotes (65, 66). This is not to say that protein phosphorylation is never used as a regulatory device in bacteria (see Volume XVIII, Chapter 14) but the extent to which it is employed is much less than in higher organisms in which appropriate response to extracellular signals is so important. On the other hand, allosteric control as a means of response to intracellular signals is highly developed in bacteria. It is of interest that whereas many protein kinases are regulated by second messengers generated in response to extracellular signals (Tables I and II and Fig. 2), relatively few of them are regulated by ordinary metabolites. The (at least partial) immunity of protein kinases to metabolite control may help to provide a mechanism whereby regulation by phosphorylation-dephosphorylation is segregated from allosteric control.
B. DIVERSITY OF PHOSPHORYLATION-DEPHOSPHORYLATION CONTROL MECHANISMS The existence of phosphoproteins first became known as a result of their nutritional significance. Thus, the early work in this field was concerned with the caseins of milk and the various phosphoproteins of egg yolk which serve as a source of phosphorus and amino acids for developing organisms. The second set of proteins to receive attention as targets for phosphorylation-dephosphorylation were the enzymes, many of which are reviewed in this volume. Concomitantly with work on enzyme phosphorylation-dephosphorylation, however, investigators extended their studies of this process to include a host of nonenzymic proteins involved in many different cellular functions, some of which (e.g., ion movements, receptor activity, and muscle contraction) are also treated here. Protein phosphorylation reactions are important in modulating nuclear events within the cell as is evidenced by the extensive work on histone and protamine phosphorylation as well as studies on the phosphorylation of nonhistone proteins. The exact nature of the role of protein phosphorylation reactions within the nucleus remains elusive, however, inasmuch as the precise function of the proteins involved is not always clear. An unusual role for phosphoproteins is that seen for a highly phosphorylated dentine protein that appears to function in the calcification process in teeth (67). Even under circumstances in which investigators are well aware of the physiological function of a particular protein known to be phosphorylated, they are not always able to find an effect of phosphorylation on the activity of these proteins.
18
EDWIN G. KREBS
Reactions in this category are often referred to euphemistically as “silent phosphorylations.” A possible explanation for such phosphorylations is that they may be targeting particular proteins for destruction. This possibility is discussed in Volume XVIII Chapters 2 and 7 in relation to pyruvate kinase and HMG-CoA reductase respectively; for each of these proteins phosphorylation causes the formation of a configuration that leads to enhanced susceptibility to proteases. A related role for protein phosphorylatin would be the part that it may play in the processing of certain proteins by proteases (68, 69). Other possible explanations for silent phosphorylations should also be considered. Protein-protein interactions within the cell may be regulated by phosphorylation-dephosphorylation. The intracellular localization of proteins may be influenced by phosphorylation. These and many other protein functions are difficult to measure outside of the natural intracellular environment. Finally, with respect to silent phosphorylations, it is possible that some protein phosphorylation-dephosphorylationsserve no particular purpose other than generating heat and simply constitute futile cycles. REFERENCES I. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26.
Monod, J . , Changeux, J.-P., and Jacob, F. (1963). JMB 6, 306-329. Con, G. T., and Green, A. A. (1943). JBC 151, 31-38. Con, G. T., and Cori, C. F. (1945). JBC 158, 321-332. Fischer, E. H., and Krebs, E. G. (1955). JBC 216, 121-132. Sutherland, E. W., and Wosilait, W. D. (1955). Nurure (London) 175, 169-171. Krebs, E. G., Graves, D. J., and Fischer, E. H. (1959). JEC 234, 2867-2873. Friedman, D. L., and Lamer, J . (1963). Biochemistry 2,669-675. Rizak, M. A. (1964). JBC239, 392-395. Mendicino, J . , Beaudreau, C., and Bhattachryya, R. N. (1966). AEB 116,436-445. Linn, T. C., Pettit, F. H., Hucho, F., and Reed, L. J. (1969). PNAS 64, 227-234. Linn, T. C., Pettit, F. H., and Reed, L. J. (1969). PNAS 62, 234-241. Walsh, D. A . , Perkins, J. P., and Krebs, E. G. (1968). JBC 243, 3763-3765. Kuo, J. F., and Greengard, P. (1969). JBC 244, 3417-3419. Krebs, E. G. (1983). Philos. Trans. R. Soc. London, Ser. B 302, 3-11. Krebs, E. G. (1985). Trans. Biochem. Soc. 13, 813-820. Krebs, E. G. (1972). Curr. Top. Cell. Regul. 5 , 99-133. Armstrong, R. N., Kando, H., Geanot, J., Kaiser, E. T., and Mildvan, A. S. (1979). Biochemisrry 18, 1230-1238. Hixson, C. S . , and Krebs, E. G. (1979). JBC 254, 7509-7514. Flockhart, D. A., and Corbin, J. D. (1982). CRC Crir. Rev. Eiochem. 13, 133-186. Hathaway, G. M . , and Traugh, J. A. (1982). Curr. Top. Cell. Regul. 21, 101-127. Quirin-Steicker, C., and Schmitt, M. (1981). EJB 118, 165-172. Graziani, Y., Erikson, E., and Enkson, R. L. (1983). JBC 258, 6344-6351. Khandelwal, R. L., Mattoo, R. L., and Waygood, E. B. (1983). FEBSLerr. 162, 127-132. Mattoo, R. L., Waygood, E. B., and Khandelwal, R. L. (1984). FEBS Len. 165, 117-120. Simoni, R. D., and Postma, P. W. (1975). Annu. Rev. Biochem. 44, 523-554. Hunter, T., and Cooper, J. A. (1985). Annu. Rev. Eiochem. 54, 897-930.
1.
ENZYMOLOGY OF CONTROL BY PHOSPHORYLATION
19
27. Urishizaki, Y., and Seifter, S. (1985). Biophys. J . 47, 233a. 28. Smith, D. L., Chen, C. C., Bruegger, B. B., Holtz, S. L., Halpern, R. M., andsmith, R. A. ( I 974). Biochemistry 13, 3780-3785. 29. Smith, R. A,, Halpern, R. M., Bruegger, B. B., Dunlop, A. K., and Fricke, 0. (1978). Merhods Cell Biol. 14, 153-159. 30. Huebner, V. D., and Mathews, H. R. (1985). FP 44, Abstr. 3882. 31. Titanji, V. P. K., Ragnarsson, U., Humble, E., and Zetterquist, 0. (1980). JBC 255, 1133911343. 32. Rabinowitz, M., and Lipmann, F. (1960). JBC 235, 1043-1056. 33. Shizuta, Y., Beavo, J. A., Bechtel, P. J., Hofmann, F., and Krebs, E. G. (1975). JBC 250, 6891 -6896. 34. Lerch, K., Muir, L. W., and Fischer, E. H. (1975). Biochemisrry 14, 2015-2023. 35. Rosen, 0. M., and Erlichman, J. (1975). JBC 250, 7788-8894. 36. Shizuta, Y . , Khandelwal, R. L., Maller, J. L., Vandenheede, J. R., and Krebs, E. G. (1977). JBC 252, 3408-3413. 37. El-Maghrabi, M. R., Haston, W. S., Flockhart, D. A , , Claus, T. H., and Pilkis, S. J. (1980). JBC 255, 668-675. 38. Fukami, Y., and Lipmann, F. (1983). PNAS 80, 1872-1876. 39. Hemmings, B . A , , Yellowlees, D., Kernohan, J. C., and Cohen, P. (1981). EJB 119,443-451. 40. Kikkawa, U., Takai, Y., Minakuchi, R., Inohara, S., and Nishizuka, Y. (1982). JBC 257, 13341- 13348. 41. Kahn, C. R., White, M. F., Grigorescu, F., Takayarna, S., Haring, H. U., and Crettaz, M. (1985). In “Molecular Basis of Insulin Action” (M. P. Czech, ed.), pp. 67-93. Plenum, New York. 42. DeLange, R. J . , Kemp, R. G., Riley, W. D., Cooper, R. A,, and Krebs, E. G. (1968). JBC 243, 2200-2208. 43. Rangel-Aldao, R., and Rosen, 0. M. (1976). JBC 251, 7526-7529. 44. Lincoln, T. M., Flockhart, D. A , , and Corbin, C. D. (1978). JBC 253, 6002-6009. 45. Erlichman, J . , Rosenfeld, R., and Rosen, 0. M. (1974). JBC 249, 5000-SO03. 46. Rosen, 0. M., Herrara, R., Olowe, Y., Petruzzeli, L. M., and Cobb, M. (1983). PNAS 80, 3237-3240. 47. Blumenthal, D. K., Takio, K., Edelman, A. M., Charbonneau, H., Titani, K., Walsh, K. A., and Krebs, E. G. (1985). PNAS 82, 3187-3191. 48. Edelman, A. M., Takio, K., Blumenthal, D. K., Hansen, R. S., Walsh, K. A., Titani, K., and Krebs, E. G. (1985). JBC 260, 11275-11285. 49. Vandenheede, J. R., Yang, S. D., Goris, J., and Merlevede, W. (1980). JBC 255, 1176811774. 50. Walker, A. I . , Hunt, T., Jackson, R. H., and Anderson, C. W. (1985). EMBO J . 4, 139-145. 51. Racker, E., Abdel-Ghany, M., Sherril, K., Riegler, C., and Blair, E. A. (1984). PNAS 81, 4250-4254. 52. Casnellie, J . E., Gentry, L. E., Rhorschneider, L. R., and Krebs, E. G. (1984). PNAS 81, 6676-6680. 53. Swamp, G., Dasgupta, J . D., and Garbers, D. L. (1983). JBC 258, 10341-10347. 54. Goldberg, A. R., and Wong, T. W. (1984). Adv. Enzyme Regul. 22, 289-308. 5 5 . Migliaccio, A,, Rotondi, A,, and Auricchio, F. (1984). PNAS 81, 5921-5925. 56. Shozo, S., Parmelee, D. C., Wade, R.D., Kumar, S., Ericsson, L. H., Walsh, K. A., Neurath, H., Long, G. L., Demaille, J. G., Fischer, E. H., and Titani, K. (1981). PNAS 78, 848-851. 57. Barker, W. C., and Dayhoff, M. 0. (1982). PNAS 79, 2836-2839. 58. Takio, K., Wade, R. D., Smith, S. B., Krebs, E. G., Walsh, K. A,, and Titani, K. (1984). Biochemisrry 23, 4207-4218.
20
EDWIN G. KREBS
59. Reimann, E. M., Titani, K., Ericsson, L. H., Wade, R. D., Fischer, E. H., and Walsh, K. A. (1984). Biochemistry 23, 4185-4192. 60. Takio, K., Blumenthal, D. K., Edelman, A. M., Walsh, K. A,, Krebs, E. G., and Titani, K. (1985). Biochemistry 24 (in press). 61. Mark, G. E., and Rapp, U. R. (1984). Science 224, 285-289. 62. Czernilofsky, A. P., Levinson, A. D., Varmus, H. E., Bishop, J. M., Tischer, E., and Goodman, H. (1980). Nature (London) 287, 198-203. 63. Ullrich, A., Cousens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W.,Lee, J., Yarden, Y.,Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. (1984). Nature (London) Jo9, 418-425. 64. Ullrich, A., Bell, J. R., Chen, E. Y.,Herrera, R., Petruzzelli, L. M., Dull, T. J., Gray, A,, Coussens, L., Liao, Y .-C., Tsubokawa, M., Mason, A., Seeburg, P. H., Grunfeld, C., Rosen, 0. M., and Ramachandran, J. (1985). Nature (London) 313, 756-761. 65. Sedmak, J., and Ramaley, R. (1968). BBA 170, 440-442. 66. Forsberg, H., Zetterqvist, O., and Engstrom, L. (1969). BBA 181, 171-175. 67. Pal, B. K., and Roy-Berman, P. (1978). BBRC 81, 344-350. 68. Kaufman, J. F., and Strominger, J. L. (1979). JBC 76, 6304-6308. 69. Veis, A., and Perry, A. (1967). Biochemistry 6, 2409-2416.
Cyclic Cascades and Metabolic Regulation EMILY SHACTER* P. BOON CHOCK SUE GOO RHEE EARL R. STADTMAN Laboratory of Biochemistry National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland 20892
1. Perspectives ................................... ...... 11. Features of Cyclic Cascade Systems . . . . . . . . . . . . . . . A. Unidirectional versus Interconvertible Cascades .................... B. Theoretical Analysis .......................................... 111. Experimental Verification of the Cyclic Cascade Model ................ IV. Energy Consumption ...... V. Covalent Interconversion ve VI. Concluding Remarks ............................................. ........ References .............
1.
21 27 28 33 37 37
Perspectives
Reversible covalent modification of an interconvertible protein involves the enzymic transfer and removal of a modifying group from a donor molecule to a specific amino acid residue. The different forms of reversible covalent modification are listed in Table I (1-14). Each of these modifications and demodifications *Resent address: Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 21 THE ENZYMES,Vol. XVII Copyright 8 1986 by Academic Press, Inc. All rights of repduction in any form reserved.
22
SHACTER, CHOCK, RHEE, AND STADTMAN TABLE I REVERSIBLE COVALENT MODIFICATIONS OF PROTEINS Modification
Donor molecule
Phosphorylation
ATP, GTP
ADP-ribosylation
NAD +
Nucleotidylylation (adenylylation and uridylylation) Methylation
ATP, UTP
Acetylation Tyrosylation Sulfation
S-Adenosyl-methionine
Acetyl-CoA Tyrosine 3-Phosphoadenosine 5-phosphosulfate
Amino residue(s)
References
Serine Threonine Tyrosine Hydroxylysine Arginine Glutamate Lysine (terminal COOH) Diphthamide Tyrosine Serine Aspartate Glutamate Lysine Histidine Glutamine Lysine Carboxyl terminus Tyrosine
is catalyzed by specific converter enzymes such as protein kinases and phosphoprotein phosphatases. The unification of two opposing converter enzymes and an interconvertible enzyme forms a cyclic cascade system. Thus, any enzyme or protein that undergoes reversible covalent modification is a member of a cyclic cascade. The number of enzymes and pathways regulated by cyclic cascade systems has increased dramatically since the discovery in 1955 by Sutherland and Wosilait (15) and by Fischer and Krebs (16) that glycogen phosphorylase exists in two forms: an active phosphorylated form and a relatively inactive unmodified form. A comprehensive list of interconvertible enzymes and proteins is given in Table I1 (17-159).Proteins that undergo covalent modification but that have not been are not included. functionally defined, such as miscellaneous lens proteins (160), Nonetheless, Table I1 is almost five times as long as a similar list published in 1978 (161) and its volume continues to increase. It should be pointed out that tyrosine sulfation is not known to be cyclic nor has it been shown to regulate any enzyme activity. However, in light of evidence that the membranal receptor for interleukin-2 contains tyrosine sulfate (88) and other results showing that the level of tyrosine sulfate decreases in cells that are transformed by retroviruses
2. CYCLIC CASCADES AND METABOLIC REGULATION
23
TABLE I1 INTERC0NVtRTIBI.E
ENZYMG (PRO T t l N S )
Enzyme
Rcferences
Phosphorylution Acetyl-CoA carboxylase Acetylcholine receptor (nicotinic) Actin Acyl coenzyme A: cholesterol acyltransferase Alpha-ketoacid dehydrogenase complex Aminoacyl-tRNA synthetase Angiotensin Asialoglycoprotein receptor ASpdrdginaSe ( L . WiichOtii) ATP citrate lyase Beta-adrenergic receptor Beta-glucuronidase Branched-chain 2-oxoacid dehydrogenase complex Ca2 -ATPase C-protein (cardiac muscle) Casein CAMP-dependent protein kinase (regulatory subunit) CAMP-dependent protein kinase (catalytic subunit) cGMP-dependent protein kinase Cholesterol esterase Cholesterol 7a-hydroxylase Cyclic nucleotide phosphodiesterase Cytochrome P-450 (adrenocortical) DARPP-32 DNA topoisomerase I DNA topoisomerase 11 Enolase Epidermal growth factor receptor Erythrocyte membrane band 3 protein Eukaryotic intiation factor-2 (eIF-2) Eukaryotic initiation factor-3 (eIF-3) Eukaryotic peptide elongation factor- I Fibrinogen Fodrin (nonerythroid spectrin) Fructose- I ,6-bisphosphatase Fructose-:! ,6-bisphosphatase-fructose-6-P-2-kinase y-Aminobutyric acid (GABA) receptor complex Glucocorticoid receptor (liver) Glutamate dehydrogenase, NAD-dependent (yeast) Glycerol phospate acyltransferase Glycogen phosphorylase Glycogen synthase G-substrate (brain) +
(continued)
24
SHACTER, CHOCK, RHEE, AND STADTMAN TABLE 11 (Conrinued) Enzyme Guanylate cyclase High-mobility group (HMG) proteins Histones HLA antigens (Class I) Hormone-sensitive lipase-diglyceride lipase 3-Hydroxy-3-methylglutarylcoenzyme A reductase Hydroxymethylglutaryl coenzyme A reductase kinase Immunoglobulin G Insulin receptor Interleukin-2 (IL-2, T-cell growth factor) receptor lsocitrate dehydrogenase Keratin (Type I) Lactate dehydrogenase Microtubule-associated protein-2 (MAP-2) Myelin basic protein Myeloperoxidase Myosin heavy chains Myosin light chains Myosin light chain kinase Na+ channel, a subunit Na+ -K -ATPase Omithine decarboxylase 3-0x0-Sa-steroid A4-dehydrogenase Phenylalanine hydroxylase Phosphofructokinase Phosphoglycerate mutase Phospholamban Phospholipid methyltransferase Phosphoprotein phosphatase inhibitor- 1 Phosphoprotein phosphatase inhibitor-2 Phosphorylase kinase Phosvitin Platelet-derived growth factor receptor Poly(A) polymerase Polyoma T antigen Prolactin Protamine Pyruvate dehydrogenase Pyruvate kinase Pyruvate, Pi, dikinase (lean Retroviral oncogenes Reverse transcriptase Rhodopsin Ribosomal protein S6 RNA Polymerase (DNA-dependent) Synapsin I (brain) +
References
25
2. CYCLIC CASCADES AND METABOLIC REGULATION TABLE I1 (Continued) Enzyme Tau factor Troponins I and T Tubulin Tyrosine hydroxylase Vinculin ADP-ribosylation Actin Adenylate cyclase Ca2+ ,Mg2+ -dependent endonuclease DNA ligase I1 DNA polymerases a and p DNA topoisomerase I Elongation factor I1 (E. coli) Glutamine synthetase (mamm.) High-mobility group proteins Histones Micrococcal nuclease Nitrogenase (bacterial) Phosphorylase kinase (skeletal muscle) Poly(ADP-ribose) synthetase Protamines RNA polymerase (E. coli) RNase (bovine) SV40 T antigen (large) Terminal deoxynucleotidyl transferase Transducin Nucleofidylylafion Aspartokinase (E. coli) Glutamine synthetase ( E . coli) Regulatory protein, PI, ( E . coli) SV40 T antigen (large) Methylation ACTH Actin Calmodulin Citrate synthase Cytochrome c EF-TU y-Globulin High-mobility group (HMG) proteins -1 and -2 Histones Methyl-accepting chemotaxis proteins (MCPs) Myosin Opsin Ovalbumin Ribonuclease
References
(153) (8) (8) (9) (154)
(10) (154)
(10) (11)
(10) (154) (10) (21)
(155) (1555)
(10) (154) ( 154 1
26
SHACTER, CHOCK, RHEE, AND STADTMAN TABLE I1 (Continued) Enzyme
References
Acetylation High-mobility group (HMG) proteins Histones Tyrosinolation Tubulin a-subunit Sulfation Complement C4 Fibrinogens, fibrins Gastrin I1 Phyllokinin Caerulein Cholecystokinin Leu-enkephalin Fibronectin Immunoglobulins Interleukin-2 (IL-2, T-cell growth factor) reCeptor
(158), it seems possible that sulfation may have a regulatory function and, therefore, it has been included in the tables. Perusal of Table I1 reveals that a broad array of cellular pathways, such as protein, carbohydrate, lipid, and nucleic acid metabolism; interferon action (162); DNA repair (163); viral oncogenesis (164-166); muscle contraction (98); and membranal signal transduction are regulated by cyclic covalent modification. In addition, a number of regulatory enzymes undergo multiple covalent modifications. For example, glycogen synthase is phosphorylated on seven different sites by five different protein kinases (108),each of which is regulated by different stimuli and effectors. Furthermore, some proteins, such as phosphorylase kinase, histones, and the interleukin-2 receptor undergo more than one form of modification. Such multisite modification not only expands the potential of regulatory networks numerically, but also creates the possibility for competition between different converter enzymes and, hence, between different cyclic cascade systems. This has been suggested specifically in the case of ADPribosylation and phosphorylation of phosphorylase kinase and miscellaneous nuclear proteins (148, 167). Cyclic cascade systems respond to metabolic requirements by shifting an interconvertible protein between different extents of modificakon. In the case of an interconvertible enzyme, this produces a change in its specific activity either by increasing or decreasing the K , or V,,, of the enzyme or by modulating its response to allosteric effectors. For example, phosphorylation of glycogen phosphorylase results in activation of the enzyme by increasing the V,,,, whereas phosphorylation of myosin light chain kinase by CAMP-dependent protein kinase
2. CYCLIC CASCADES AND METABOLIC REGULATION
27
inhibits the enzyme by decreasing its affinity for the essential activation complex, Ca2+-calmodulin. Analogously, in the case of a binding protein (e.g., eIF-2, histones), covalent modification can either enhance or diminish binding efficiency. Key to their pivotal role in cellular regulation is the fact that cyclic cascade systems are regulated by allosteric interactions of metabolic effectors with either the converter enzymes or the interconvertible enzymes. Moreover, as previously mentioned, covalent modification can modulate the allosteric interactions between metabolic effectors and an interconvertible enzyme. Thus, these two major mechanisms of enzyme regulation are inextricably intertwined [see Ref. (168) for a review of the multimodulation of enzyme activity]. Covalent modification has also been implicated in regulating specific protein degradation in the cell. That is, phosphorylation of several regulatory enzymes has been shown to increase their susceptibility to proteolysis both in virro and in vivo; these include HMG-CoA reductase (169), pyruvate kinase (170), glutamate dehydrogenase from yeast, (171), fructose-1,6-bisphosphatase (172), and cardiac troponin (173). Similarly, ubiquitination of proteins (which is not known to be cyclic) has been proposed to be involved in marking proteins for ATPdependent proteolysis (174). Thus, covalent modification may be a mediator for the third major mechanism of metabolic regulation-that of controlling intracellular enzyme levels. Clearly, a thorough understanding of cyclic cascades is requisite to our ability to understand and manipulate normal and abnormal cell function. The following sections present a brief update and summary of the characteristics of cyclic cascade systems that make them so well suited for their central position in cellular regulation. More detailed reviews can be found in Refs. (8) and (161).
II. Features of Cyclic Cascade Systems A.
UNIDIRECTIONAL VERSUS INTERCONVERTIBLE CASCADES
Covalent modifications of enzymes (proteins) is catalyzed by converter enzymes such as kinases and phosphatases. They involve the action of one enzyme upon another and are therefore referred to as cascade systems (8, 161, 175). These systems can be divided into two classes-unidirectional cascades and cyclic cascades. Unidirectional cascades are irreversible and are usually involved in proteolytic cleavage of a specific peptide bond, as occurs in the activation of zymogens (176). Well-recognized unidirectional cascades include the bloodclotting cascades (177) and the cascade involved in complement fixation (178). They are designed as amplifiers that, in response to certain alarm signals, generate an avalanche of product required to meet specific biological challenges. When the need suhsides the cascade are terminated. Therefore, unidirectional
28
SHACTER, CHOCK, RHEE, AND STADTMAN
cascades are contingency systems serving as biological switches that can be turned ON to meet occasional emergency situations. In contrast, cyclic cascades involve the derivatization of one or more specific amino acid residues within the protein as occurs in the ATP-dependent phosphorylation of the hydroxyl groups of serines, threonines, or tyrosines ( I ) , in the ATP-dependent adenylylation of the hydroxyl group of a specific tyrosine in E. coli glutamine synthetase (179, 180), and others described in Table I. These enzyme derivatizations are cyclic processes resulting from the coupling of two opposing cascades-one concerned with the covalent modification and the other with the demodification of an interconvertible enzyme. The properties of cyclic cascades elucidated by the theoretical analysis discussed in the following section show that they are endowed with unique characteristics that provide the cell with the capacity to regulate and coordinate a multitude of metabolic pathways. B. THEORETICAL ANALYSIS In view of the vast number of interconvertibleproteins listed in Table 11, many of which are key enzymes in metabolic control, we have carried out a theoretical analysis designed to reveal the advantages of such a complex mechanism for cellular regulation (161, 181). In this analysis, it has been ascertained that the covalent modification of enzymes does not function simply as an ON-OFF switch for various metabolic pathways, but rather that it is part of a dynamic process in which the fractional activities of the interconvertible enzymes can be varied progressively over a wide range. This concept derived from the experiments of Brown et al. (182) demonstrating that the adenylylation of glutamine synthetase is not an all-or-none process; instead, a steady state is established and its level is modulated by the concentrations of effectors involved. Similar observations have been reported by Pettit et al. (183) for the mammalian pyruvatedehydrogenase complex. The cyclic cascade model, as depicted in Fig. 1 , derives from the coupling of a forward cascade and a reverse cascade. The forward cascade involves the activation of the inactive converter enzyme, PK, by an allosteric effector, e,. The activated converter enzyme, PK,, then catalyzes the modification (i.e., phosphorylation) of the interconvertible enzyme from its unmodified form, S, to its modified form, S-P. In the reverse cascade, the inactive converter enzyme, PT, is activated by an allosteric effector, e2, and the active converter enzyme catalyzes the demodification (i.e., dephosphorylation)of the modified interconvertible enzyme, S-P, to its unmodified form. The coupling of these two cascades results from the fact that the substrate of the converter enzyme in one cascade is the product of the opposing cascade. Note also that for each complete cycle, a molecule of ATP is hydrolyzed to ADP and Pi. When the ATP concentration is maintained in excess relative to the enzymes involved and at a fairly constant
29
2. CYCLIC CASCADES AND METABOLIC REGULATION PK
+
el
K1 + PK,
I I I
ADP
ATP
PT
+ 82 +PT, K2
FIG. 1 . Schematic representation of a monocyclic cascade. K,,KZ,K l f , KI,are dissociation constants for PK,, P",, S-PK,, and S-P.FTa,respectively; klf and k I r are specific rate constants for the reactions designated.
level, a steady state is established in which the rate of S-P formation is equal to the rate of S regeneration. Using the parameters shown in Fig. 1, it is possible to derive a relatively simple equation to quantitate the fractional phosphorylation of the interconvertible enzyme (161, 181). When the modified interconvertible enzyme in one cycle catalyzes the modification of an interconvertible enzyme in another cycle, the two cycles are coupled such that the fractional modification of the second interconvertible enzyme is a function of all the quantitative parameters that define both cycles. Similarly, when the cascade is composed of n interconvertible enzymes and the modified interconvertible enzyme in one cycle functions as the converter enzyme for the next interconvertible enzyme, a multicyclic cascade composed of n cycles is obtained (161, 184). Quantitative analysis of cyclic cascades reveals (8, 161, 182, 184) that ( a ) they are endowed with an enormous capacity for signal amplification. As a result, they can respond to primary effector (e, in Fig. 1) concentrations well below the dissociation constant of the effector-enzyme complex; ( b ) they can modulate the amplitude of the maximal response that an interconvertible enzyme can accomplish at saturating concentrations of allosteric effectors; ( c ) they can enhance the sensitivity of modification of the interconvertible enzyme to changes in the concentrations of allosteric effectors (i.e., they are capable of eliciting apparent positive and negative cooperativity in response to increasing concentrations of allosteric effectors); (d)they serve as biological integration sysrems that can sense simultaneous fluctuations in the intracellular concentrations of numerous metabolites and adjust the specific activity of the interconvertible enzymes
30
SHACTER, CHOCK, RHEE, AND STADTMAN
accordingly; (e) they are highly flexible with respect to allosteric regulation and are capable of exhibiting a variety of responses to primary allosteric stimuli; and v) they serve as rule amplifiers and therefore are capable of responding extremely rapidly to changes in metabolite levels (185, 186). 1. Signal Amplification This is a time-independent parameter defined (161, 181) as the ratio of the concentration of the primary allosteric effector (el in Fig. 1) required to attain 50% activation of the converter enzyme PK to the concentration required to produce 50% modification of the interconvertible enzyme S. This exceptional property derives from the fact that enzymes (catalysts) act as intermediaries between the metabolic effectors (signals) and the target interconvertible enzymes. Signal amplification can be quantified using the steady-state expression for the fractional modification of the interconvertible enzyme. It is a multiplicative function of the variables shown in Fig. 1; each of these parameters is susceptible to modulation by allosteric effectors. Because of the multiplicative nature of the fractional modification expression, small changes in several of the parameters can lead to enormous changes in fractional modification of the intercovertible enzyme in response to effector. Moreover, signal amplification increases exponentially as a function of the number of cycles in the cascade. Due to signal amplification, interconvertibleenzymes can respond to effector concentrations that are well below the dissociation constant of the effector-converter enzyme complex. In other words, only a relatively small fraction of converter enzyme need be activated in order to obtain a significant fractional modification of the interconvertible enzyme. It should be pointed out that the signal amplification described here is distinctly different from catalytic amplification, which is solely a function of the expansion of the relative concentrations and catalytic efficiencies of the converter and interconvertible enzymes. For the unique case in which the maximal specific catalytic activities of the converter enzyme, PK, and the interconvertible enzyme, S, are the same, the catalytic amplification potential is equal to the concentration ratio [S]/[PK]. In fact, in most cascades that have been studied, there exists a pyramidal increase in the concentration of the cascade enzymes; that is, the concentration of converter enzymes is significantly lower than that of the interconvertible enzyme substrate. Therefore, they possess a high catalytic amplification potential. This enhances the signal amplification of the cascade. 2 . Amplitude Amplitude is defined (161) as the maximal value of fractional modification of the interconvertible enzyme attainable with saturating concentrations of an effector. By changing the magnatude of the cascade parameters, the amplitude can change smoothly from nearly 100% to nearly 0%. Therefore, even at saturating
2. CYCLIC CASCADES AND METABOLIC REGULATION
31
levels of an effector (e.g., e , in Fig. 1) interconvertibleenzymes do not function as ON-OFF switches. Gresser has pointed out (1860) that all modification reactions would proceed to their individual equilibrium. For physiological cascades, e.g., phosphorylaton/dephosphorylation,adenylylation/deadenylylation, etc., almost all interconvertible proteins would be present in only one form when one considers the individual equilibria for either the modification or demodification reaction. Thus, under certain extreme conditions, such as the temporary loss of either the regeneration cascade or forward cascade, enzyme cascades can effectively function as ON-OFF switches for enzymic activity.
3 . Sensitivity Cyclic cascades can generate either apparent positive or negative cooperative responses of fractional modification (i.e., enzymic activity) of the interconvertible enzyme to increasing concentrations of an allosteric effector (161). These apparent cooperativities can derive from the synergistic or antagonistic effects that a single allosteric effector exerts on two or more steps in the cascade. Thus, a sigmoidal response need not reflect positive cooperativity in the binding of an effector to multiple binding sites on the converter enzyme. Instead, it can be accomplished when an effector activates the forward converter enzyme and inactivates the reverse converter enzyme, or vice versa. Consequently, an effective way for obtaining high sensitivity is to have both forward and reverse converter enzyme activities combined in a single polypeptide such that binding of one effector can activate one activity while inactivating the other activity. Four such bifunctional enzymes have been isolated and characterized. They are the uridylyltransferase-uridylyl-removing enzyme activities that catalyze the uridylylation-deuridylylation of the P,, regulatory protein in the E. coli glutamine synthetase cascade (183, the adenylyltransferase that catalyzes the adenylylation-deadenylylation of glutamine synthetase (188, 189), a protein kinasephosphatase that catalyzes the phosphorylation and dephosphorylation of isocitrate dehydrogenase in E. coli (190), and the 6-phosphofructose-2-kinase-fructose-2, 6-bisphosphatase that catalyzes the synthesis and breakdown of fructose 2, 6-bisphosphate (191, 192). All four of these bifunctional enzymes are involved in cyclic cascade systems. A sigmoidal response can also be achieved by the regulatory mechanism reported by Jurgensen (193) in which the type I1 regulatory subunit of CAMPdependent protein kinase inhibits the MgATP-dependent protein phosphatase. In addition, apparent cooperativity can be obtained when the active converter enzyme forms a tight complex with the interconvertible enzyme as shown by Shacter e f al. (194, 195) and independently by Goldbetter and Koshland (196). The latter authors showed that when the converter enzyme is saturated by its interconvertible substrate, the cyclic cascade can exhibit a sigmoidal response to effector concentration. They call this effect “zero-order ultrasensitivity.”
32
SHACTER, CHOCK, RHEE, AND STADTMAN
4. Flexibility and Biological Integration There are two aspects of flexibility that need to be considered in discussing the properties of cyclic cascades; namely, the flexibility for generating various allosteric control patterns and the flexibility in regulation by multiple metabolites. The control pattern depicted in Fig. 1 illustrates just one of many variations that can be derived by changing the nature of the interactions between the allosteric effectors, e l and e2, and the converter enzymes, PK and PT. For the case in which the converter enzyme PK is activated by effector e l , four different regulatory mechanisms may result depending upon whether e, and e2 activate or inhibit the activity of converter enzyme PT (181). Numerical analysis of these four mechanistic schemes shows that they can yield an array of patterns of fractional modification of the interconvertible enzyme in response to increasing concentrations of e l (161, 181). These patterns differ with respect to their amplitude, signal amplification, and sensitivity to changes in e, concentration. In fact, three of these four regulatory patterns have been obseived in regulation of the mammalian pyruvate dehydrogenase cascade (183, 197). Furthermore, because the number of converter enzymes in multicyclic cascades is greater than in monocyclic cascades, it is possible to obtain an even greater number of unique regulatory patterns in response to positive and negative allosteric interactions. The fact that a minimum of two converter enzymes and one interconvertible enzyme is required to form a single interconversion cycle, and each enzyme can be a separate target for one or more allosteric effectors, cyclic cascades provide a high degree of flexibility for metabolic input. Through allosteric interactions with the cascade enzymes, fluctuations in the concentrations of numerous metabolites lead to automatic adjustments in the activities of the converter enzymes that determine the steady-state levels of fractional modification (specific activity) of the interconvertible enzymes. In essence, cyclic cascades serve as biological integrators that can sense changes in the concentrations of innumerable metabolites and modulate the activities of pertinent enzymes accordingly. 5 . Rate Amplification Kinetic analysis of multicyclic cascades reveals that the rate of covalent modification of the last interconvertible enzyme in the cascade is a multiplicative function of the rate constants of all the reactions that lead to the formation of the modified enzyme (8, 186). Therefore, following an initial lag period, cyclic cascades can function as rate amplifiers to generate an almost explosive increase in catalytic activity of the target interconvertible enzyme in response to stimuli. This rate amplification potential increases with the number of cycles in the cascade. The magnitude of the rate amplification is further enhanced if the multicyclic cascade involved possesses a pyramidal relationship with respect to the concentrations of its interconvertible enzymes. Employing reasonable esti-
2. CYCLIC CASCADES AND METABOLIC REGULATION
33
mates for the rate constants, it has been demonstrated that multicyclic cascades are capable of generating large biochemical responses to primary stimuli in the millisecond time range. Moreover, if the converter and interconvertible enzymes are topographically positioned close to each other, an even greater rate of response is possible. Such topographic positioning does occur in the case of mammalian pyruvate dehydrogenase (198) and the enzymes of the glycogen cascade, which have been shown to be adsorbed to glycogen particles (199). Experimentally, Cori and his associates reported (200) that following electrical stimulation of frog sartorius muscle at 30"C, phosphorylase b is converted to phosphorylase a with a half-time of 700 msec. The fact that cyclic cascades can respond to stimuli in the millisecond time range, together with their capacity for signal amplification, indicates that they can be involved in the regulation of neurochemical processes (186).
6. ATP Flux As shown in Fig. 1, for each complete cycle of a phosphorylation-dephosphorylation cascade, one equivalent of ATP is consumed and one equivalent each of ADP and Pi is generated. Similarly, the energy-rich donor molecules for all other forms of covalent modification (see Table I) also are degraded continuously when the cyclic cascade is in operation. The rate of ATP hydrolysis is regulated by the parameters that control the fractional modification of the intercovertible enzyme. In the theoretical analysis (161, 181),the ATP concentration is assumed to be constant because, in vivo, the concentration of ATP is metabolically maintained at fairly constant levels which are several orders of magnitude greater than the concentrations of the enzymes involved in the cascades. This ATP flux is an essential feature of the cyclic cascade regulatory mechanism because it provides the free energy required to maintain the steady-state distribution between the modified forms of the interconvertible enzyme at metabolitespecified levels which are different from those specified by thermodynamic considerations (see Section IV).
111.
Experimental Verification of the Cyclic Cascade Model
To verify the properties of cyclic cascades described in the previous sections, the following systems have been investigated: (a) a simple in vitro phosphorylation-dephosphorylation cyclic cascade which was developed to study the validity of the theoretical predictions; (b) the bicyclic cascade of glutamine synthetase employing both purified proteins and permeabilized cells. The in v i m system consists of type I1 CAMP-dependent protein kinase and a
34
SHACTER. CHOCK, RHEE, AND STADTMAN
38-kDa, type 2A protein phosphatase (201) as converter enzymes, and a nanopeptide as interconvertible substrate (195). Both converter enzymes were purified to near homogeneity from bovine heart. The nanopeptide, Leu-Arg-ArgAla-Ser-Val-Ala-Gln-Leu, is homologous to the phosphorylation site of rat liver pyruvate kinase (202). The allosteric effectors used are CAMP, an activator of the kinase, and Pi, an inhibitor of the phosphatase. This model cascade is useful both as a tool for studying the mechanism whereby enzymes regulate each other and as a relatively simple system to aid our conceptualization of metabolic regulation through cyclic cascades. U$e results show that when the ATP concentration is maintained at a relatively 'constant level, a steady state is established for the fractional phosphorylation of the nanopeptide. Under this condition, ATP hydrolysis continues at a constant rate, which is a measure of the interconversion rate of the nanopeptide between its phosphorylated and dephosphorylatedforms. In addition, as predicted by the cyclic cascade analysis, this monocyclic cascade exhibits both the capacity for signal amplification and the capacity to generate a cooperative response to increasing effector concentrations. Due to signal amplification, only one-tenth of the CAMPconcentration required to half-activate the kinase is required to obtain a 50% phosphorylation of the nanopeptide. Because of an increase in sensitivity in this system, phosphorylation of the nanopeptide responds more sharply to increasing concentrations of CAMP than does the activation of the CAMP-dependent protein kinase. This apparent cooperativity derives from the fact that the catalytic subunit of the protein kinase forms a tight complex with the nanopeptide. Furthermore, in the presence of Pi, an inhibitor of the phosphatase, both the sensitivity and signal amplification were enhanced considerably (195). Experiments have been carried out also using purified proteins of the bicyclic glutamine synthetase cascade of E. coli (189, 203) and permeabilized E . coli cells (204). Despite complications resulting from the dual roles of the effectors glutamine and a-ketoglutarate in the adenylylation and deadenylylation reactions, and the fact that six of the converter enzyme-effector complexes are catalytically active, the data confirmed the predictions of the theoretical analysis. They illustrated that cyclic cascades can serve as a signal amplifier and can elicit a cooperative response to increasing effector concentrations. Similar results were obtained both in vitro and with permeabilized cells. In addition, comparative studies (204) show that cells in which both cycles of the bicyclic cascade are functioning possess a higher signal amplification and are more sensitive to changes in metabolite concentrations than those with only one cycle functioning. In essence, most of the predicted properties of cyclic cascades have been confirmed experimentally in v i m and in vivo through studies of the phosphorylation-dephosphorylation monocycle and the glutamine synthetase bicyclic cascade.
2. CYCLIC CASCADES AND METABOLIC REGULATION
35
IV. Energy Consumption The steady states that develop in cyclic cascades are dynamic, energetic conditions in which the interconvertible proteins are being cycled constantly between modified and unmodified states. The capacity of a cyclic cascade system to maintain a steady state is dependent upon a constant supply of metabolic energy to drive the modification reactions, for in the absence of adequate donor molecules, the interconvertible protein would be converted completely to the unmodified form. Thus, the constant flux of metabolic energy through the cyclic cascade is the fuel required to maintain such an exquisite mechanism of cellular regulation. The question arises, then, as to how much energy is consumed by reversible covalent modification systems. Detailed quantitation of the ATP flux through a model monocyclic phosphorylation-dephosphorylation cascade (205) demonstrated that in the presence of a relatively constant amount of ATP, a number of general characteristics are observed, which can be summarized as follows: 1. The ATP turnover is directly proportional to the concentration of both converter enzymes in the system; i.e., the higher the concentration of both protein kinase and phosphatase, the higher the cycling rate and, hence, the higher the ATP flux. 2. Attainment of a specific steady-state level of phosphorylation is dependent upon the ratio of concentrations of protein kinase and phosphatase and is independent of their absolute concentrations. 3. The time required to reach a given steady state is inversely proportional to the concentrations of converter enzymes. 4. For a given concentration of protein kinase, phosphatase, and phosphorylatable protein, the rate of ATP consumption is directly proportional to the steady-state level of phosphorylation (determined by the effector concentrations for the converter enzymes); in other words, to maintain a protein in a highly phosphorylated, thermodynamically unstable state, proportionately more energy must be expended than to maintain it at a lower steady-state level of modification.
Note that these characteristics are relevant for all forms of reversible covalent modification. It seems likely that the cell must maintain a delicate balance between a requirement to reach a new steady state within the metabolic time frame while not expending an excessive amount of energy. In fact, the levels of converter enzymes in the cell are relatively high (in the p M range), and, not unexpectedly, steady-state levels of phosphorylation of specific proteins in vivo are reached within seconds after an extracellular stimulus (205). It was of interest, therefore,
36
SHACTER, CHOCK, RHEE, AND STADTMAN
to estimate what the actual ATP turnover in an in vivo cyclic cascade might be (205).To this end, all relevant experimental parameters were compiled for two well-characterized cellular cyclic cascade systems: phosphorylation of hepatic pyruvate kinase by CAMP-dependent protein kinase and phosphorylation of skeletal muscle glycogen phosphorylase by phosphorylase kinase following neural stimulation. The values were used to quantitate the ATP flux through each monocyclic cascade. It was estimated that each of these cyclic covalent modification systems consumes less than 0.02% of the total cellular energy flux. This analysis did not take into account the fact that multiple cascades are activated simultaneously following hormonal and neuronal stimuli, nor did it include the energy conservation mechanisms inherent in the cyclic cascade system (205). Nevertheless, even allowing for a large margin of error, this result suggests that cyclic cascade systems not only are exceptional in their regulatory potential, but they are highly energy efficient as well.
V. Covalent lnterconversion versus Simple Allosteric Control
Although the cyclic cascade model was derived for enzyme systems undergoing covalent interconversion, the reaction scheme shown in Fig. 1 theoretically does not require covalent modification. Hence, it is reasonable to question whether allosteric interactions alone between metabolites and enzymes can exhibit the properties of cyclic cascade systems, such as signal amplification, flexibility, and sensitivity with respect to increasing effector concentrations. It should be remembered that the cyclic cascade model utilizes both covalent modification of enzymes and allosteric control. To accomplish signal amplification by means of simple allosteric control, the following conditions would have to be met: (a) very tight binding between the allosteric effector and the target enzyme; and (b) a reaction that possesses catalytic properties such that one effector can activate more than one target enzyme molecule. Note that signal amplification in cyclic covalent modification cascades is achieved without a requirement for tight binding between effector and converter enzyme. Because the binding rate for the effector is limited by the diffusion rate, a slow off-rate for the enzyme-bound effector would be required to achieve tight binding. However, tight binding would reduce the temporal efficiency of the control process. Furthermore, in order to achieve a catalytic effect in a simple allosteric model, the effector would first have to bind to the target enzyme, induce an active conformation, and then dissociate from the active enzyme which would have to remain in the active conformation. Such a mechanism has been implicated in the past (206).However, to remain regulatable by the effector, the active enzyme would have to be able to relax back to its inactive form. This kind
2. CYCLIC CASCADES AND METABOLIC REGULATION
37
of mechanism is thermodynamically unfavorable (207). Finally, without the presence of converter enzymes, the capacity for allosteric interactions would be reduced considerably. Nevertheless, the apparent cooperativity that provides the sensitivity observed in cyclic cascade systems can be accomplished by allosteric interaction alone, particularly if the enzyme involved contains multiple subunits. So, some of the advantages derived from cyclic cascade regulation cannot be achieved without invoking reversible covalent modification, while others can be accomplished but with less regulatory efficiency.
VI. Concluding Remarks The cyclic cascade model, derived mainly from data based upon detailed studies of glutamine synthetase, is applicable to all covalent interconvertible enzyme systems. It reveals many regulatory advantages such as signal amplification, rate amplification, sensitivity, and flexibility. This regulatory mechanism makes use of both covalent modification and allosteric interactions. By means of allosteric interactions with one or more enzymes, cyclic cascades can continuously monitor fluctuations in the concentrations of a multitude of metabolites and adjust the specific activities of the target enzymes according to biological requirements. Thus, they serve as biological integrators. Although a cyclic cascade modulates the specific activity of the interconvertible enzyme smoothly and continuously over a wide range of conditions, it can under extreme physiological situations serve as an ON-OFF switch to turn on or off an interconvertible enzyme. The energy for maintaining such an efficient regulatory mechanism is the consumption of ATP and other energy-rich donor molecules. However, the amount of ATP consumed is negligible compared to the total cellular ATP hydrolysis. In view of the unique properties of cyclic cascades, it is not surprising that a large number of key enzymes are regulated by this mechanism.
REFERENCES I . Krebs, E. G., and Beavo, J. A . (1979). Annu. Rev. Biochem. 48, 923-959. 2. Engstrom, L., Ekman, P., Humble, E., Ragnarsson, U., andZetterqvist, 0. (1984). “Methods in Enzymology,” Vol: 107, pp. 130-153. 3. Cooper, J . A , , Sefton, B. M . , and Hunter, T. (1983). “Methods in Enzymology,” Vol. 99, pp. 387-402. 4. Urushizaki, Y . , and Seifter, S. (1985). PNAS 82, 3091-3095. 5. MOSS,J . , and Vaughan, M. (1982). In “ADP-Ribosylation Reactions: Biology and Medicine” (0.Hayaishi and K . Ueda, eds.), pp. 637-645. Academic Press, New York. 6 . Ueda, K . , and Hayaishi, 0. (1984). “Methods in Enzymology,” Vol. 106, pp. 450-461. 7 . Bodley, J . W . , Van Ness, B. G . , and Howard, J . B. (1980). In “Novel ADP-Ribosylations of Regulatory Enzymes and Proteins” (M. Smulson and T. Sugimura, eds.), pp. 413-422. ElsevierlNorth-Holland, New York. 8. Chock, P. B . , Rhee, S. G . , and Stadtman, E. R. (1980). Annu. Rev. Biochem. 49, 813-843.
38
SHACTER, CHOCK, RHEE, AND STADTMAN
9. Bradley, M. K., Hudson, J., Villanueva, M. S . , and Livingston, D. M. (1984). PNAS 81, 6574-6578. 10. Paik, W. K. (1984). “Methods in Enzymology,” Vol. 106, pp. 265-268. 11. Paik, W. K., and Di Maria, P. (1984). “Methods in Enzymology,” Vol. 106, pp. 274-287. 12. Allfrey, V. G., Di Paola, E. A., and Sterner, R. (1984). “Methods in Enzymology,” Vol. 107, pp. 224-240. 13. Flavin, M., and Murofushi, H. (1984). “Methods in Enzymology,” Vol. 106, pp. 223-237. 14. Huttner, W. B. (1984). “Methods in Enzymology,” Vol. 107, pp. 200-223. 15. Sutherland, E. W., Jr., and Wosilait, W. D. (1955). Nature (London) 175, 169-170. 16. Fischer, E. H., and Krebs, E. G. (1958). JBC 231, 65-71. 17. Holland, R . , Hardie, D. G., Clegg, R. A., and Zammit, V. A. (1985). BJ 226, 139-145. 18. Kim, K.-H. (1983). Curr. Top. Cell. Regul. 22, 143-176. 19. Davis, C. G., Gordon, A. S . , and Diamond, I. (1982). PNAS 79, 3666-3670. 20. Huganir, R. L., Miles, K., and Greengard, P. (1984). PNAS 81, 6968-6972. 21. Walsh, M. P., Hinkins, S . , and Hartshorne, D. J. (1981). BBRC 102, 149-157. 22. Steinberg, R. A. (1980). PNAS 77, 910-914. 23. Field, F. J., Henning, B., and Mathur, S. N. (1984). BBA 802, 9-16. 24. Paxton, R., and Harris, R. A. (1982). JBC 257, 14433-14439. 25. Damuni, Z . , Caudwell, B., and Cohen, P. (1982). EJB 129, 57-65. 26. Wong, T. W., and Goldberg, A. R. (1984). JBC 259, 3127-3131. 27. Takahashi, T., Nakada, H., Okumura, T., Sawamura, T., and Tashiro, Y. (1985). BBRC 126, 1054-1060. 28. Jerebzoff, S . , and Jerebzoff-Quintin, S. (1984). FEBS Lett. 171, 67-71. 29. Ramakrishna, S . , Pucci, D. L., and Benjamin, W. B. (1981). JBC 256, 10213-10216. 30. Houston, B., and Nimmo. H. G . (1985). BBA 844, 193-199. 31. Sibley, D. R., Peters, J. R., Nambi, P., Caron, M. G., and Lefkowitz, R. J. (1984). JBC 259, 9742-9749. 32. Fujita, M., Taniguchi, N., Makita, A , , Ono, M., and Oikawa, K. (1985). BBRC 126, 818824. 33. Cook, K. G . , Bradford, A. P., Yeaman, S. J., Aitken, A,, Fearnley, I. M., and Walker, J. E. (1984). EJB 145, 587-591. 34. Michalak, M., Famulski, K., and Carafoli, G. (1984). JBC 259, 15540-15547. 35. Hartzell, H. C., and Glass, D. B. (1984). JBC 259, 15587-15596. 36. Hathaway, G. M., and Traugh, J. A. (1982). Curr. Top. Cell. Regul. 21, 101-127. 37. Erlichman, J., Rangel-Aldao, R., and Rosen, 0. M. (1983). “Methods in Enzymology,” Vol. 99, pp. 176-186. 38. Shoji, S . , Titani, K., Demaille, S. G., and Fischer, E. H. (1979). JBC 254, 6211-6214. 39. Lincoln, T. M., and Corbin, J. D. (1983). Adv. Cyclic Nucleotide Res. 15, 139-192. 40. Boyd, G. S., and Gorban, A. M. (1980). Mol. Aspecrs Cell. Regul. 1, 95-134. 41. Khoo, J. C., Mahoney, E. M., and Steinberg, D. (1981). JBC 256, 12659-12661. 42. Scallen, T. J., and Sanghvi, A. (1983). PNAS 80, 2477-2480. 43. Sharma, R. K., Wang, T. H., Wirch, E., and Wang, J. H. (1980). JBC 255, 5916-5923. 44. Sharma, R. K., and Wang, J. H. (1985). PNAS 82, 2603-2607. 45. Vilgrain, I . , Defaye, G., and Chambaz, E. M. (1984). BBRC 125, 554-561. 46. Hemming, H. C., Jr., Greengard, P., Tung, H. Y., and Cohen, P. (1984). Nature (London) 310, 503-505. 47. Durban, E., Roll, D., Beckner, G., and Busch, H. (1981). Cancer Res. 41, 537-545. 48. Ackerman, P., Glover, C. V. C., and Osheroff, N. (1985). !“AS 82, 3164-3168. 49. Cooper, J. A., Reiss, N., Schwartz, R. J., and Hunter, T. (1983). Narure (London) 302, 218223. 50. Cohen, S. (1983). “Methods in Enzymology,” Vol. 99, pp. 379-387. 51. Dekowski, S . A., Rybicki, A,, and Drickamer, K. (1983). JBC 258, 2750-2753.
2. CYCLIC CASCADES AND METABOLIC REGULATION
39
52. Jagus, R., Crouch, D., Konieczny, A., and Safer, B. (1982). Curr. Top. Cell. Regul. 21, 3564. 53. Ochoa, S., de Haro, C., Siekierka, J . , and Grosfeld, H. (1981). Curr. Top. Cell. Regul. 18, 421-435. 54. Petryshyn, R., Levin, D. H., and London, 1. M. (1983). “Methods in Enzymology,” Vol. 99, pp. 346-362. 55. Kramer, G., and Hardesty, B. (1981). Curr. Top. Cell. Regul. 20, 185-203. 56. Lengyel, P. (1982). Annu. Rev. Biochem. 51, 251-282. 57. Traugh, J. A., and Lundak, T. S. (1978). BBRC 83, 379-384. 58. Tuhackova, Z . , Ullrichova, J . , and Hradec, J. (1985). EJB 146, 161-166. 59. Engstrom, L., Edlund, B., Ragnarsson, U., Dahlqvist-Edberg, U., and Humble, E. (1980). BBRC 96, 1503-1507. 60. Kadowaki, T., Nishida, E., Kasuga, M., Akiyama, T., Takaku, F., Ishikawa, M., Sakai, H . , Kathuria, S., and Fujita-Yamaguchi, Y. (1985). BBRC 127, 493-500. 61. Ekman, P., and Dahlqvist-Edberg, U. (1981). BBA 662, 265-270. 62. Claus, T. H., El-Maghrabi, M. R., Regen, D. M., Stewart, H. B., McGrane, M., Kountz, P. D., Nyfeler, F., Pilkis, J., and Pilkis, S. J . (1984). Curr. Top. Cell. Regul. 23, 57-86. 63. Wise, B. C . , Guidotti, A , , and Costa, E. (1984). Adv. Cyclic Nucleotide Protein Phosphorylation Res. 17, 511-519. 64. Singh, V. B., and Moudgil, V. K. (1985). JBC 260, 3684-3690. 65. Hemmings, B. A. (1978). JBC 253, 5255-5258. 66. Nimmo, G. A , , and Nimmo, H. G. (1984). BJ 224, 101-108. 67. Krebs, E. G. (1981). Curr. Top. Cell. Regul. 18, 401-419. 68. Roach, P. J . (1981). Curr. Top. Cell Regul. 20, 45-105. 69. Woodgett, J. R., and Cohen, P. (1984). EJB 143, 267-272. 70. Akatsuka, A , , Singh, T. J., Nakabayashi, H., Lin, M. C., and Huang, K. P. (1985). JBC 260, 3239-3242. 71. Detre, J . A , , Naim, A. C . , Aswad, D. W., and Greengard, P. (1984). J . Neurosci. 4, 28432849. 72. Zwiller, J . , Revel, M. O., and Malviya, A. N. (1985). JBC 260, 1350-1353. 73. Taylor, S. S. (1982). JBC 257, 6056-6063. 74. Walton, G . M., Spiess, J., and Gill, G. N. (1982). JBC 257, 4661-4668. 75. Langan, T. A., Zeilig, C., and Leichtling, B. (1981). In “Protein Phosphorylation” (0.M. Rosen and E. G . Krebs, eds.), pp. 1039-1052. Cold Spring Harbor Lab., Cold Spring Harbor, New York. 76. Feurstein, N., Monos, D. S., and Cooper, H. L. (1985). BBRC 126, 206-213. 77. Belfrage, P., Fredrikson, G . , Olsson, H., and Stralfors, P. (1984). Adv. Cyclic Nucleoride Protein Phosphorylation Res. 17, 35 1-359. 78. Steinberg, D. (1976). Adv. Cyclic Nucleotide Res. 7, 157-198. 79. Ingebritsen, T. S., and Gibson, D. M. (1980). Mol Aspects Cell. Regul. 1, 63-93. 80. Beg, Z. H., Stonik, J . A , , and Brewer, H. B., Jr. (1985). JBC 260, 1682-1687. 81. Ingebritsen, T. S. (1983). Biochem. Soc. Trans. 11, 644-646. 82. Beg, Z. H., Stonik, J. A., and Brewer, H. B., Jr. (1984). BBRC 119, 488-498. 83. Swamp, G . , Dasgupta, J . D . , and Garbers, D. L. (1984). Adv. Enzyme Regul. 22, 267-288. 84. Cobb, M. H., and Rosen, 0. M. (1984). BBA 738, 1-8. 85. Kasuga, M., Karlsson, F. A , , and Kahn, C. R. (1982). Science 215, 185-187. 86. Zick, Y., Whittaker, J . , and Roth, J. (1983). JBC 258, 3431-3434. 87. Shackelford, D. A., and Trowbridge, I . S. (1984). JBC 259, 11706-1 1712. 88. Leonard, W. J., Depper, J. M., Kronke, M . , Robb, R. J., Waldmann, T. A , , and Greene, W. C. (1985). JBC 260, 1872-1880. 89. Garland, D., and Nimmo, H. G. (1984). FEBS Lett. 165, 259-264. 90. Gibbs, P. E., Zouzias, D. C., and Freedberg, 1. M. (1985). BBA 824, 247-255.
40
SHACTER, CHOCK, RHEE, AND STADTMAN
91. Theurkauf, W. G., and Vallee, R. B. (1982). JBC 257, 3284-3290. 92. Turner, R. S., Chou, C. H., Mazzei, G. J., Dembure, P., and Kue, J. F. (1984). J . Neurochem. 43, 1257-1264. 93. Hasilik, A., Pohlmann, R., Olsen, R. L., and von Figura, K. (1984). EMBO J. 3,2671-2676. 94. Albanesi, J. P., Fujisaki, H., and Korn, E. D. (1984). JBC 259, 14184-14189. 95. England, P. J. (1984). J. Mol. Cell. Curdiol. 16, 591-595. 96. Walsh, M. P., Hinkins, S., Dabrowska, R., and Hartshorne, D. J . (1983). “Methods in Enzymology,” Vol. 99, pp. 279-288. 97. Westwood, S. A,, Hudlicka, 0.. and Perry, S. V. (1984). BJ 218, 841-847. 98. Adelstein, R. S. (1983). J . Clin. Invest. 72, 1863-1866. 99. Costa, M. R., Casnellie, J. E., and Catterall, W. A. (1982). JBC 257, 7918-7921. 100. Mardh, S. (1983). Curr. Top. Membr. Trunsp. 19, 999-1004. 101. Atmar, V. J., and Kuehn, G. D. (1983). “Methods in Enzymology,” Vol. 99, pp. 366-372. 102. Golf, S. W., and Graef, V. (1984). J. Clin. Chem. Clin. Biochem. 22, 705-709. 103. Donlon, J., and Kaufman, S. (1978). JBC 253, 6657-6659. 104. Wretborn, M., Humble, E., Ragnarsson, U., and Engstrom, L. (1980). BBRC 93, 403-408. 105. Soling, H.-D., and Brand, I. A. (1981). Curr. Top. CeN. Regul. 20, 107-138. 106. Le Peuch, C. J., Haiech, J . , and Demaille, J . G. (1979). Biochemistry 18, 5150-5157. 107. Villalba, M., Varela, I., Mdrida, I., Pajares, M. A., Martinez del Pozo, A , , and Mato, J. M. (1985). BBA 847, 273-279. 108. Cohen, P. (1982). Nature (London) 296, 613-620. 109. Resink, T. S., Hemmings, B. A., Tung, H. Y. L., and Cohen, P. (1983). EJB 133,455-461. 110. Jurgenson, S., Shacter, E., Huang, C. Y., Chock, P. B., Yang, S.-D. Vandenheede, J. R., and Merlevede, W. (1984). JBC 259, 5864-5870. 1 11. Villa-Moruzzi, E., Ballou. L. M., and Fischer, E. H. (1984). JBC 259, 5857-5863. 112. Singh, T. J . , Akatsuka, A., and Huang, K. P. (1984). JBC 259, 12857-12864. 113. Katbh, N., and Kubo, S. (1983). BBA 760, 61-68. 114. Stiles, C. D. (1983). Cell 33, 653-655. 115. Jacob, S. T., and Rose, K . M. (1984). Adv. Enzyme Regul. 22, 485-497. 116. Stetler, D. A., Seidel, B. L., and Jacob, S. T. (1984). JBC 259, 14481-14485. 117. Schaffhausen, B. S., and Benjamin, T. L. (1979). Cell 18, 935-946. 118. Oetting, W. S., Tuazon, P. T., Traugh, J. A., and Walker, A. M. (1986). JBC 261, 16491652. 119. Qi,D. F., Turner, R. S., and Kuo, J. F. (1984). J. Neurochem. 42, 458-465. 120. Reed, L. J . (1981). Curr. Top. Cell. Regul. 18, 95-106. 121. Pettit, F. H., Yeaman, S. J., and Reed, L. J. (1983). “Methods in Enzymology,” Vol. 99, pp. 331-336. 122. Engstrom, L. (1978). Curr. Top. Cell. Regul. 13, 29-51. 123. Burnell, J. N., and Hatch, M. D. (1985). TrendsBiochem. Sci. 10, 288-291. 124. Lee, S. G., Miceli, M. V., Jungmann, R. A., and Hung, P. P. (1975). PNAS 72,2945-2949. 125. Shichi, H., Somers, R. L., and Yamamoto, K. (1983). “Methods in Enzymology,” Vol. 99, pp. 362-366. 126. Cobb, M. H., and Rosen, 0. M. (1983). JBC 258, 12472-12481. 127. Trevillyan, J. M., Perisic, O., Traugh, J. A., and Byus, C. V. (1985). JBCMO, 3041-3044. 128. Rose, K. M., Duceman, B. W., Stetler, D., and Jacob, S. T. (1983). Adv. EnzymeRegul. 21, 307-320. 129. Nestler, E. J., Walaas, I., and Greengard, P. (1984). Science 225, 1357-1364. 130. Yamamoto, H., Fukunaga, K., Goto, S . , Tanaka, E., and Miyamoto, E. (1985). J. Neurochem. 44, 759-768. 131. Perry, S . V. (1979). Biochem. Soc. Trans. 7, 593-617. 132. Card. D. L.. and Kirschncr. M. W. ,1985) I Cell Bio! 100 769-774.
2.
CYCLIC CASCADES AND METABOLIC REGULATION
41
133. Albert, K. A,, Helmer-Matyjek, E., Nairn, A. C., Muller, T. H., Haycock, J. W., Greene, L. A,, Goldstein, M., and Greengard, P. (1984). PNAS 81, 7713-7717. 134. Cahill, A. L., and Perlman, R. L. (1984). PNAS 81, 7243-7247. 135. Werth, D. K., Niedel, J. E., and Pastan, 1. (1983). JBC 258, 11423- 11426. 136. Kun, E. Romaschin, A. D., Claisdell, R. J., and Jackowski, G. (1981). In “Metabolic Interconversion of Enzymes” (H. Holzer, ed.), pp. 280-293. Springer-Verlag, Berlin and
New York. 137. Moss, J., and Vaughan, M. (1984). “Methods in Enzymology,” Vol. 106, pp. 411-418. 138. Nomura, H., Tanigawa, Y., Kitamura, A , , Kawakami, K., and Shimoyama, M. (1981). BBRC 98, 806-814. 139. Creissen, D., and Shall, S. (1982). Nature 296, 271-272. 140. Yoshihara, K., Itaya, A,, Tanaka, Y., Ohashi, Y., Ito, K., Teraoka, H., Tsukada, K., Matsukage, A,, and Kamiya, T. (1985). EBRC 128, 61-67. 141. Ferro, A. M., and Olivera, B. M. (1984). JBC 259, 547-554. 142. Van Ness, B. G., Howard, J. B., and Bodley, J. W. (1980). JBC 255, 717-720. 143. Moss, J., Watkins, P. A , , Stanley, S. S . , Purnell, M. R., and Kidwell, W. R. (1984). JBC 259, 5100-5104. 144. Poirier, G. G., Niedergang, C., Champagne, M., Mazen, A., and Mandel, P. (1982). EJB 127, 437-442. 145. Ueda, K., Ogata, N., Kawaichi, M., Inada, S., and Hayaishi, 0. (1982). Curr. Top. Cell. Regul. 21, 175-187. 146. Tanaka, Y., Yoshihara, K., Ohashi, Y., Itaya, A,, Nakano, T., Ito, K., and Kamiya, T. (1985). Anal. Biochem. 145, 137-143. 147. Pope, M. R., Murrell, S. A,, and Ludden, P. W. (1985). PNAS82, 3173-3177. 148. Tsuchiya, M., Tanigawa, Y., Ushiroyama, T., Matsunra, R., and Shimoyama, M. (1985). EJB 147, 33-40. 149. Wong, N. C. W., Poirier, G. G., and Dixon, G. H. (1977). EJB 77, 11-21. 150. Goff, C. G. (1984). “Methods in Enzymology,” Vol. 106, pp. 418-429. 151. Goldman, N., Brown, M., and Khoury, G. (1981). Cell 24, 567-572. 152. Abood, M. E., Hurley, J. B., Pappone, M. C., Bourne, H. R., and Stryer, L. (1982). JBC 257, 10540-10543. 153. Niles, E. G., and Westhead, E. W. (1973). Biochemistry 12, 1723-1729. 154. Kim, S. (1984). “Methods in Enzymology, Vol. 106, pp. 295-309. 155. Stock, I . B., Clarke, S., and Koshland, D. E., Jr. (1984). “Methods in Enzymology,” Vol. 106, pp. 310-321. 156. Huszar, G. (1984). “Methods in Enzymology,” Vol. 106, pp. 287-295. 157. K q , D. R. (1983). JBC 258, 12745-12748. 158. Liu, M.-C., and Lipmann, F. (1984). PNAS 81, 3695-3698. 159. Baeuerle, P. A,, and Huttner, W. B. (1984). EMBO J. 3, 2209-2215. 160. Garland, D., and Russell, P. (1985). PNAS 82, 653-657. 161. Stadtman, E. R., and Chock, P. B. (1978). Curr. Top. Cell. Regul. 13, 53-95. 162. Johnston, M. I., and Torrence, P. F. (1984). In “Interferon, 3: Mechanisms of Production and Action” (R. M. Friedman, ed.), pp. 189-298. Elsevier, Amsterdam. 163. Sugimura, T., and Miwa, M. (1983). Carcinogenesis (London) 4, 1503-1506. 164. Sefton, B. M., and Hunter, T. (1984). Adv. Cyclic Nuckotide Protein Phosphorylation Res. 18, 195-226. 165. Collett, M. S . , and Erikson, R. L. (1978). PNAS 75, 2021-2024. 166. Levinson, A. D., Oppermann, H., Levintow, L., Varmus, H. E.. and Bishop, J. M. (1978). Cell 15, 561-572. 167. Tanigawa, Y.,Tsuchiya, M., Imai, Y., and Shimoyama, M. (1983). BBRC 113, 135-141. 168 Sols. A . (1981). Curr. Top. CeN. Renu/. 19, 77-101.
42
SHACTER, CHOCK, RHEE, AND STADTMAN
Parker, R. A., Miller, S. J., and Gibson, D. M. (1984). BBRC 125, 629-635. Bergstrom, G., Ekman, P., Humble, E., and Engsuom, L. (1978). BEA 532, 259-267. Hemmings, B. A. (1980). FEBS Lett. 122, 297-302. Muller, D., and Holzer, H. (1981). BBRC 103, 926-933. Toyo-oka, T. (1982). BBRC 107, 44-50. Hershko, A., and Ciechanover, A. (1982). Annu. Rev. Biochern. 51, 335-364. MacFarlane, R. G. (1964). Nature (London) 202, 498-499. Neurath, H., and Walsh, K. A. (1976). In “Proteolysis and Physiological Regulation” (E. W. Ribbons and K. Brew, eds.), pp. 29-40. Academic Press, New York. 177. Davie, E. W., and Fujikawa, K. (1975). Annu. Rev. Biochem. 44, 798-829. 178. Miiller-Eberhard, H. J . (1975). Annu. Rev. Biochem. 44, 697-724. 179. Kingdon, H. S . , Shapiro, B. M., and Stadtman, E. R. (1967). PNAS 58, 1703-1710. 180. Wulff, K., Mecke, D., and Holzer, H. (1967). BBRC 28, 740-745. 181. Stadtman, E. R., and Chock, P. B. (1977). PNAS 74, 2761-2765. 182. Brown, M. S . , Segal, A., and Stadtman, E. R. (1974). ABB 161, 319-327. 183. Pettit, F. H., Pelley, J. W., and Reed, L. 1. (1975). BBRC 65, 575-582. 184. Chock, P. B., and Stadtman, E. R. (1977). PNAS 74, 2766-2770. 185. Chock, P. B., and Stadtman, E. R. (1979). In “Modulation of Protein Function” (D. E. Atkinson and C. F. Fox, eds.), pp. 185-202. Academic Press, New York. 186. Stadtman, E. R., and Chock, P. B. (1979). I n “The Neurosciences: Fourth Study Program” (F. 0. Schmitt, ed.), pp. 801-817. MIT Press, Cambridge, Massachusetts. 187. Garcia, E., and Rhee, S. G. (1983). JBC 258, 2246-2253. 188. Caban, C. E., and Ginsburg, A. (1976). Biochemistry 15, 1569-1580. 189. Rhee, S. G., Park, R., Chock, P. B., and Stadtman, E. R. (1978). PNAS 75, 3138-3142. 190. La Porte, D. C., and Koshland, D. E., Jr. (1982). Nature (London) 300, 458-460. 191. El-Maghrahi, M. R., Claus, T. H., Pilkis, J., Fox, E., and Pilkis, S. J. (1982). JBC 257, 7603-7607. 192. Van Schaftingen, E., Davies, D. R., and Hers, H. G. (1982). EJE 142, 143-149. 193. Jurgensen, S. R., Chock, P. B., Taylor, S. S., Vandenheede, J. R., and Merlevede, W. (1985). FP 44, 1052. 194. Shacter-Noiman, E., Chock, P. B., and Stadtman, E. R. (1983). Philos. Trans. R . SOC. London 302, 157-166. 195. Shacter, E., Chock, P. B., and Stadtman, E. R. (1984). JBC 259, 12252-12259. 196. Goldbetter, A., and Koshland, D. E., Jr. (1981). PNAS 78, 6840-6844. 197. Hucho, F., Randell, D. D., Roche, T. E., Burgett, M. W., Pelley, J. W., and Reed, L. J. (1972). ABB 151, 328-340. 198. Reed, L. J. (1969). Curr. Top. Cell. Regul. 1, 233-251. 199. Meyer, F., Heilmeyer, L. M. G., Jr., Haschke, R. H., and Fischer, E. H. (1970). JBC 245, 6642-6648. 200. Danforth, W. H., Helmreich, E., and Cori, C. F. (1962). PNAS 48, 1191-1 199. 201. Shacter-Noiman, E., and Chock, P. B. (1983). JBC 258, 4214-4219. 202. Titanji, V. P. K., Ragnarsson, U . , Humble, E., and Zetterqvist, 0. (1980). JBC 255, 1133911343. 203. Rhee, S. G., Chock. P. B., and Stadtman, E. R. (1985). In “The Enzymology of PostTranslational Modification of Proteins” (R. Freedman, ed.), Vol. 2, pp. 273-297. Academic Press, New York. 204. Mura, U., Chock, P. B., and Stadtman, E. R. (1981). JBC 256, 13022-13029. 205. Shacter, E., Chock, P. B., and Stadtman, E. R. (1984). JBC 259, 12260-12264. 206. Hatfield, G. W., and Bums, R. 0. (1970). Science 167, 75-76. 207. Astumian, D., and Chock, P. B. (1985). Unpublished results. 169. 170. 171. 172. 173. 174. 175. 176.
Cyclic NucleotideDependent Protein Kinases STEPHEN J. BEEBE JACKIE D. CORBIN Howard Hughes Medical Institute Department of Molecular Physiology and Biophysics Vanderbilt University Nashville, Tennessee 37232
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. Purification ............................. A. Cyclic AMP-Dependent Protein Kinase . . . B. Cyclic GMP-Dependent Protein Kinase ........................... 111. Characterization and Physical Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Cyclic AMP-Dependent Protein Kinases B. Cyclic GMP-Dependent Protein Kinase ........................... C. Evolutionary Relationships among Cyclic AMP-Binding Proteins and Protein Kinases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IV. Mechanism of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Mechanism of Regulatory Subunit Action B. Mechanism of Catalytic Subunit Action .......................... V. Biological Role of Protein Kinases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Criteria to Establish Biological Role . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B. Distribution of Isozymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C. Selective Activation of Cyclic AMP-Dependent Protein Kinase Isozymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D. Use of Cyclic Nucleotide Analogs in Intact Cells . . . . . . . . . . . . . . . . . . . E. The Role of Cyclic AMP and the Cyclic AMP-Dependent Protein Kinase Isozymes in the Cell Cycle, Proliferation, and Differentiation F. Variations in the Regulatory Subunit-Catalytic Subunit Ratio
48
49 49 59 60 64
64 67 69 69 71 73 80
85
93
43 THE ENZYMES,Vol. XVII Copyright 0 1986 by Academic Press, Inc. All rights of reproduction in any form reserved
44
STEPHEN J. BEEBE AND JACKIE D. CORBIN G . Regulation of the Amount of Certain Proteins by Cyclic AMPDependent Protein Kinases ..................................... References .....................................................
1.
96 100
Introduction
Since the first report of a protein kinase in liver by Burnett and Kennedy (I) and the classical work on interconvertible forms of enzymes involved in glycogen metabolism, as well as investigations of protein kinases reported by Rabinowitz (2), phosphorylation and dephosphorylation reactions have been the most intensely studied mechanisms of posttranslational modification. Many different protein kinases have since been identified and studied, but the cyclic nucleotide-dependent protein kinases have probably received the most attention. The primary impetus for research in this area was the Nobel Prize-winning work of Sutherland and co-workers who developed the concept of cAMP as an intracellular second messenger of hormone action (3, 4), and the discovery of the CAMP-dependentprotein kinase (5). It was eventually recognized that in mammalian cells the CAMP-dependent protein kinase is the major, if not the only, intracellular receptor for CAMP.The activation-inactivation reaction is indicated by the following equation (6):
+
R2Cz 4 CAMP (inactive)
R ~ ( c A M P )+~ 2C (active)
In the holoenzyme form (R2C2), the catalytic subunit (C) is inhibited by the regulatory subunit (R). The CAMP-dependent protein kinase is represented by two different major types of isozymes which are operationally defined by the salt gradient elution behavior from DEAE-cellulose. Type I elutes as NaCl concentrations less than 0.1 M and type I1 elutes at concentrations greater than 0.1 M (7). Both holoenzymes are tetramers composed of dimeric regulatory subunits with four CAMP-bindingsites (two sites/monomeric chain) (6-9) and two monomeric catalytic subunits. When cAMP binds to the regulatory subunit of protein kinase the equilibrium shifts to the right and the catalytic subunit is released from the inhibition imposed by the regulatory subunit. It is the free, active catalytic subunit that mediates protein phosphorylation, which is established to be the primary, if not the only, mechanism of cAMP action in mammals. When cAMP is hydrolyzed by cAMP phosphodiesterases (see Chapter 2), the equilibrium shifts back to the left, the catalytic subunit reassociates with the regulatory subunit and phosphotransferase activity is terminated (IO-I5). In order for the unmodified form of the protein substrate to be regenerated, a phosphoprotein phosphatase catalyzes a dephosphorylation reaction (see Chapter 8). The steadystate, phosphorylation-dephosphorylation equilibrium between an active and
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
45
inactive form of a protein is dynamically regulated by protein kinases, phosphoprotein phosphatases, and their respective effectors. This constitutes a cyclic cascade system and can provide the cell with an efficient and sensitive control mechanism that has potential for amplification and cooperativity of response (16-20, 20u). The ubiquity of the cyclic nucleotide protein kinases in nature and the central role of cyclic nucleotides in eukaryotic metabolic regulation makes the involvement of cyclic nucleotides as effectors of this system of particular interest and importance. The cGMP-dependent protein kinase, which has received less attention, may also play a role in the phosphorylation-dephosphorylation control of cellular events. It has a different mechanism of activation-inactivation as indicated by the following equation (21): E2
+ 4 cGMP (inactive)
E2 . c G M P ~
(active)
The cGMP kinase is a dimer with each monomeric chain containing both a regulatory, cGMP-binding component and a catalytic component (21-24). There are four cGMP-binding sites per enzyme dimer or two sites in each of the two regulatory components. When cGMP binds to the regulatory domain of the enzyme, the equilibrium shifts to the right and the active catalytic domain carries out the phosphorylation reactions. No separation of subunits occurs (see Ref. 29) as is the case for activation of the CAMP-dependent protein kinase, where the regulatory and catalytic subunits physically separate. When cGMP dissociates from the active form of the enzyme and is hydrolyzed by cGMP phospbdiesterase, the equilibrium shifts back to the left and the inactive conformation of the enzyme is reestablished. The reader is referred to several reviews (5, 10-15, 25-40) and the monograph edited by Rosen and Krebs (41), which are related to cyclic nucleotidedependent protein kinases and their role in phosphorylation-dephosphorylation mechanisms. The aim of this chapter is to review the characteristics and functions of cyclic nucleotide-dependent protein kinases. A brief review of methods for purifying the enzyme is presented. The characteristics of the enzymes are described as they relate to functional aspects of the isozymes, to evolutionary relationships and homologies among protein kinases and other cyclic nucleotide binding proteins, and to the mechanisms of catalytic and regulatory subunit action. The regulation of enzyme activity by cyclic nucleotides and other effectors is reviewed and the role the enzymes play in cellular function is assessed. The role of these kinases in the short-term control of cellular function through the regulation of enzyme activities and the long-term control of processes such as transcription, protein induction and cell growth, and differentiation are highlighted. In addition, several methods used for deducing the biological role of the kinases are compared and critiqued.
46
STEPHEN J. BEEBE AND JACKIE D. CORBlN
II. Purification A.
CYCLICAMP-DEPENDENT PROTEINKINASE
1. Regulatory Subunit Before the development of affinity chromatography the regulatory subunit of the CAMP-dependent protein kinase could be obtained by purification of the respective holoenzymes followed by subunit dissociation. Since then the regulatory subunit can be more easily purified to homogeneity by affinity chromatography using immobilized cAMP analogs ( 4 2 4 5 ) . Both type I and type I1 regulatory subunits can be purified using this approach, but it is often advantageous to use different affinity ligands for each (46). The regulatory subunits can be eluted from affinity columns using 8 M urea, followed by urea removal and renaturation. Alternatively, they can be specifically eluted by CAMP. The urea elution method allows the recovery of a relatively CAMP-free regulatory subunit but it usually has altered properties compared to the subunit prepared by cAMP elution (47). Even though elution with cAMP alleviates some anomalies, removal of bound cAMP from the regulatory subunit without deleterious effects is very difficult (6). The type I regulatory subunit binds very effectively to N6-(2-aminoethy1)amino-CAMP-Sepharose(44) and is readily purified to homogeneity by specific cAMP elution (44,46).The type I subunit is not readily eluted from 8-(6arninohexy1)amino-CAMP-Sepharose using cAMP but can be eluted using 8 M urea (46). This subunit has also been purified using a N6-(6-aminohexyl)-cAMP derivative attached to Sepharose (45). The subunit is not eluted from this ligand using 2.5 M salt or 0.5 mMcAMP but is eluted with 0.5 mM cAMP in the presence of a low concentration of catalytic subunit. The type I1 regulatory subunit has been prepared to homogeneity by Corbin et al. (6, 46) by using a cAMP elution from 8-(6-aminohexyl)amino-cAMPSepharose. The type I1 subunit has also been purified using a cAMP or cGMP (0.1 mM) elution from N6-aminoethyl-cAMP-Sepharose(48). Since cGMP binds weakly and is thus more easily removed, it has the advantage of allowing the preparation of a relatively cyclic nucleotide-free regulatory subunit. In order to obtain a nondenatured, CAMP-free regulatory subunit, Seville and Holbrook (49) used a method where cGMP is exchanged for cAMP while the subunit is bound to DEAE-cellulose. The subunit is then eluted with salt and the weakly bound cGMP is removed by washing and dialysis. In general, the type I1 regulatory subunit is eluted from cyclic nucleotide affinity columns at lower cAMP concentrations than is the type I subunit. For example, the elution of type I1 subunit from 8-(6-aminohexyl)amino-cAMP-Sepharose is carried out with 10 mM cAMP (6)but elution of type I requires urea denaturation (46). While the type I1 subunit
.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
47
is eluted from N6-aminoethyl-CAMP-Sepharoseat 0.1 mM cAMP or 0.1 mM cGMP, the type 1 subunit is eluted with 30 mM cAMP (48).
2. Catalytic Subunit The catalytic subunit of the CAMP-dependent protein kinase has been purified from a large number of tissues including bovine heart; rabbit, rat, and porcine skeletal muscle; bovine and rabbit liver [see Ref. (38) for review]; rabbit kidney and porcine stomach mucosa (50);rat adipose tissue (51); and porcine kidney (52). The most efficient purification procedures are based on the facts that the holoenzyme and regulatory subunit have different ion exchange properties from the catalytic subunit, and that the subunits specifically dissociate in the presence of cAMP or cAMP analogs (50).Two different approaches have been used to purify the catalytic subunit to homogeneity. A partially purified preparation of type I and/or type I1 holoenzyme is treated with cAMP before chromatography on carboxymethylcellulosewhich binds the catalytic subunit but not the regulatory subunit (53,54). Alternatively the holoenzyme can be treated with cAMP while it is bound to DEAE-cellulose which does not retain the dissociated catalytic subunit (50).Subsequent purification or concentration of catalytic subunit may be necessary on hydroxylapatite (50, 5 3 , carboxymethylcellulose (53), Sephadex G-100 (52, 54), or Blue Dextran (52). 3 . Holoenzymes The holoenzymes are usually obtained in pure form by first purifying the regulatory and catalytic subunits by the procedures previously described. These subunits are then combined. It is not clear, however, whether or not in all cases the holoenzyme produced by this recombination resembles in all respects the native holoenzymes. Although the methods are more difficult, it may be necessary for some studies to purify the holoenzymes as such. The partial purification of the CAMP-dependent protein kinase was first reported by Walsh et al. (56). Since then the holoenzymes have been purified to homogeneity in a number of laboratories. The type I isozyme has been purified from rabbit (53,57-59) and porcine skeletal muscle (60, 61) and the type I1 holoenzyme from bovine heart (62-64). The rabbit skeletal muscle type I and the bovine heart type I1 are often taken as the prototype isozymes. These tissues are ideal for purifying the respective enzymes since they contain predominately one isozyme. Conventional purification steps have been used to purify the enzymes. The isozymes are first separated on DEAE-cellulose based on their different salt elution (7). C,-Aminoalkyl-agarose chromatography has also been used to separate the isozymes (65).The procedures for most homogeneous preparations of either holoenzyme have successfully employed DEAE-cellulose chromatography, ammonium sulfate fractionation, alumina C, chromatography, and gel filtration techniques. Beavo et al. (53, 54) and Hofmann et al. (57) used negative chro-
48
STEPHEN J. BEEBE AND JACKIE D. CORBIN
matography by batch adsorption to remove some contaminating proteins on carboxymethylcellulose. Hydroxylapatite has also been used (58, 59, 61-64), but Rubin et al. (63) found that in their procedure, rechromatography on DEAEcellulose could substitute for the hydroxylapatite step. Hofmann et al. (57) used histone IIA-Sepharose to purify the bovine heart type I1 kinase, and Taylor et al. (60, 61) used 8-(6-aminohexyl)amino-ATP-Sepharose and 3-aminopyridineNAD -Sepharose affinity chromatography in addition to isoelectric focusing to purify porcine muscle type I holoenzyme to homogeneity. Hydrophobic chromatography on hexyl-Sepharose (58) or phenyl-Sepharose (64) has also been used as very effective purification steps for type I and type I1 isozymes, respectively. Cobb and Corbin (64) have successfully used Bio-Rad 1EX545-DEAE and Bio-sil TSK-250 high-performance liquid chromatography in addition to conventional procedures to purify the type II holoenzyme from bovine heart to homogeneity. These homogeneous preparations are generally purified 10003000-fold depending on the tissue and the isozyme. +
B.
KINASE CYCLICGMP-DEPENDENT PROTEIN
The cyclic GMP-dependent protein kinase has been purified to homogeneity from soluble fractions of bovine lung by Lincoln et al. (66), Gill et al. (22), Corbin and Doskeland ( 2 4 , and MacKenzie (24) and from bovine heart by Flockerzi et al. (67). A unique form of the enzyme has also been highly purified from intestinal brushborder membranes by de Jonge (68). The purification procedures generally utilize DEAE-cellulose chromatography, ammonium sulfate precipitation, and cyclic nucleotide affinity Chromatography. All of the cyclic nucleotide-dependent protein kinases bind to DEAE-cellulose, and this is a convenient early step in the purification procedure. The cGMP-dependent protein kinase from bovine lung binds more tightly to DEAEcellulose than does the type I CAMP-dependent protein kinase and less tightly than does the type I1 isozyme of the cAMP protein kinase (22, 66), and is separated from the latter enzymes using NaCl(Z2, 60) or ammonium sulfate (22, 66, 67, 69, 70). Corbin and Doskeland (21) also used a procedure through the DEAE-cellulose step designed for purification of guanylate cyclase (71). Triethanolamine (pH 7.5) elutes the cGMP-dependent protein kinase slightly before it elutes the cyclase on this column. At least three different immobilized cyclic nucleotide analogs have been used to obtain pure preparations of the cGMP kinase. Sepharose-bound 8-(2-aminoethyl)thio-cGMP was first used by Lincoln et al. (66) and 8-(2-aminoethyl)aminocAMP by Gill et al. (22) to purify the enzyme to homogeneity. Corbin and Doskeland (21) and MacKenzie (24) used 8-(6-aminohexyl)amino-cAMP-Sepharoseto purify the cGMP kinase in their studies. When N6-[(6-aminohexyl)carbamoylmethyl]-cAMPwas used to purify the enzyme, it was not homogeneous (24). Since the CAMP-dependent protein
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
49
kinases also bind to these affinity resins, preliminary purification on DEAEcellulose is important. Additionally, specific elution of the enzyme from the affinity columns with cGMP allows for a high degree of purification. If trace contamination by regulatory subunit is still present at this stage, it can be removed by sucrose gradient centrifugation ( 2 1 ) . The purification of the cGMPdependent protein kinase from intestinal brushborder membranes requires a modified procedure (68). Following the extraction of the enzyme from the membranes with detergent and high salt concentration, it is further purified on 8-(2aminoethy1)-amino-CAMP-Sepharose.Except for the presence of 0.1% Triton and high salt concentration during all steps of affinity chromatography, the procedure is similar to the ones for purification of the lung enzyme. Several factors can be manipulated to maximize or minimize binding of these cyclic nucleotide protein kinases to affinity supports (48, 72).In addition to the relative affinities for binding, other factors such as steric hindrance, density of substitution, and availability of ligand can be of potential importance.
111.
Characterization and Physical Properties
A.
CYCLICAMP-DEPENDENT PROTEIN KINASES
There are two major classes of CAMP-dependent protein kinase isozymes designated type I and type I1 (58). Each isozyme has a tetrameric structure consisting of two monomeric catalytic subunits and a dimeric regulatory subunit (65-68). The catalytic subunits from both isozymes are indistinguishable by a large number of criteria. They have similar chromatographic, chemical, physical, immunological, and catalytic properties, and can reassociate with both type I and type I1 regulatory subunits ( 1 1 , 12, 14, 35, 38, 55). However, several investigators have found two or three different froms of catalytic subunit with different isoelectric points from both type I and type I1 isozymes (55, 73-78). Sugden et al. identified at least three forms of the bovine liver catalytic subunit with pl values of 6.72,7.04, and 7.35 (55). Yamamura et al. (74-76) found that the rabbit skeletal muscle type I and the rat liver type I1 catalytic subunits each contained two forms with isoelectric points of 7.4 and 8.2. These forms have similar heat stability, K,,,for ATP, and rate of phosphorylation of several proteins; they phosphorylate the same serine and threonine residues in histone, protamine, glycogen synthase, and phosphorylase (74- 76).The significance of these different isoelectric forms of the catalytic subunit is not clearly understood. It has been discovered that there are at least two bovine genes coding for the catalytic subunit. One of these gene codes for a protein of 351 amino acids that is 98% homologous with the bovine heart catalytic subunit (78a).The second gene codes for a protein closely related to the bovine heart catalytic subunit. The
50
STEPHEN 1. BEEBE AND JACKIE D. CORBIN
nucleotide sequences of the two genes are 85-93% homologous, with differences clustered in the sequences coding for the amino terminal portion of the molecules, believed to be the ATP binding site (79), in the carboxy terminal region of the protein, and in the 3’-untranslatedportion of the gene (S. McKnight and R. Maurer, personal communication). It is presently unclear whether the products of these two genes are related to the different isoelectric forms of the catalytic subunit discussed above. However, this is possible since the two genes code for proteins which would be expected to have different isoelectric points and, consequently, different tryptic peptides. It is also possible that the second gene could be related to the “mute” catalytic subunit like the one isolated and characterized from rat skeletal muscle by Reed et al. (786).The “mute” subunit is released from the regulatory subunit by cAMP but must be activated by a heatand acid-stable modulator. Some evidence suggests that these two genes may have different tissue distributions. For example, the mRNA for the second gene appears to be more abundant in brain (S. McKnight and R. Mauer, personal communications). Although there is presently no evidence to correlate the association of either of these catalytic subunit gene products with one or the other regulatory subunits, it is known that the type IIB (85) or neural type I1 regulatory subunit (125, 126) is also abundant in the brain. These recent developments suggest a potential for greater specificity of protein kinase action, and firm conclusions regarding possible functional differences should be forthcoming. Future work will undoubtedly focus on the expression of these two genes and possibly others, so that their protein products can be characterized. The amino acid sequence of the catalytic subunit from type I1 bovine heart has been determined to consist of 350 residues (79),giving it a molecular weight of 40,862, including a myristyl amino terminal blocking group and phosphates at threonine-197 and serine-338. This molecular weight is in fairly good agreement with a molecular weight of 39,000-42,000 determined by SDS-gel electrophoresis, sedimentation-equilibrium centrifugation, amino acid analysis, or calculated from the Stokes radius (2.7 nm) and sedimentation coefficient = 3.6) (38).The protein has a frictional ratio of 1.2 and an axial ratio of 4.5, indicating a globular, symmetrical shape (38, 55). At present it is known that there is at least one gene for the type I regulatory subunit and at least two genes for the type I1 regulatory subunit. The type I subunit has been cloned from bovine testes (78a),and one of the type I1 subunits has been cloned from rat ovary. The gene for the type I regulatory subunit codes for a protein with the same amino acid sequence as the rabbit skeletal muscle type I. The DNA for the rat ovary type I1 subunit codes for a M, = 52,000 protein, which is distinct from the bovine heart type I1 subunit ( 7 9 4 . These two type I1 subunits are homologous, have similar amino-terminal and carboxylterminal amino acid sequences, and have two duplicated sequences which are presumably the cAMP binding domains. However, these two duplicated se-
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
51
quences and the sequences surrounding the autophosphorylationsite are different between the two proteins. Sequences around the autophosphorylationsite of the rat ovary type I1 regulatory subunit are also different from sequences in the same area of the rat heart regulatory subunit (J. S. Richards, personal communication). Further developments in this field will undoubtedly strengthen our understanding of these proteins and their functions. The type I and type I1 isozymes are homologous proteins which have the same tetramenc structure, similar mechanisms of CAMPactivation (see Section II,C), and two different intrasubunit cyclic nucleotide-binding sites on the regulatory subunit (6,59).Although the sequence homologies of the regulatory subunits are strongest in the CAMP-binding domains, the sequences of other domains are less well conserved (see Section 11,C) and several features of the regulatory subunits or their respective holoenzymes can be used to differentiate them. These include physical, immunological, and kinetic differences (10, 11, 14, 38, 57). The type I1 subunit has an axial ratio of 12 and a frictional rateo of 1.6 (82),indicating an oblong asymmetric structure. It consists of 43% a helices, 23-30% P-strands, and has 23 p-turns (81). The type I regulatory subunit has an axial ratio of 8.5 and a frictional ratio of 1.47 (86).The molecular weights have been determined from amino acid sequence to be 42,804 for the bovine skeletal muscle type I regulatory subunit (379 residues) (80) and 45,004 for the bovine heart type I1 subunit (400 residues) (81). These values are slightly lower than the molecular weights determined by sedimentation equilibrium centrifugation (15,82)or nondenaturing gel electrophoresis (34, 62, 83) according to the method of Hedrick and Smith (84), but considerably lower than the apparent molecular weights determined from SDS-gel electrophoresis [M, = 49,000 for the type I from porcine, bovine, and rabbit skeletal muscle and 56,OOO-58,000 for the bovine heart type I1 subunit Refs. (14, 57)]. Robinson-Steineret al. (85) showed that the apparent molecular weight of the type I1 regulatory subunits determined by SDSgel electrophoresis differ significantly among different species and tissues. In addition, the extent of migration differs for some forms of type I1 regulatory subunit depending on the presence of phosphate in the autophosphorylation site (33,34,85).The type I regulatory subunit does not undergo autophosphorylation and shows similar but slightly less pronounced discrepancies in molecular weights when determined by different methods (14, 59). The explanation for the error in apparent molecular weight for the type I1 regulatory subunit determined by SDS-gel electrophoresis is not certain. It is possible that the protein structure may not be completely denatured by SDS and therefore does not migrate strictly according to molecular weight. If this is correct, the presence or absence of phosphate on the autophosphorylation site affects the binding of SDS more to some than to other forms of type I1 regulatory subunit (85). The physical properties of the holoenzymes have been reviewed and conveniently tabulated by Nimmo and Cohen (14) and by Carlson et al. (38). The
52
STEPHEN J. BEEBE AND JACKIE D . CORBIN
molecular weights of the holoenzymes are now known from amino acid sequences to be 167,332 for type I (79, 80) and 171,732 for type I1 (79, 81). Estimates of molecular weights from sedimentation equilibrium centrifugation and nondenaturing gel electrophoresis (62, 83) are essentially the same as these values. The isolation of the CAMP-dependentprotein kinases by anion-exchangechromatography, using DEAE cellulose, has been used as a standard procedure to define, separate, and quantitate the type I and type II isozymes (7, 35). The different elution behaviors are predicted from their respective isoelectric points (PI) and differences in amino acid composition. The type I subunit has a higher pl(5.45-5.57) (87, 88) and elutes at lower salt concentrations than does the type I1 subunit, which has a pl of 5.34-5.40. In addition the type I1 isozyme has a higher acidic amino acid content (6). Using a standard, low-ionic-strength phosphate buffer, the type I and type I1 isozymes elute from DEAE cellulose at less than and greater than 100 mM NaCl, respectively. The type I and type I1 holoenzymes have distinct antigenic determinants (8992). When the holoenzymes or the regulatory subunits are used as antigens, antibodies are produced that recognize the individual regulatory subunits (89, 92). Specific antibodies to the catalytic subunit are generated only when the free subunit is used as the antigen, and the immunological properties appear to be similar among the subunits from distinct tissues and species (15, 54, 55, 93). Although antisera are isozyme specific, they lack absolute species specificity. For example, Fleischer er al. (89) generated antibodies against the bovine heart type I1 isozyme that cross-reacted identically with the type I1 isozymes from other bovine tissues, but reacted in a nonparallel manner with the type I1 isozymes from rat tissues and procine heart. Weldon et al. (94) prepared monoclonal antibodies against the type I1 bovine heart regulatory subunit that had an antigenic site localized in a region near the dimerization domain, the autophosphorylation site, and the CAMP-binding site 2. This was a conserved sequence in the bovine and porcine heart isozymes and was recognized with similar affinities in both species by one monoclonal antibody. The type I and type I1 isozymes are also different in some of their kinetic properties and these have been used to distinguish the isozymes when mixtures are present. The type I holoenzyme is more readily dissociated than the type I1 holoenzymes in the presence of histone and high salt concentration (7, 35, 95). The presence of MgATP prevents the dissociation of the type I holoenzyme under these conditions (7, 57) probably by inhibition of CAMPbinding (57). The type I1 holoenzyme reassociates rapidly in the absence of salt but slowly in the presence of salt, while the type I holoenzyme associates slowly in the presence or absence of salt (7, 35). The presence of phosphate in the autophosphorylation site of the type I1 regulatory subunit [serine-95of the primary sequence (81, 96)] increases the dissociation constant for the regulatory and catalytic subunit com-
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
53
plex and slows the rate of reassociation (9, 34, 97, 98). Although the physiological significance of the autophosphorylation reaction is not clear, it has been proposed that the type I1 holoenzyme exists in vivo primarily in the phosphorylated form (99), which is apparently favored for dissociation (9). Recently, Scott and Mumby (100)demonstrated that both phosphorylated and dephosphorylated forms exist in intact trachael smooth muscle and that the relative amounts are changed by intracellular CAMP. The type I1 regulatory subunit is also phosphorylated in vitro at serines-44 and -47 by glycogen synthase kinase 3 (101) and at serines-74 and -76 by casein kinase I1 (101, 102). These latter two serines are also phosphorylated in vivo (102). The physiological significance of these phosphorylations, if any, has not been established. Other kinetic differences have been revealed through the use of cAMP analogs. Although the cAMP binding domains have been highly conserved (see Section II,C), differences in cyclic nucleotide binding to the type I and type I1 isozymes have been found. Although both the 3' and 5' oxygens in the ribose portion of cAMP are important for activation of both isozymes, use of analogs substituted with sulfur at these positions suggests that differences exist between the two isozymes in one or both of the binding sites that recognize the 4' position of the ribose ring and the 3',5' cyclic phosphate (103). In addition, C8-aminoalkyl-CAMP analogs preferentially activate the type I isozyme and 2-phenyl- 1, N6-etheno-CAMP, the only significant one of over 100 analogs tested, preferentially activates the type I1 isozyme (104). More striking differences between the binding sites of cyclic nucleotide-dependent isozymes are evident when both CAMP-binding sites are considered (Fig. 1). For the CAMP-dependent protein kinase isozymes as well as the cGMPdependent protein kinase, site-1 (site B) has a slower cAMP dissociation rate (59, 86, 105-107) and a relative selectivity for cAMP analogs modified at the C8 carbon of the base (C8 analogs) (86, 105, 107), while site-2 (site A) has a faster dissociation rate and a relative selectivity for analogs modified at the C6 position (C6 analogs) with the CAMP-dependent protein kinase isozymes. This site has a relative selectivity for analogs modified at the C1 position (C1 analogs) for cGMP analogs with the cGMP-dependent protein kinase (108). [3H]cIMP (site-2 selective), 8-a~ido-[~~P]cAMP (site- 1 selective), and [3H]cAMP-bindingexperiments establish that binding of cyclic nucleotides at either site stimulates binding at the other site for both type I and type I1 protein kinase isozymes (107, 109, 110). This positive cooperativity in cyclic nucleotide binding is reflected by a positive cooperativity of protein kinase activation (111). The cAMP and cGMP kinases have Hill coefficients of approximately 1.6 for their respective activators (12, 85, 112). In addition, a synergism of protein kinase activation for each isozyme occurs using a combination of a site 1 and site 2 selective analog (111, 113). An important point in this regard is that the analog combinations that cause synergism of protein kinase activation differ for the isozymes. The type I iso-
54
STEPHEN J. BEEBE AND JACKIE D. CORBIN
Lu
C6-ANALOGS
4 TYPE
C 8 AMNO-ANALOGSC-
I cAMP
KINASE
f$
C 6 -ANAL OGS
TYPE IL cAMP KINASE C 8 TMIO-ANALOGS
OR
8- PIPERIDIN0- C A W
NI-ANALOGS
cGMP KINASE C8- ANALOGS
FIG. I . Proposed structural homologies between CAMP-dependent and cGMP-dependent protein kinases. The cyclic nucleotide analog selectivities for the two intrasubunit binding sites are indicated.
zyme generally shows better relative selectivity at site I for C8 amino analogs and the type I1 isozyme generally shows a better relative selectivity at site 1 for C8 thio analogs, while both isozymes show selectivity at site 2 for C6 analogs. Consequently, a combination of a C6 and a C8 amino analog causes a synergism of type I but not type I1 activation while a combination of a C6 and a C8 thio analog causes a synergism of type I1 but not type I activation (1 11, 113). An unusual analog, 8-piperidino-cAMP, has been characterized (104). This analog is selective for site 1 on the type I1 isozyme but selective for site 2 on the type I isozyme. Therefore, 8-piperidino-CAMPis used with C8 amino analogs as a type I directed-analog pair or used with C6 analogs as a type I1 directed-analog pair. [3H]cGMP-bindingto the cGMP-dependent protein kinase is stimulated by analogs that are selective for site 2, but not by those selective for site 1 (108); This enzyme is synergistically activated by a combination of a C1 and a C8 analog. Interestingly, cGMP itself also exhibits synergism with a C1 analog (108). By using cAMP analogs that are highly selective for one site on the regulatory subunit of one isozyme, analog combinations can be chosen that maximize the
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
55
synergism of the response of a single isozyme in a tissue that contains both isozymes. Ogreid et al. (104) have used a quantitative in vitro approach which should predict the best analog combination to use for in vivo experiments so that only a single isozyme is activated. The C8 amino analogs are most highly selective for site 1 on the type I isozyme, but analogs that are optimally selective for other sites on the respective isozymes are unavailable. Analog pairs that have been used in intact tissues (113) may not measure the optimal synergism potential for a given isozyme. However, when appropriate site-selective analogs are used in intact tissues at relatively low concentrations so that the protein kinase(s) is activated only slightly above its basal state (5-15% of maximum), a slight elevation of the physiological response occurs. The synergism observed with an appropriate type I- or type 11-directed analog pair can then be attributed to a single isozyme with a minimum synergistic activation of the other isozyme (114). Regardless of whether optimal pairs of analogs are used or not, optimal synergism will be observed only when the protein kinase and the cell responses are slightly activated above the basal state with single analogs. While the classification of isozymes into major type I and I1 classes is useful, the development of more advanced techniques to prove the isozyme structure indicates that at least the type II kinase is represented by a continuum of microheterogeneous forms. The DEAE-cellulose elution behavior of several type I1 isozymes is different (7, 35, 112). Malkinson et al. (115) found that an apparent murine adipose tissue type I elutes at a higher salt concentration and contaminates the type I1 isozyme. Toru-Delbauffe et al. (116) reported a similar result with the type I1 isozyme from rat thyroid. Robinson-Steiner et al. (85)found that a second fractionation on DEAE-cellulose is sometimes required to completely resolve the two isozymes. This is especially the case when the type I to type I1 ratio is high. However, several potential artifacts can result in an incorrect isozyme identification from DEAE-cellulose analysis alone. The free regulatory subunits of both isozymes elute at higher salt concentrations than do the holoenzymes (35, 117), and type I regulatory subunit can contaminate the type I1 holoenzyme. This can be a complication when the holoenzymes are artifactually activated by the homogenization procedure. It is also difficult to rule out that during chromatography free catalytic subunit reassociates with free regulatory subunit and modifies the protein kinase elution behavior. Limited proteolysis of the two regulatory subunit isozymes produces similar fragments with apparent molecular weights of 30,000 to 40,000 (118), and the DEAE-cellulose elution behavior of partially proteolyzed type I and type I1 isozymes may be less well resolved (119). It has been demonstrated that limited trypsinization of the type I1 bovine heart holoenzyme produces a CAMP-dependent dimeric enzyme, containing a proteolyzed regulatory subunit of M, = 45,000-48,000 on denaturing gels and a single intact catalytic subunit (120, 120a) (see Fig. 4 and Section III,A). A similar molecule was found in aged preparations of type I1 protein kinase from
56
STEPHEN J . BEEBE AND JACKIE D. CORBIN
rat liver (121) and adipose tissue (S. J. Beebe and J. D. Corbin, unpublished). Since both the dimeric enzyme from bovine heart (120) and the native adipose tissue holoenzyme (35, 112) elute at a relatively low salt concentration on DEAE-cellulose and each has a regulatory subunit with an apparent molecular weight by SDS-gel electrophoresis of M, = 48,000 (120) and M, = 5 1,000 (85, 112), respectively, isozyme classification can be erroneous. Since the type 11, but not the type I, regulatory subunit is autophosphorylated (57, 122, 123), a simple method is available to aid the identification of the type I1 isozyme. The type I isozyme can be identified since MgATP inhibits cAMP binding to this holoenzyme but not to the type I1 holoenzyme (57, 124). When the existence of the two main isozyme types of the CAMP-dependent protein kinase was first described (35, 112), it was pointed out that there is more than one class of type I1 in the same animal species. It was found that rat adipose tissue and rat heart type I1 elute at different NaCl concentrations from DEAEcellulose and that mixtures of the enzymes from the two tissues can be separated by chromatography on these columns. In spite of these physical differences, they were found to exhibit similar kinetic properties. From immunological studies of type I1 regulatory subunit, Erlichman et al. (125, 126) described neural and nonneural subclasses. Corbin et al. (85, 112) suggested that this classification may not include all type I1 subforms. By comparing mobility upon gel electrophoresis, Stokes radii measurements, and the effect of autophosphorylation and proteolysis on the type I1 regulatory subunit from different tissues and species, several different forms could be resolved (85).An operational classification separates type I1 regulatory subunits into those that shift mobility on SDS gels after autophosphorylation (type HA) and those that do not (type IIB) (85). These forms are further distinguished by apparent molecular weights. An examination of the distribution of types IIA and IIB in different species of heart tissue revealed a definite pattern (Fig. 2) (85).Type IIB is present in hearts of rodents, lagomorphs, and primates: while type IIA is present in hearts of carnivores and ungulates. These two broad groups of species diverged from each other about 70 million years ago. That type IIB is a more recent evolutionary development is suggested by the finding of type IIA in chicken heart. More than one form is also found in different tissues of the same species. Bovine lung contains equal amounts of M, = 56,000 type IIA (like bovine heart) and M, = 52,000 type IIB. Bovine brain contains a small amount (-15%) of this same type IIA and a predominant M, = 52,000 type IIB. The same forms are also found in different species. Both rat brain and bovine brain contain type IIB. The rat adipose tissue (M,= 51,000 type IIB) and the bovine heart (M,= 56,000 type IIA) holoenzymes differ in several other properties, including Stokes radius, calculated molecular weight, and frictional ratio (85, 112). Even though the adipose tissue enzyme is quite similar to other type I1 forms in the kinetics of cAMP action, the
57
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
HUMAN CHI MPA N 2 EE RHESUS ATELES
SLOW L O R I S
WHALE H I PPOPOTAMU s
GUANACO CAMEL
2 EBRA
Y
DONKEY I 0
I
I
I
1
1
40
80
120
160
200
MILLIONS OF YEARS B P
FIG. 2. Distribution of types IIA and B in hearts of various species. Shaded symbols represent type IIA and cross-hatched symbols represent type IIB. Different geometric symbols indicate molecular weight differences as determined by SDS-polyacrylamide gels: circle, M, = 56,000 (dephospho-); parallelogram, M, = 54,000 (dephospho-); ellipse, M, = 52,000; rectangle, M, = 51,000. The evolutionary tree is from Goodman (1034.
58
STEPHEN J . BEEBE AND JACKIE D. CORBIN
CAMP-binding sites are different from them based on the kinetics of activation by certain CAMP analogs. Several analogs modified at the N6-position of the adenine ring have higher apparent K, values for protein kinase activation for the adipose tissue enzyme than for the bovine heart and several other heart isozymes (112). The M, = 51,OOO type IIB enzymes from bovine brain and monkey heart, like that from adipose tissue, show similar but less striking differences compared to the bovine heart and other heart isozymes (S. J. Beebe and J. D. Corbin, unpublished). Jahnsen er af. (127) purified and characterized three isoforms (M, = 54,000, 52,000, and 5 1 ,000) of the type I1 regulatory subunits from rat ovarian granulosa cells using immunological, electrophoretic, photoaffinity labeling, and phosphorylation criteria. Antiserum against rat heart type I1 regulatory subunit recognizes the M, = 54,000 form while antibovine heart type I1 regulatory subunit serum recognizes the other two forms. The M, = 51,000 and 52,000 forms, unlike the M, = 54,000 form, are regulated by hormone in preovulatory follicles and do not readily change mobility on SDS-gels following phosphorylation. In addition, the M, = 54,000 form has a distinct peptide map. The authors suggest that the hormone-regulated forms are distinct gene products. Other apparent type I1 forms have been described. Schwartz and Rubin (128) have identified two distinct forms of M, = 54,000 and 52,000 from Friend erythroleukemic cells using monoclonal antibodies and peptide map analysis. Further distinctions between subclasses of the type I1 isozyme are indicated by differences in the amino acid composition, two dimensional tryptic peptide maps, and the peptide containing the autophosphorylation site between porcine brain and skeletal and cardiac muscles (129). Weldon et af. (130) have reported that the type I1 regulatory subunit from bovine brain binds only 2 mol of CAMP/ mol subunit, although the two different classes of binding sites are present. This is in contrast to bovine heart and other regulatory subunit isozymes which bind 4 mol cAMP/mol subunit. The explanation for the lower total CAMP-binding to the brain subunit requires further study. Furthermore, two different monoclonal antibodies with antigenic determinants at the NH,-terminal third of the heart regulatory subunit class react very poorly with the brain subunit. This information, in conjunction with comparative amino acid sequence analysis of this region suggest that these two forms of type I1 regulatory subunit are unique gene products (130). In summary, the demonstration of microheterogeneous forms of the type I1 isozyme tends to blur the distinction between isozyme forms. Consequently a careful examination using a series of tests is required to positively identify an isozyme. Although the number of isozymes studied in detail is small, the kinetic differences between the isozymes is most reliable. In addition, no type I isozymes have been reported to undergo autophosphorylation.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
59
B. CYCLICGMP-DEPENDENT PROTEINKINASE The soluble cGMP-dependent protein kinase from bovine lung is a dimer composed of two identical monomeric chains each containing 670 amino acid residues (131). The monomer has a molecular weight of 76,33 1 determined from the amino acid sequence. Each chain contains a regulatory domain with two homologous cGMP-binding domains and a catalytic domain carboxyl-terminal to the binding domains (131). The dimer has a molecular weight of 152,662. This is in fairly good agreement with the molecular weight of 150,000-162,000 determined from SDS-gel electrophoresis (22, 66) or calculated from the sedimentation coefficient (6.7s-7.8s) (66, 132), and the Stokes radius (5.0-5.2 nm) (66, 132). The molecular weight of the cGMP kinase is therefore only slightly less than that of the cAMP kinase and considerably higher than that of the catalytically active component of the cAMP kinase. The cGMP-dependent kinase has an isoelectric point of 5.4 and is probably somewhat less asymmetric than the cAMP kinase since both the axial ratio of 7.4 and the frictional ratio of 1.4-1.5 are slightly less (132). Like the cAMP kinase, the cGMP kinase is autophosphorylated (70). Although this occurs in the presence of either cGMP or cAMP (25, 133), autophosphorylation with cAMP is distinctly different from that with cGMP. First, 2-6 mol phosphate per mol subunit is incorporated, instead of 0.75 mol/mol with cGMP (134). Stimulation of phosphate incorporation into seines-50 and -72 and theonines-58 and -84 (134) occurs with the occupancy of only one of the two intrasubunit binding sites (135). The most rapidly phosphorylated residue, theonine-58, is the major site phosphorylated in the presence of cGMP (134). Second, autophosphorylation in the presence of CAMP, but not cGMP, causes a 10-fold reduction in the concentration of cAMP required for half-maximal activation of phosphotransferase activity (133). Furthennore, following maximal autophosphorylation (total of -4 mol phosphate/mol subunit) the dissociation rate of cGMP from site 1, measured with an excess of cold cGMP, is decreased approximately 1O-fold. Autophosphorylation therefore primarily affects the binding at site 1 and elimates cooperative binding at this site (136). Other properties of the soluble cGMP-dependent protein kinase have been more completely reviewed by others (25-29) and the effects of cyclic nucleotide analogs are discussed in conjunction with the CAMP-dependent protein kinase in Section II,A. De Jonge (68) has characterized an intestinal, brush border membrane-specific cGMP-dependent protein kinase (type 11) that is distinct from the enzyme characterized in lung, heart, and smooth muscle (type I). In contrast to the soluble enzyme, the brush border cGMP kinase has an apparent molecular weight of 86,000 and is anchored to the membrane or to the contractile core of the microvilli by a 15,000-dalton fragment containing a site which is preferentially phos-
60
STEPHEN J. BEEBE AND JACKIE D. CORBIN
phorylated in situ in a cGMP-dependent manner. An apparent M, = 7 1,000 form, which contains the cGMP-binding and catalytic domains, is generated from the apparent M, = 86,000 form by proteolysis. The brushborder cGMP kinase is further differentiated from the soluble enzyme by isoelectric point (7.5) and phosphopeptide pattern following limited proteolysis. However, the brushborder cGMP kinase is immunologically similar to the soluble form and also undergoes autophosphorylation in the absence of cGMP.
C, EVOLUTIONARY RELATIONSHIPS AMONG CYCLIC AMP-BINDINGPROTEINS AND PROTEIN KINASES The first proposal of homology between protein kinases was based on similarities in physical and kinetic properties, and in amino acid composition, between CAMP- and cGMP-dependent protein kinases (23, 29). A model for structural homology between the two enzymes was also proposed (25), and it was suggested that the two intrasubunit cyclic nucleotide-binding sites on each enzyme were evolved by contiguous gene duplication (10,21,25,86).Structural models, slightly modified from the original, are shown in Fig. 3. Conclusive proof of a common progenitor for these kinases was the subsequent finding of a high degree of amino acid sequence homology in both the regulatory and in the catalytic domains (131). In the case of the regulatory component, the homology occurs not only between the two intrasubunit cyclic nucleotide-binding sites in the carboxy terminal two-thirds of this sequence, suggesting a tandem gene duplication, but also between the corresponding binding sites of the two different cyclic nucleotide-dependent protein kinases. There is much less apparent homology between these kinases in the amino terminal one-third of the primary sequence, which contains the dimerization domain. As expected, the regulatory subunits of the two main isozymic forms of CAMP-dependent protein kinase, types I and 11, also exhibit strong homology. The finding of several microheterogeneous forms of type I1 regulatory subunit, which can generally be classified into types IIA and IIB subclasses (85), and the finding that the primary amino acid sequence of a short segment of at least one type IIB form is very different from that of type IIA (85), are additional lines of evidence that the entire primary sequence of the regulatory subunit has not been well conserved. The regulatory and catalytic components of cyclic nucleotide-dependent protein kinases have been independently derived in the course of evolution since there is no apparent homology between them. Each of them is a member of one or the other of two distinct families, the CAMP-binding proteins and protein kinases, as illustrated in Fig. 3. All higher eucaryotes examined so far contain the regulatory components of cyclic nucleotide-dependent protein kinases. The enzymes in fungi (137-143, slime mold (146), and insects (147-149) appear to have the same basic structure as the mammalian enzymes. Vardanis has reported
PROTEIN KINASES
cAMP BINDING PROTEINS
S€RlNE- THR€WlNE PROTEIN KINASK3
w
PHOSPHORYLAS€ KINASE MYOSIN LIGHT CHAIN KINASE A
\\
PROCAR VOWS
4fl
OTHERS
€UCARVOT€S COOH
VIRUS ENCODE0 PROTEIN KINASES
CAMP - DEPENDEN PROJ€lN KINAS€
r
EGF RECEPTOb INSUL IN RECEPTOR OTHER GROWTH FACTOR RECEPTtS
OTHER CYCLIC NUCLEOTIDE BINDING PROTEINS DICTYOSTELIUM CAMP RECEPTOR TRYPANOSOMA cAMP BINDING PROTEIN c GMP-BINDING PHOSPHODIESTERASES 1
cGMP -D€fENDENT PROJElN KINASE
FIG.3. Possible evolutionq relationships among cyclic nucleotide binding proteins and protein kinases.
62
STEPHEN J. BEEBE AND JACKIE D. CORBIN
the existence in insects of a protein kinase that lacks specificity with regard to cAMP and cGMP (150), and of a CAMP-dependent protein kinase in nematodes, which does not dissociate into subunits during activation (151). There is no consistent evidence of cyclic nucleotide-dependent protein kinases in procaryotes, but these organisms contain a CAMP-bindingprotein (152, 153) named catabolite gene activator protein (CAP). This protein serves a similar function in E. coli as the regulatory subunit serves in the mammalian liver: when sugar availability declines, cAMP is elevated, binding of cAMP to the respective protein occurs and this leads to increased sugar availability. In mammals sugar is made available by increased glycogenolysis and gluconeogenesis; in bacteria sugar is made available by the switching on of catabolic gene operons for proteins involved in various sugar transport and utilization. Thus, CAP contains, in addition to a CAMP-bindingdomain, a domain at the carboxy terminus (indicated in black in the model of Fig. 3) which binds to DNA and regulates gene expression. This domain is known to have structural and sequence homologies with the DNA-binding protein of bacterial and viral repressors (154,155). The CAMP-binding domain of CAP is strongly homologous with the CAMP-binding domains of cyclic nucleotide-dependent protein kinases (156). From both X-ray crystallographic analysis of CAMP-bound CAP and from sequence homology between CAP and regulatory subunit, certain predictions of cAMP binding to cyclic nucleotide-dependent protein kinases have been made (156). It has been suggested that each CAMP-binding site contains a p-roll structure and perhaps an a-helix. If the regulatory components of the kinases are like CAP they could contain a deep pocket for cAMP binding between the p-roll and a-helix. Each site presumably also contains an essential arginine for binding the ribose phosphate moeity of CAMP. The CAP protein is an asymmetric dimer, the monomeric components presumably containing identical amino acid sequences (155). Two molecules of cAMP bind to the dimer, and each molecule binds to both monomers. The binding of cAMP to CAP exhibits cooperativity (157). In several respects the two CAMPbinding sites of the dimeric CAP resemble the two intrasubunit CAMP-binding sites of the regulatory components of the protein kinases. This suggests that one possible evolutionary precursor of the CAMP-binding sites of each protein is a dimeric, asymmetric precursor as illustrated in Fig. 3. CAP could have evolved from it by acquiring a DNA-binding domain through gene fusion. The regulatory subunit could have evolved from it by acquiring at least a catalytic subunitbinding domain and a dimerization domain at the amino terminus. In addition, by gene duplication and fusion, two CAMP-binding sites on the same protein chain could have been produced. These two sites might then have similar relative emplacements as the two sites on the dimeric CAP. If this theory is correct, then one might predict that the two cooperative intrasubunit cyclic nucleotide-binding sites of the regulatory component of protein kinase could be close to each other, and that each cyclic nucleotide binds to components of both binding domains.
3 . CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
63
Other cyclic nucleotide-binding proteins which are not components of a protein kinase have been described. These should be examined to see if they are related in evolution to the CAP proteins and to the cyclic nucleotide-binding sites of cyclic nucleotide-dependent protein kinases. In the cellular slime mold Dictyosrelium discoideum, cAMP acts as a chemotactic agent to induce cell aggregation during exhaustion of food supplies (158). This effect is mediated by a cell surface receptor which has physical and kinetic properties different from either CAP or the cyclic nucleotide-dependent protein kinases (159, 160). In species of Trypanosoma, a parasitic lower eucaryote, cAMP is believed to be involved in the regulation of cell growth and differentiation. These organisms are low or completely devoid in cyclic nucleotide-dependent protein kinase activity, but they contain a CAMP-binding protein of M, = 62,000 which differs from the kinase or CAP protein in several respects (161). Another well-known cyclic nucleotide-binding protein is the family of phosphodiesterases which possess a cGMP-specific-binding site in addition to a catalytic site (162-164). As seen in Fig. 3, the protein kinase family of proteins includes the catalytic component of CAMP- and cGMP-dependent protein kinases. This family can conveniently be divided into serine-threonine-specific protein kinases and tyrosine-specific protein kinases (see Chapter 6). As is the case for cyclic nucleotide-dependent protein kinases, two Ca2 -calmodulin regulated protein kinases, phosphorylase kinase and myosin light chain kinase, catalyze phosphorylation of serine or threonine in protein substrates. These kinases are also known to be closely related to the cyclic nucleotide kinases by amino acid sequence homology (165, 166). More distantly related to the catalytic component of cyclic nucleotide-dependent protein kinases is the group of tyrosinespecific protein kinases (167). A lysyl residue that binds the ATP analogue affinity label [(fluorosulfonyl)-benzolladenosineis apparently conserved in all of the protein kinases and could represent a part of the active site that interacts with the terminal phosphate of ATP (162, 164). It is not unreasonable to expect that other protein kinases, which have similar physical and kinetic properties but which have not yet been examined at the protein chemical level of those shown in Fig. 3, will be shown to be in this same family of proteins related to each other in evolution. Speculation is in order for the mechanism by which “marriage” of ancestral protein kinase catalytic proteins and inhibitory proteins such as the regulatory subunit occurred. One possibility is that originally the regulatory protein was simply a protein kinase substrate. Through mutational alteration, this protein could have developed such a strong affinity that it prevented, in a competitive manner, the phosphorylation of other protein substrates. Support for this theory is derived from the fact that the regulatory components of the cyclic nucleotidedependent kinases contain either a phosphorylation site or phosphorylation analog site for the catalytic component of the enzymes. Furthermore, the phosphorylation site is believed to be located in the catalytic component inhibitory +
64
STEPHEN J . BEEBE AND JACKIE D. CORBIN
region of the regulatory component (6, see Ref. 174), even though the phosphorylation site is known not to be the only component of the inhibitory domain of the regulatory subunit (4). Finally, it is known that several different protein kinases catalyze autophosphorylation (10). Whether or not the phosphorylation site of any of these enzymes is in an inhibitory domain has not been established.
IV. Mechanism of Action A. MECHANISM OF REGULATORY SUBUNIT ACTION The precise mechanism by which the regulatory subunit inhibits the catalytic subunit is not certain, although some progress has been made in understanding this phenomenon. In higher organisms all of the isozymes that have been characterized have a tetrameric structure (R2C2),but the functional unit of these forms appears to be a dimer (RC). This proposal is based on the observation that proteolytically modified type I1 holoenzyme (R’C) from either bovine liver (121), rabbit skeletal muscle (120),or bovine heart (120, 120~) behaves as a dimer (Fig. 4) on sucrose density gradients and gel filtration. The modified enzymes of muscle and heart have been studied in detail and it has been determined that the site of proteolysis, using either endogenous proteases or added trypsin, is in the amino terminal onefourth of the molecule (120, 1 2 0 ~ )It. has been further established that the carboxy terminal monomeric fragment, which contains the two CAMP-binding sites and the autophosphorylation site, retains virtually unaltered ability to inhibit the catalytic subunit. Thus, even though the native dimeric structure of regulatory subunit has been highly conserved, it is apparently not required for the inhibitory action. Perhaps all forms of holoenzyme do not contain a dimeric regulatory subunit. The inhibitory domain(s) of the type I1 regulatory subunit must be contained, at least in part, around the autophosphorylation site (residue 95) of the primary sequence (total residues = 400). This conclusion is based on the observation that modifications of this region abolish the inhibitory activity (6, 10, 168, see Ref. 174),and supports the suggestion (6, 10, 174)that the regulatory subunit inhibits the catalytic subunit by acting as a “substrate analog” of high affinity which shields the protein or peptide substrate binding site of the catalytic subunit. The autophosphorylation site could be the substrate analog site in question. From the magnetic resonance studies of Granot and co-workers ( 9 ) ,the type I1 regulatory subunit might be considered to be a “dead-end” substrate since the respective holoenzyme binds MgADP with high affinity. Type I isozyme does not undergo autophosphorylation, but it does contain a homologous autophosphorylation analog site (80) that could serve a similar purpose. In addition to the autophosphor-
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
65
m
@ I
U
I
FIG.4. Formation of the functionally competent dimer by trypsin treatment of the tetrameric holoenzyrne.
ylation primary sequence of type 11, the inhibitory domain must also include a structure(s) of higher order since heat denaturation destroys the regulatory subunit inhibitory activity, but not its ability to act as a substrate for autophosphorylation (174). With regard to this second postulated structure, since autophosphorylation can take place, the regulatory subunit does not block the MgATP-binding site of the catalytic subunit, but it could block the transfer of phosphate from ATP to substrate (10). It follows that the inhibitory action of the regulatory subunit could be exerted in two ways. First, it may act as a competitive inhibitor of high affinity; and second, it could block the ability of catalytic subunit to transfer phosphate from ATP to substrate. Several isoforms of a heat-stable protein kinase inhibitor of high specificity for the CAMP-dependent protein kinase are present in mammalian tissues (169171). Although the physiological role of this inhibitor has not been established conclusively, it has been quite useful in studies of mechanism and cellular role of the kinase. As is probably the case for the regulatory subunit, this inhibitor may act at least in part by serving as a competitive substrate analog of the CAMPdependent protein kinase (172). Scott ef al. have isolated a proteolytically derived fragment of the inhibitor that retains inhibitory activity (173). This fragment contains a substrate analog sequence as indicated by the presence of tandem arginines followed by alanine in the usual position of a phosphorylatable serine or threonine of natural protein kinase substrates. These investigators have synthesized a potent (K; = 0.8 @ peptide I)kinase inhibitor of an amino acid sequence corresponding to the first twenty amino acids of the proteolytically derived fragment. The amino acid sequence of this peptide resembles the sequence in the regulatory subunit which, as previously noted, is part of the domain that inhibits the catalytic subunit. Several findings are indicative that a ternary complex is formed between CAMP and holoenzyme during activation of the kinase (175-177). Although difficulties have been encountered in isolating and studying a stable ternary complex, several reports suggest that this is possible. Cobb et af. (64, 64a) separated and characterized two distinct peaks of homogeneous Type I1 bovine heart tetrameric holoenzymes. Using HPLC-DEAE chromatography, both peaks had similar molecular weights as calculated from their Stoke’s radii and szo.w
66
STEPHEN J. BEEBE AND JACKIE D. CORBIN
values or determined by denaturing electrophoresis. They contained equimolar amounts of regulatory and catalytic subunits and were highly CAMP-dependent. One of these peaks was identified as a relatively stable ternary complex which appeared to be holoenzyme (R2C2)with approximately half-filled cAMP binding sites. This ternary complex was further distinguished from the CAMP-deficient holoenzyme by an enhanced positive cooperativity in nonequilibrium [3H]cAMP binding and in kinase activation. This complex could represent an enzyme form that is primed for activation. At least two other reports have provided evidence for the presence of a ternary complex between cAMP and a trimeric form of CAMP-dependent protein kinase. Rangel-Aldao and Rosen (122a) and Connelly ef al. (83) identified an intermediate assigned an R,C structure. In contrast to the ternary complex reported by Cobb er al. (64, 64a), these trimer complexes were formed during reassociation of catalytic and regulatory subunits. The significance of these complexes remain to be fully determined. It is assumed that CAMPbinds in a step-wise manner to the four binding sites of the holoenzyme. The binding exhibits positive cooperativity with reported Hill constants of 1.6-1.8 for kinase activation (10). More direct demonstration of positive cooperativity is by the use of site-selective cAMP analogs. These investigations have shown that binding of cyclic nucleotide to either of the two intrasubunit sites (sites 1 and 2) has a strong stimulatory effect on binding to the other site (109). There may be several mechanisms for these stimulations. Although it cannot be ruled out that all four binding sites of the holoenzyme are accessible to the first mole of CAMP, the results of several experiments using type I1 suggest that binding to site 2 is blocked by the presence of catalytic subunit, but this site is made available by site 1 occupancy (12, 109). Thus, cAMP probably binds first to site 1, which then stimulates site 2 to bind. Using the free regulatory subunit of type I, it has been found that when cAMP occupies site 2, the dissociation of cAMP from site 1 is retarded (179). These characteristics could explain at least in part the observed stimulation of binding to both sites 1 and 2 noted above. The additional finding, using the free regulatory subunit of type I, that binding to site 2 of one subunit retards dissociation of cAMP from site 2 of the other subunit could also explain part of the stimulation (15). This latter intersubunit stimulatory effect is probably minor using type I1 since the cooperative binding is essentially unaltered in the dimeric (RC) holoenzyme as compared with the native tetramer (R2C2)( 2 ) . However, it has been calculated that an intersubunit positive cooperativity is necessary in order to explain the high Hill constant for cAMP activation of the protein kinase (180). The precise mechanism by which binding of cAMP to the enzyme causes activation is not yet clear. At the time of the discovery of the two intrasubunit CAMP-binding sites, it was suggested that, because of the high affinity of each, both are involved in activating the kinase (6). Subsequent experimental evidence has verified this claim (111, 181). The exact involvement of site 1 or site 2, and
3. CYCLIC NUCLEOTIDE-DEPENDENTPROTEIN KINASES
67
of the binding of the four total cAMP molecules to this enzyme in the activation process is not certain, however. Binding of cAMP to one of the sites could simply serve the function of stimulating the other site to bind without being directly involved in kinase activation. From the results of fluorescence-polarization spectroscopy studies, Seville er al. have concluded that the binding of two cAMP molecules to the holoenzymes is sufficient to cause the dissociation of both catalytic subunits (182). Studies of cGMP-dependentprotein kinase suggest that at least binding to site 1 of this enzyme is directly involved in partially activating the kinase (21). Binding to site 2 causes an additional increase in enzyme activity. Even though the CAMP-dependent protein kinase is a homologue of this enzyme, it cannot be assumed that it behaves identically with respect to kinase activation. Since the functional unit of the enzyme is a hetero-dimer (RC), this implies that one C at a time is replaced from the native tetramer (R2C2)during activation by CAMP. This suggests the existence of an intermediate form (R2C) (83, 122a). The process of CAMP-dependent protein kinase inactivation has also been investigated. It has been known for many years that the catalytic subunit induces release of cAMP from the R-CAMP complex (183). For type I enzyme, this process is stimulated by the presence of MgATP (183). 0greid and Doskeland have examined the effect of the catalytic subunit on the release of cAMP from each of the binding sites (184). From the experimental results, it has been determined that cAMP is first released from site 2, and that site 2 vacancy retards the release of cAMP from site 1. It has been also determined that both of the cAMP molecules are released from one subunit of the dimer before cAMP is released from the other subunit.
B. MECHANISM OF CATALYTIC SUBUNIT ACTION The catalytic subunit action has been reviewed extensively (23) and will be addressed only briefly in this chapter. The available evidence indicates that the catalytic subunit has a single active site on each monomer. The monomer incorporates a single substituent when photoaffinity labeled either with the 2 ' 3 ' dialdehyde derivative of ATP (185) or with p-fluorosulfonylbenzoyl adenosine (186, 187). In the latter case, the label is attached to lysine-71 of the primary amino acid sequence of the catalytic subunit. The sequence of this region of the molecule, which presumably represents at least part of the active site, is Leu-Val-Lys-His-Lys-Glu-Thr-Gly-Asn-His-Phe-Ala-Met-Lys* -1le-Leu-AspLys-Glu-Lys-Val-Val-Lys-Leu-Lys-Gln-Ile. The catalytic subunit can also be labeled in a single site per monomer with o-phthalaldehyde (188)or with peptide substrates containing reactive groups such as 3-nitro-2-pyridinesulfenyl (189). It is well known that sulfhydryl modifying agents abolish activity of the catalytic subunit and that MgATP protects against these agents (54, 55, 77, 79,
68
STEPHEN J . BEEBE AND JACKIE D. CORBIN
190). Of two -SH groups in the catalytic subunit, cysteine-199 appears to be located in the active site (189). The amino acid sequence around this residue is GIy-Arg-Thr-Thr-Thr-Leu-Cys* -G1y-Thr-Pro-Glu-Tyr-Leu-Ala (79). From the observation that catalytic subunit modified at both lysine-71 and cysteine- 199 does not form an isoindole derivative on treatment with o-phthalaldehyde, together with consideration of transition energy measurements on the o-phthaladehyde modified enzyme, the lysine and cysteine residues in the active site are about 3 A apart and are proposed to be in a hydrophobic environment (188). From NMR (191) and ATP analog specificity studies (192), it is known that the ATP is bound in the anri-conformation in the active site. Data from several laboratories (191) indicate that the catalytic subunit utilizes P,y-bidentate MgATP with the geometry shown below. The coordinates of the binding of this complex in the active site have been mapped (191).
There have been numerous inconsistencies concerning the kinetic mechanism by which the catalytic subunit catalyzes the transfer of the y-phosphate of ATP to substrate (193-198). Whitehouse et al. have carefully analyzed the reaction mechanism using the enzyme, MgATP, peptide substrate, substrate analogs, and protein kinase inhibitor (198). They have concluded that the steady-state kinetics follow an ordered bi bi mechanism in which ATP binds first. The terminal anhydride bond is then proposed to undergo a conformational change, induced either as a consequence of ATP binding per se or by the subsequent binding of protein substrate. Catalysis then ensues, leading to the sequential release of phospho-substrate and ADP. The substrate specificities of CAMP- and cGMP-dependent protein kinases have been reviewed extensively (13, 14, 31, 38, 39). Although there are slight differences in virro in specificity, in general, they both require a pair of basic amino acids on the amino terminal side of phosphorylated serines or threonines. Small peptides with amino acid sequences of this type are excellent substrates for the enzymes. Granot et al. determined by a process of elimination that if a particular conformation of protein or peptide substrate is required in the active site, then it is probably a coil (199). From results of induced circular dichroism, Reed and Kinzel have concluded that binding of the protein substrate results in a . change apparently conformational change at the ATP-binding site ( 2 0 0 ~ )This takes place in at least two steps, one dependent on the presence of a phosphorylatable serine or threonine in the substrate, and the other dependent on the pair of basic amino acids. The authors have also postulated from the results of competition experiments that the binding site closes over the substrate protein
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
69
following the initial binding. The catalytic subunit from porcine heart has been crystallized, which should allow for more detailed studies of its structure and mechanism (200).
V. Biological Role of Protein Kinases A. CRITERIA TO ESTABLISH BIOLOGICAL ROLE Several approaches have been used to elucidate the roles of cAMP and the CAMP-dependent protein kinase in cell function. Sutherland ( 4 ) first proposed criteria that should be satisfied to justify that a given hormone acts through CAMP. These criteria include the demonstration that the hormone activates adenylate cyclase and elevates the intraceliular level of CAMP. Additionally, the response should be potentiated by phosphodiesterase inhibitors and should be mimicked by the addition of exogenous cAMP or cAMP analogs. The discovery of the CAMP-dependent protein kinase (5,56) led to the hypothesis that all of the effects of cAMP are mediated by phosphotransferase reactions catalyzed by this enzyme. Subsequently, Krebs proposed a set of criteria that should be satisfied before a CAMP-mediated response could be established to be carried out by the CAMP-dependent protein kinase (201). These criteria have also been reevaluated (11, 13, 37). It should be demonstrated that a protein substrate, which is shown to be involved in the response, can be stoichiometrically phosphorylated (and dephosphorylated) at an appropriate rate in vitro and in vivo and that this is correlated with an appropriate coordinant change in the function of the substrate. It is the in vivo aspects of these criteria that are the most difficult to satisfy. In many instances the measurement of the CAMP-dependent protein kinase activity ratio (kinase activity in the absence of cAMP divided by activity in the presence of CAMP) in crude extracts from hormone-stimulated intact cells or tissues is a valid indication of the activation state of the enzyme. The cooperative binding of cAMP to the regulatory subunit causes a cooperative activation of protein kinase (12, 85, 112). It can therefore be expected that small changes in the level of cAMP will result in large changes in the activation of protein kinase. Consequently, since this enzyme is at a pivotal point in the overall metabolic regulation of the cell, an accurate determination of the protein kinase activity ratio is probably a more informative indicator of the potential of a tissue to respond to hormone stimulation than is determination of the level of CAMP. The difficulty in detecting small changes in the level of cAMP may be partially responsible for some controversies concerning the involvement of cAMP in mediating certain physiological responses. Although activity ratio measurements can be a useful and valid method for evaluating hormone action and protein kinase activation, it is critical that these studies are carried out carefully and that certain pitfalls are recognized and avoided. Since Flockhart and Corbin have
70
STEPHEN J. BEEBE AND JACKIE D. CORBIN
reviewed the method and potential pitfalls (10, 202), only brief comments and later developments are included here. The most fundamental requirement for valid activity ratio determination concerns maintaining the intracellular protein kinase activation state following homogenization. Postextraction activation or inactivation causes an overestimation or underestimation of the activity ratio, respectively. Both of these potential artifacts can be controlled (10, 202). The most important advance in this procedure is the use of a synthetic peptide as substrate (203).In general, use of this substrate instead of histone is recommended since it is more specific and sensitive, does not cause protein kinase dissociation, is not inhibited by NaCl under any recommended homogenizing technique (S. J. Beebe and J. D. Corbin, unpublished), and is a poor substrate for phosphoprotein phosphatases. The cGMP-dependent protein kinase also phosphorylates this substrate but this generally is not a problem since this kinase activity is a minor component of most tissues. Another approach used to define the biological role of the CAMP-dependent protein kinase is genetic analysis using mutant cells that have a single lesion in the pathway of cAMP action, preferably an altered or absent protein kinase [see Ref. (204) for a review]. If the CAMP-dependent protein kinase were required for a given response, a mutant deficient in protein kinase would be unable to elicit the response. Such mutant cells provide advantages since, in contrast to the wildtype cells, their growth is not inhibited by cAMP or cAMP analogs. Several criteria have been used to determine that a phenotypic variation is due to a mutation (205).Cyclic AMP-resistant cells must arise spontaneously, be clonally inherited, and the phenotype must be stable. In addition, the mutation must arise at a frequency consistent with mutation in microbial systems and increase in frequency in the presence of known bacterial mutagens. Conclusions derived from these studies are valid only if the mutation in question is not a pleiotropic one affecting multiple cellular functions. Several other approaches have been used to establish that the protein kinase mediates a given response. The direct introduction of the catalytic subunit of protein kinase or its specific heat-stable inhibitor into a cell can be achieved by microinjection. This approach was used in Xenopus oocytes (206). Although the technique is generally restricted to relatively large cells, cAMP and the subunits of the CAMP-dependent protein kinase were successfully injected into isolated guinea pig ventricular myocytes (207, 208). A similar method was used to fuse vesicles with isolated or cultured cells. Culpepper and Liu (209) fused CAMPcontaining and 8-azido-CAMP-containingvesicles with H4 and H35 hepatoma cells, and Boney et af. (210) incorporated catalytic subunit and protein kinase inhibitor into H35 hepatoma cells using protein-loaded human erythrocyte ghosts. Bkaily and Sperelakis (211)fused cultured myocytes with phosphotidylcholine liposomes containing catalytic subunit and protein kinase inhibitor.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
71
Another approach that has been used is incubation of intact cells or tissues in the presence and absence of hormone or other agent. The potential protein substrate is then isolated and phosphorylated in v i m by addition of [32P]ATP and the catalytic subunit of protein kinase. The decrease in 32P content of the protein substrate that occurred in the presence of the agent compared to the control can be assumed to have occurred in vivo (212). A technique has been used that is based on a variation of the Sutherland criteria requiring that cAMP analogs mimic a given CAMP-mediated response. It is basically a shortcut to the Krebs criteria, which were designed to establish that a given response is mediated by the CAMP-dependent protein kinase. The procedure is modified to account for the presence of two different intrasubunit cyclic nucleotide-binding sites on the regulatory subunit of protein kinase. Intact cells are incubated with two cAMP analogs either alone or in combination (113, 114, 1141). The procedure takes advantage of two properties of cAMP analogs, (a) the passage of analogs across cell membranes and the direct activation of the protein kinase; and ( b ) the site selectivity of the two different analogs each of which binds to one or the other of two distinct intrachain binding sites (Fig. 1). This occurs in such a way as to facilitate the positively cooperative activation of protein kinase. The advantages are that it is highly specific to the protein kinase isozymes and it does not require the measurement of cAMP binding to or activation of protein kinase. Instead, measurements of the response are made due to protein kinase activation in the intact tissue. Furthermore, proper use of this procedure can potentially differentiate between type I and type I1 protein kinasemediated metabolic events. Since the technique measures the metabolic response itself, it does not specifically require the identification of the phosphorylated protein which leads to the response. Although it does establish that the response is due to protein kinase activation, it does not specifically correlate the response to a phosphorylation reaction. For example, it does not rule out that the free regulatory subunit is involved in the response. In addition, the use of analogs cannot necessarily predict hormone responses, but it can modify them. For instance, cAMP analogs have been shown to block the endogenous cAMP elevation in glucagon-stimulated hepatocytes (213). Furthermore, the insulin blockade of adipocyte lipolysis or hepatocyte glycogenolysis depends on the cAMP analog used to elicit the response (214). Several other procedures have been used to correlate a metabolic response with the activation of one or the other of the protein kinase isozymes. These are discussed in Section V,C.
B. DISTRIBUTION OF ISOZYMES An examination of the relative tissue and species distribution of the isozymes of the cAMP kinase does not provide proof for specific roles for the isozymes but does present some interesting considerations. While the ratios of the regulatory
72
STEPHEN J. BEEBE AND JACKIE D. CORBIN
subunit to the catalytic subunit of the CAMP-dependent protein kinase are relatively constant among various tissues (90, 216), some tissues contain either predominantly type I or type I1 protein kinase while others contain an equal mixture of the two isozymes (7, 14). For instance the brain, stomach mucosa, and adipose tissue from many species contain predominantly the type I1 isozyme while rabbit psoas muscle, bovine corpus lutea, rat testes, and bovine neutrophils contain primarily the type I protein kinase. Rabbit soleus muscle, rat liver, rabbit reticulocytes and erythrocytes, and human neutrophils contain a mixture of both isozymes. Cardiac tissues are particularly interesting regarding isozymes. While bovine and guinea pig heart contain predominantly type 11, rat and mouse heart contain type I and rabbit and human heart contain an equal mixture of the isozymes (215). In addition, cardiac tissue has been shown to contain a CAMPdependent protein kinase in the particulate fraction (216), which has been reported to be primarily associated with sarcolemma (217-223) and sarcoplasmic reticulum (224-228). Although in most cells and tissues the enzyme is predominantly in the soluble fraction, membrane-bound CAMP-dependent kinase activity has also been found in brain (229), erythrocytes (230), corpus luteum (231), sperm (232, 233), and thyroid (116).The membrane-associated kinase is usually found to be the type I1 isozyme, but the type I isozyme has been reported in membranes from erythrocytes (230), sperm (232, 233), and thyroid (116). The holoenzyme is apparently attached to particulate material by its regulatory subunit (216). However, the catalytic subunit has been reported to nonspecifically bind to membranes under conditions of low ionic strength (234).Both the particulate-bound holoenzyme and the regulatory subunit are readily solubilized by a number of conditions, which, according to the criteria of Singer (235),classifies them as “peripheral,” as opposed to “integral” proteins. Immunochemical studies, using antibodies that are specific for the regulatory subunit of the cyclic nucleotide-dependentprotein kinases, have allowed a more precise localization of the isozymes and subunits. The advantages and limitations of these techniques have been reviewed (236-238). An increase in nuclear protein kinase has been reported in regenerating liver (239), ACTH-stimulated adrenal medulla (240),and growing human breast cancer cells (241). Van Sande et af. (242)reported that the type I1 regulatory subunit is present in the nucleus of thyroid follicular cells and the type I regulatory subunit, catalytic subunit, and cGMP-dependent protein kinase are primarily in the cytoplasm and associated with the apical membrane. Jungmann and co-workers, using an indirect colloidal immunogold technique (243), found that only the catalytic subunit is present in the nucleus of glucagon- or dibutyryl-CAMP-stimulated hepatocytes (244), but the catalytic subunit and both type I and type I1 regulatory subunits are in the nuclei of regenerating liver cells (245). Fletcher and Byus (246, 247), using a fluorescein-conjugated heat-stable protein kinase inhibitor, determined that catalytic subunit appears rapidly (5-15 min) in the cytoplasm and nucleolus but
3. CYCLIC NUCLEOTIDE-DEPENDENTPROTEIN KINASES
73
slowly (1 h) in the nucleus of glucagon- or dibutyryl-CAMP-stimulated H35 hepatoma cells. In contrast, Murtaugh et al. (248) were unable to detect any apparent redistribution of catalytic subunit in 8-bromo-CAMP-stimulated CHO cells and observed a diffuse staining pattern in several other cultured cell types. It is presently not clear if these differences are due to variations in basic mechanisms among cell types or to technical differences. The type I1 isozyme has been reported to be bound to a number of proteins, including microtubule-associated protein 2, a brain cytoskeletal protein (249-252); the mitotic spindle and nuclei of human breast cancer cells during different phases of growth (253);calcineurin (254), a calcium-calmodulin-activatedprotein phosphatase (255); P75, an unidentified brain protein with M, = 75,000 (256);and to some other brain proteins which are distinct from several type I1 regulatory subunit-bound proteins in heart (252). It is interesting that many of these examples are calcium-calmodulinbinding proteins which serve as substrates for the CAMP-dependent protein kinase. The cGMP-dependent protein kinase was first discovered in arthropod tissues (257) and was subsequently demonstrated in mammalian tissues (258). In contrast to the CAMPkinase, the cGMP-dependent protein kinase represents a minor component in most cells and is more restricted in its distribution (259-261). However, the cGMP kinase is found in significant concentrations in heart, lung, intestine, adrenal cortex, cerebellum, and smooth muscle tissue (25). Immunocytochemical studies localize the cGMP kinase in the cerebellum and the smooth muscle cells of major and minor blood vessels, intestinal wall and respiratory tract (262).It is presently not clear whether there are specialized functions in various tissues which require a specific cyclic nucleotide-dependent protein kinase isozyme or if there is a special advantage for a given tissue to contain a specific isozyme or isozyme mixture. An alternative explanation, that either isozyme can serve the physiological function equally well, and that the presence of different isozyme ratios in the various tissues is only fortuitous, has not been proved. However, the cGMP and the cGMP-dependent protein kinase has been reported to mediate the effects of certain agents, such as nitroglycerin and atrial natriuretic factor, on smooth muscle relaxation and kidney functions (262~2, 262b). ACTIVATION OF CYCLIC AMP-DEPENDENT C. SELECTIVE PROTEIN KINASEISOZYMES
Several factors regarding the physiological roles of the isozymes can be considered. One of these relates to the subunit structure of the kinases and the proposed mechanism of regulation of metabolism in the cell. As already described, both isozymes are composed of an inhibitory regulatory subunit dimer and two catalytic subunits. It is the difference between the regulatory subunits
74
STEPHEN J . BEEBE AND JACKIE D. CORBIN
that determine the isozyme type. According to the prevailing view, in higher organisms all of the effects of cAMP are mediated by the CAMP-dependent protein kinase and all regulatory processes are believed to be brought about by phosphorylation reactions catalyzed by the catalytic subunit of the enzyme. Since the catalytic subunit is identical in both isozymes, it can be argued that either isozyme can mediate the responses initiated by elevations in intracellular concentrations of CAMP. This does not exclude the possibility that an isozyme may be compartmentalized so that a single isozyme is activated by hormone stimulation. One should interpret with caution the finding that the type I isozyme is activated in vitro at lower concentrations of cAMP than is the type I1 isozyme. Activation of type I isozyme is inhibited by physiological concentrations of MgATP and autophosphorylation of the type I1 regulatory subunit inhibits subunit reassociation. Hofmann presented in vitro evidence indicating that in the presence of MgATP and sodium chloride the concentration of cAMP required to dissociate each isozyme is similar (57).Other factors such as dissociation of the isozymes by basic protein substrates (263, 264) and differential salt activation of the isozymes may be important in vivo. The extent of activation will also depend upon the relative concentrations of the regulatory and catalytic subunit present (265). As previously mentioned enzyme compartmentalization may be an important factor if selective activation of a single isozyme occurs. Buxton and Brunton (266)demonstrated selective activation of protein kinase based on the subcellular localization of the enzyme in a homogeneous population of cardiac myocytes. Specifically, isoproterenol and prostaglandin E, cause an elevation of cytosolic cAMP and an activation of cytosolic protein kinase. However, isoproterenol, but not prostaglandin E l , causes an elevation of particulate CAMP, a translocation of protein kinase activity from the particulate to the cytosolic fraction, and an activation of glycogen phosphorylase. This isoproterenol-specific response is rapid and is temporally related to the phosphorylase activation. That differential calcium availability is responsible for the observed differences is largely ruled out (266).These results suggest that the P-receptor adenylate cyclase, protein kinase, and phosphorylase are spatially isolated from the prostaglandin El system in cardiac myocytes. This agonist-specific protein kinase activation has been demonstrated in isolated, perfused hearts from several species (267-269). In the following discussion, reports supporting selective isozyme activation are examined and then reports of simultaneous activation of the isozymes are reviewed. Selective activation of the CAMP-dependent protein kinase isozymes has been reported in intact organisms and in intact cells. Schwoch (270)evaluated the extent of activation of the type I and type I1 protein kinases in rat liver after the animals were injected with glucagon. This analysis was based on DEAE-cellulose separation of inactive holoenzyme and free catalytic subunit and the property of the type I1 isozyme to rapidly associate in low ionic strength.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
75
Although the technique has a potential for artifactual enzyme activation (see Section II,A), it was one of the first studies designed to evaluate the physiological significance of two CAMP-dependent protein kinase isozymes. The data suggested a sequential activation of type I and then type I1 protein kinase. More specifically, 2 min after glucagon injection the type I isozyme was completely activated for at least 60 min while the type I1 isozyme was only partially activated. The type I1 kinase remained active for only about 30 min while the levels of CAMP were relatively high. Byus et al. (271) also found that a sequential activation of type I and type I1 protein kinase occurs when normal hepatocytes are incubated with glucagon or dibutyryl-CAMP. They used a method to distinguish type I and type I1 kinase activation based on separation of free catalytic subunit, type I and type I1 protein kinase using C6-aminoalkyl agarose chromatography. Maximal glycogenolysis was correlated with a selective activation of type I protein kinase, which was predominantly activated by the lowest effective concentrations of either agonist. Hunzicker-Dunn (272) also used a technique that separated subunits of CAMPdependent protein kinase on DEAE-cellulose. Data from this study suggested a preferential activation of the type I isozyme in the corpora lutea obtained from ovaries of 4-day pseudopregnant rabbits treated with a single injection of human chorionic gonadotropin. Livesey and co-workers (273) developed a rapid batch elution method for separating the two isozymes of protein kinase on DEAE-cellulose columns. In these studies rigorous attempts were made to exclude the possibility of postextraction activation of protein kinase. One study evaluated the effects of parathyroid hormones and prostaglandin E, on the activation of type I and type I1 protein kinase from normal and neoplastic osteocytes from rat calveria (273). These data suggested that the isozyme response not only is specific for a particular hormone effector but also depends upon the cell type. Parathyroid hormone predominantly activated the type I isozyme in the neoplastic osteocytes but activates both isozymes to the same extent in the normal cells. Prostaglandin E, also caused a predominantly type I isozyme activation in the malignant cells but specifically activated the type I1 isozyme in the normal calveria cells. This technique was modified and validated to evaluate the effects of conditions and prostaglandin E, on protein kinase activation in two human breast cancer cells lines, T47D and MCF7 (274, 275). In both of these cells, calcitonin selectively activated the type I1 isozyme, however, the duration of the response was different. While type I1 activation in the MCF7 cells was transient over 4-6 h, it was persistent in the T47D cells for at least 24 h. Mizuno et al. (276) analyzed the cytosolic protein kinases from the submandibular glands of control and isoproterenol-treated rats. Using DEAE-cellulose, they concluded that 10 min after isoproterenol injection, the type I1 isozyme readily dissociated into regulatory and catalytic subunits which are separated on
76
STEPHEN J . BEEBE AND JACKIE D. CORBIN
the column. The type I isozyme eluted from the column at 0.1 M KCI but had an activity ratio of about 1.0; they concluded that the type I isozyme was less dissociable than the type I1 isozyme, but was highly active in an undissociated form. Therefore, activation of both isozymes correlated with salivary secretion but the type I remains active for as long as an hour while the activity ratio of the type I1 isozyme decreases slightly. This latter result is similar to the timedependent behavior of glucagon-stimulated rat liver protein kinase isozymes reported by Schwoch (270). Chew (277) investigated histamine-stimulated acid secretion in parietal cells isolated from rabbit gastric mucosa. These cells contained the type I isozyme in the cytosol and the type I1 kinase in the cytosol and particulate-fraction. Histamine activated only the type I isozyme while forskolin activated both isozymes. This conclusion was obtained from results of DEAE-cellulose chromatography, differential isozyme reassociation after cAMP removal by Sephadex G-25 chromatography, and 8-a~ido-[~~P]cAMP photoaffinity labeling of crude extracts. The results suggest that the type I isozyme mediates histaminestimulated acid secretion and that this isozyme is compartmentalized with the histamine H, receptor-coupled adenylate cyclase. Other techniques have been used to evaluate the biological role and the physiological significance of the two isozymes of the CAMP-dependent protein kinase. Litvin and co-workers (278) used an approach based on specific antibody precipitation of type I or type I1 protein kinase. They demonstrated a parallel release of ACTH and a selective type I protein kinase activation when AtT20 mouse pituitary tumor cells were stimulated with corticotropin releasing factor. Maximal ACTH release was seen with a 2-fold increase in cAMP and only a slight activation of the type I1 isozyme. When 0.5 mM 3-methylisobutylxanthine was added, no further increase in ACTH release occurred and the type 11 isozyme is now activated by 50%. 3-Methylisobutylxanthine alone (0.5 mM) fully activates type I, while type I1 was activated by about 25%. The earliest report of simultaneous activation of types I and I1 in a tissue was that of Corbin and Keely (215). This study was done using epinephrine-perfused hearts from several mammalian species which were known to possess different relative amounts of the two isozymes. From examination of the degree of reversal of the hormone effect by Sephadex G-25 chromatography, no apparent selectivity was observed and it was concluded that both isozymes are activated by epinephrine. Ekanger et al. (279) developed an approach in which endogeneous cAMP bound to the regulatory subunit of type I or type I1 protein kinase was quantitated after specific adsorption to protein A-agarose coated with antibodies directed against the respective isozymes. While the work of Schwoch with rat liver (270) and Byus et al. with isolated hepatocytes (271) indicated a preferential activation of type I protein kinase, Ekanger and co-workers demonstrated that both type I
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
77
and type I1 isozymes were equally activated in isolated hepatocytes as the concentration of glucagon is varied over a wide range. As discussed in Section II,A, certain cAMP analogs are selective for one or the other of two intrasubunit cyclic nucleotide binding sites and cAMP analog combinations can distinguish between synergistic activation of type I and type I1 protein kinase (Fig. 1). These in vitro findings have been extended to demonstrate a synergism of CAMP-mediated responses in a number of isolated cell and tissue preparations (113, 114, 1 1 4 ~ )It. has been demonstrated that the analogs used in these studies have no apparent special properties other than site selectivity (105, 107, 109, 111, 113). Furthermore, when hepatocyte glycogenolysis is stimulated by a series of equipotent concentrations of glucagon or 8-thioparachlorophenyl-CAMP [and the analog effectively removed (Ref. 2131, the degree of phosphorylase activation was closely correlated with the CAMP-dependent protein kinase activity ratio for both agonists (T. W. Gettys and J . D. Corbin, unpublished). Therefore, data demonstrating that a combination of site-selective cAMP analogs generate a synergism of a physiological response can be used to prove that protein kinase mediates the response. This technique also suggests that the cooperativity of cAMP binding and protein kinase activation measured in vitro are important to the function of protein kinase in vivo and that the cooperativity may be a mechanism of sensitivity amplification at the protein kinase step in the intact tissue (113). When cyclic nucleotide analogs are added to isolated cells, they cross the cell membrane, bypass the hormone receptor-adenylate cyclase system and directly activate the CAMP-dependent protein kinase isozymes (113, 114, 114a, 214). When a site-1- and a site-2-selective analog are added in combination to intact cells synergism of a physiological response occurs only if the response is mediated by the CAMP-dependent protein kinase. Furthermore, if the type I protein kinase mediates the response, synergism should occur only when two analogs selective for site 1 and site 2, respectively, for this isozyme are combined (type I directed-analog pair), and if the type I1 isozyme mediates the response synergism should only occur when two analogs selective for site 1 and 2 of this isozyme are combined (type I1 directed-analog pair) (see Section II,A, and Fig. 1). It is important to use the analogs at relatively low concentrations, which allows for a wider window for examining synergistic effects (113, 114, 1 1 4 ~ )It. is also important to use the analogs at concentrations that result in a linear doseresponse relationship for the measured effect. Additionally, controls should be included to determine that a combination of two analogs that are selective for the same site do not cause a synergism of the response. This method, which is fully described elsewhere, has now been tested in a number of different systems (114a) including adipocyte lipolysis ( I 13), hepatocyte phosphorylase activation (114), increases in mRNA for phosphoenolpyruvate carboxykinase in continuous cultures of H4IIE hepatoma cells (280),induc-
78
STEPHEN J . BEEBE AND JACKIE D. CORBIN
tion of LH receptors and increased progesterone synthesis in primary cultures of porcine granulosa cells (281), and thyroid hormone release in dog thyroid slices (J. Van Sande and J . E. Dumont, personal communication). This technique was first tested by measuring adipocyte lipolysis (113). Adipocytes contain predominately, if not exclusively, the type I1 isozyme (7). Synergism of protein kinase activation in v i m and glycerol release from intact cells was observed only with type I1 directed-analog pair. Synergism did not occur for either process with type I directed-analog pair, or with a combination of two site-I or two site-2 selective analogs. These data demonstrate that the type I1 isozyme mediates the lipolytic response. Since the first demonstration of synergism in intact cells using pairs of siteselective cAMP analogs, new analogs have been developed that, when combined with another analog selective for the opposite site, provide a more selective synergistic activation of only one isozyme. One of these analogs is 8-piperidinocAMP (104). In addition to using N6-benzoyl- and 8-aminohexylamino-CAMPas a type I directed-analog pair and N6-benzoyl- and 8-thiomethyl-CAMPas a type I1 directed-analog pair, further experiments were carried out using 8-piperidinoand 8-piperidino-CAMP as a type I directed-pair and N6-benzoyl- and 8piperidino-CAMP as a type I1 directed-pair (see Fig. 1). In these experiments, phosphorylase activation was measured in various cell types which contain different protein kinase isozyme ratios. Bovine neutrophils (85% type I), rat adipocytes (>95% type II), and rat hepatocytes (type I = type 11) were used. For all isozymes tested in v i m , type I directed-analog pairs synergistically activate only type I isozymes while type I1 directed-analog pairs synergistically activate only type I1 isozymes. In close agreement with these results, bovine neutrophil phosphorylase was synergistically activated almost exclusively by type I directed-analog pairs, adipocyte phosphorylase was synergistically activated almost exclusively by type I1 directed-analog pairs, and rat hepatocytes were synergistically activated by both type I directed- and type I1 directed-analog pairs (114). These data indicate that either type I or type I1 protein kinase can regulate phosphorylase activation. These techniques have been used to determine whether the CAMP-dependent protein kinase has a regulatory role at the nuclear level in H4IIE hepatoma cells. Since it is known that cAMP analogs increase the amount of mRNA for phosphoenolpyruvate carboxykinase (PEPCK) in these cells (283), it was of interest to see if cAMP analog combinations could act synergistically to produce this response. It was also possible to test if a synergism of PEPCK gene transcription could be demonstrated. To test these possibilities, various site-l- and site-2selective cAMP analogs were added alone (in the linear dose-response range) and in combination to H4II cell type I1 CAMP-dependent protein kinase in vitro and to H4 cells in culture. Determinations were then made of the extent of synergism for the isolated activation, increase in mRNAPEPCK,and PEPCK gene transcrip-
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
79
tion. All analog pairs that resulted in a synergistic activation of protein kinase also resulted in a synergistic increase in mRNAPEPCKand PEPCK gene transcription. Synergism, as quantitated by ratio of responses of an analog pair divided by sum of single analog responses, is approximately 2 for protein kinase activation, 3-4 for the increase in mRNAPEPCK,and 10-12 for PEPCK gene transcription. For all responses tested, synergism does not occur when two site- 1 -selective or two site-2-selective analogs are combined. The occurrence of synergism only when a site-1- and a site-2-selective analog are combined is a protein kinase-specific characteristic. These results clearly indicate the involvement of protein kinase in the cAMP regulation of PEPCK gene transcription. It is presently not clear if this effect is due to a phosphorylation event or to some other mechanism such as the CAMP-bound regulatory subunit acting in a manner analogous to the E. coli catabolite gene activator protein (CAP). Segaloff et af.(281) used these site-selective cAMP analog combinations in primary cultures of porcine granulosa cells to test whether or not induction of LH receptors and the increase in progesterone synthesis are CAMP-dependent protein kinase-mediated events. Photoaffinity 8-a~ido-[~*P]cAMP labeling of cell extracts suggested that both regulatory subunit isozymes are present. Two specifically labeled bands with apparent M, = 56,000 and 49,000 comigrate with homogeneous rabbit skeletal muscle type I and type I1 regulatory subunit standards. The type I1 isozyme is induced 5- to 10-fold by cholera toxin and represents the predominant isozyme while type I represents only a minor band. Incubation of cells in primary culture with type I directed- and type I1 directedanalog pairs resulted in a synergism of LH receptor induction, as determined by 1251 human choriogonadotropin binding, and in a synergism in progesterone synthesis, as measured by radioimmunoassay. The synergism of both of these responses was much greater with a type I1 directed- than a type I directed-analog pair. No synergism of either response was observed with two site 1-selective analogs or with two site-2 selective analogs. These data indicate that both the induction of LH receptors and the increase in progesterone are mediated by the CAMP-dependent protein kinase and that the predominant type I1 isozyme is primarily responsible for both of these responses. This method is presently being tested by J . Van Sande and J. E. Dumont (personal communication), using thyroid hormone secretion in dog thyroid slices. Secretion was measured by butanol extraction of I 3 l I from the medium as a percentage of total radioactivity present in the slices at the beginning of a 5 h incubation. Both type I and type 11 protein kinase were present in the dog thyroid (242). When tissue slices were incubated with type I directed- and type I1 directed-analog pairs, synergism of thyroid hormone secretion was present to approximately the same extent for both isozyme synergistic pairs. This result suggests that both type I and type I1 isozymes mediate thyroid hormone secretion.
80
STEPHEN J. BEEBE AND JACKIE D. CORBIN
Data from studies using type I directed- and type I1 directed-analog pairs suggest that, for the various parameters measured, either isozyme can mediate CAMP-dependent protein kinase generated responses. The extent of the contribution of each of the isozymes seems to correlate approximately with the amount of each of the isozymes present. These conclusions appear to be valid for the limited number of experimental models tested, and this technique appears to be generally applicable. It should be pointed out that through the use of cAMP analogs, the hormone-receptor-adenylate cyclase system is bypassed. It is indeed possible that the intact cell is compartmentalized to the extent that the hormone is coupled to only a single kinase isozyme. Furthermore, although for the type I and type I1 isozymes tested, the defined analog pairs appear to specifically cause a synergistic activation of only a single protein kinase isozyme, it cannot be ruled out that exceptions to these generalizations may exist. This is a concern given data describing microheterogeneous subforms of the type I1 isozyme from various tissues and species (see Section 11,A). Similar microheterogeneous subforms of the type I isozyme may also exist. However, for the responses of type I and type I1 protein kinase activation tested in v i m , the defined cAMP analog combinations appear to be isozyme specific. This is based on experiments of type I and type I1 isozymes from rabbit skeletal muscle, rat heart, rat hepatocyte, and bovine neutrophil, as well as the type I1 isozyme from rat liver plasma membrane, rat adipocytes, cultured rat hepatoma (H4IIE) cells, dog thyroid, and bovine heart. It should be pointed out that in spite of the microheterogeneous differences between the type I1 isozymes from bovine heart, rat hepatocyte, and rat adipocyte, similar effects of the cAMP analog combinations are observed with each isozymic form. D.
USE OF
CYCLIC NUCLEOTIDE ANALOGS IN INTACTCELLS
As mentioned previously, cyclic nucleotide derivatives were originally designed to be used in studies of the structural requirements of cyclic nucleotide activation of protein kinase, to develop analogs which are more potent than CAMP, and to develop antagonists of cAMP (281). These studies have been expanded to accommodate the presence of two types of CAMP-dependent protein as well as the cGMP-dependent protein kinases, designated type I and type I1 (3, kinase. Furthermore, it is now clear that the regulatory components of these three cyclic nucleotide-dependent protein kinase isozymes have two different intrasubunit cyclic nucleotide binding sites, termed site 1 or site B and site 2 or site A, which exchange bound, labeled cyclic nucleotide slowly and rapidly, respec, The development and uses of cyclic nucleotide tively ( 6 , 8 , 2 1 , 2 4 , 5 9 , 8 6105). analogs have closely paralleled and sometimes led the development of our understanding of the cyclic nucleotide-dependent protein kinases. In fact, derivatives of cyclic nucleotides which had been available for many years were used to
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
81
define and characterize the two different binding sites on the respective kinases (21, 105, 107, 108, 181). Consequently, studies are being directed toward understanding structural and functional differences among the cyclic nucleotidedependent protein kinase isozymes, finding analogs that are more potent activators of one or the other isozymes, and developing analogs that are selective for one or the other different intrasubunit binding sites. In addition to these in vifro studies, experiments applying the available knowledge concerning the mechanism of protein kinase isozyme activation, phosphodiesterase hydrolysis, and potential for analogs to be permeable to membranes have been and are being conducted using cyclic nucleotide analogs on a large number of in vivo preparations from whole animals to isolated cells. Because of the hundreds of analogs that have been synthesize, it has proved important to develop a systematic and rational approach to using analogs. Miller and Jastorff and their collaborators have synthesized and tested a large number of analogs (103, 285-292) that have proved useful for in v i m and in vivo studies. The work of these and others have greatly advanced our knowledge concerning the cyclic nucleotide-dependent protein kinases and their role in metabolic regulation. Both of the intrasubunit sites on the CAMP-dependent and cGMP-dependent protein kinases have high specificity for the ribose-phosphate moiety and lower specificity for the base moiety of the respective cyclic nucleotide (108). The CAMP-and the cGMP-dependent protein kinases distinguish between cAMP and cGMP by specific recognition of the respective bases of the molecules. The cAMP kinase isozymes are specific for a C6-amino group (290). Although the base is not required for activation, it is thought to interact with the regulatory subunit by hydrophobic and/or 7~ electron bonding interactions rather than by hydrogen bond interactions (290, 293, 294). Substitution at C6 results in reduced specificity for cAMP kinase activation and if the C6-amino group is changed to a C6-imino group, the resulting analog shows an increased specificity for the cGMP kinase (290, 291). As expected, the cGMP-dependent protein kinase appears to prefer both a C6-oxygen and a C2-amino group for activation. The C6-oxygen apparently accepts a proton from and the C2-amino donates a proton to the enzyme (290, 291). By systematically altering the cyclic nucleotide molecule, structural requirements for cyclic nucleotide binding and protein kinase activation have been partially defined. Evidence indicates that the primary determinant of cyclic nucleotide activation of the respective isozymes is the hydrophilic cyclic phosphate moiety (103, 285). Alterations in this portion of the molecule are generally not tolerated. Activation of both cAMP protein kinase isozymes requires a charged cyclic phosphate in addition to a 3' oxygen and a 2' hydroxyl group both in the rib0 conformation. These are probably important for hydrogen bonding (103, 289, 287). Additionally, the syn conformation of the cyclic nucleotide is pre-
82
STEPHEN J . BEEBE AND JACKIE D. CORBIN
ferred (287, 289) and the orientation of the purine-cyclic phosphate is critical (287, 289). Although the CAMP- and cGMP-dependent protein kinases are believed to be homologous proteins with highly conserved cyclic nucleotide binding sites, it is clear that differences do exist. These considerations also extend to the two isozymes of the CAMP-dependent protein kinase. Recent reports indicate that the type I1 isozymes from various tissues and species appear to be microheterogeneous (see Section II,A), and may contain differences in the binding sites. It should be kept in mind that the established structure-activity relationships for cyclic nucleotide recognition by the protein kinases are from a limited number of isozyme types. Cyclic AMP analogs have been used in a number of isolated cell and tissue preparations. The efficacy of cyclic nucleotide analogs as agonists of protein kinase-mediated responses in intact cells or in intact organisms is dependent upon the concentration of the analog at its site of action. The efficacy of all analogs tested for adipocyte lipolysis and hepatocyte phosphorylase activation are explained by consideration of at least three basic analog properties (113, 114a, 214) (favorable lipophilicity, low K , for protein kinase activation, and resistance to low K,,, phosphodiesterase hydrolysis). The lipid character and porosity of the cell membrane and other cellular constituents that could “trap the analog” should also be considered (214). Table I shows the concentration of analogs required for a half maximal activation of adipocyte lipolysis, hepatocyte phosphorylase a, and induction of mRNA for phosphoenolpyruvate carboxykinase in H4IIE hepatoma cells. There are only minor differences in the cyclic nucleotide specificities between the adipocyte and hepatocyte protein kinases and between the low K,,, phosphodiesterases from the respective cells types. Therefore, lipid content of cellular constituents, membrane porosity, and phosphodiesterase activity appear to be potentially important when comparing the efficacy of analogs in adipocytes and hepatocytes ( I 14a, 214). Adipocyte lipolysis is sensitive to analogs in the millimolar concentration range and hepatocyte phosphorylase is activated in the micromolar concentration range. Generally, hepatocytes are 100- 10,000 times more sensitive than adipocytes to cAMP analog stimulation when comparing these two physiological processes. The nuclear response measured in H4IIE hepatoma cells is intermediate in sensitivity to cAMP analogs. It is possible that other physiological responses in these cell types may show a different sensitivity to cAMP analogs. The sensitivity of a cellular response to cAMP analogs may also depend upon enzyme compartmentalization, the basal activation state of protein kinase (thereby affecting sensitivity amplification at the protein kinase step), and the potential for magnitude amplification (determined to some extent by the number of steps between the initial activation event and the final response). Free et al. (295) demonstrated that cAMP analogs were generally more potent in stimulating adrenal cell steroidogenesis than in stimulating adipocyte lipolysis. These studies
83
3. CYCLIC NUCLEOTIDE-DEPENDENTPROTEIN KINASES TABLE I CONCENTRATIONS OF CYCLIC NUCLEOTIDE ANALOGS PHOSPHOENOLPYRUVATE CARBOXYKINASE ACTIVATION
FOR
Cyclic nucleotide analog 8-Thioethyl 8-Aminomethyl N6-Diethyl 8-Bromo 8-Thio-p-chloropheny l 6-Thiomethy l 8-Thiomethyl 8-Amino 8-Thioisopropyl 8-Thiobenzyl 8-Thio-p-nitrobenzyl N6-Aminohex ylcarbamoylmethy l N6,02’-Dibutyryl N6-C~bamoylpropyl N6-Benzoyl N6-Butyvl 8-Hydroxy 8-Aminohexylamino 8-Aminobenzyl
ECSO Adipocyte lipolysis
EC50 Hepatocyte phos a
EGO mRNAPEPCK
(CLM)
(W)
(W)
0.3 6.0 I .3 0.1
>5,000 25
-
-
0.5 2.0 -
330 -
0.1
-
-
-
900 7,900 2,000 3,900 1,000 600 1,000 6,100 500 1,900 I ,200 10,000 1,100 500 700 1,900 900 8,600 >15,000
3.0 0.5 4.8 60 -
-
50
580 2,250 1,000 780
illustrate a degree of cellular specificity and suggest the possibility of using cAMP analogs in whole organisms to selectivity stimulate some cell types and not others. One of the originally defined objectives for the synthesis of cyclic nucleotide analogs was to find an antagonist of protein kinase (284). Some cAMP analogs have proven to be competitive antagonists of cAMP binding to the catabolite gene activator protein (CAP) and prevent specific DNA binding and stimulation of gene transcription in E. cofi (296, 297). For example, cGMP, cIMP, and N6monobutyryl-CAMP apparently interfere with optimal hydrogen bonding while the bulky groups of 8-bromo- and 8-thio-CAMPcause steric interferences. Presumably, these competitive antagonists and cAMP both bind to CAP but the antagonists do not induce the necessary conformational change required for specific DNA binding. The competitive antagonists of cAMP E . coli gene transcription mentioned above are agonists of protein kinase activation. The structural requirements for antagonism of protein kinase activation are therefore considerably different than for the CAP protein (298, 299).
84
STEPHEN J. BEEBE AND JACKIE D. CORBIN
Several reports using diastereomers of cyclic monophosphorothioate and cyclic monophosphodimethylamidate derivatives of cAMP [CAMPSand CAMPN(CH,),, respectively], which contain chiral phosphorus centers (RRp and SSp) suggest that some of these analogs may fulfill the criteria as useful protein kinase antagonists (300-306). These criteria include (a) binding to but not activating protein kinase; (b) having a relatively good affinity for protein kinase so that competition with cAMP at the cyclic nucleotide binding site is effective; and (c) having structural features that allow membrane penetration so that antagonists can be used in intact tissues. This latter criterion may vary for cells with different lipid characters. DeWit et al. (294, 305) used the diastereomeric forms of both of the above analogs to determine the characteristics of cyclic nucleotide binding to site 1 (stable site) on the type 1 isozyme from rabbit skeletal muscle. They observed that all the cAMP analogs tested, except Rp CAMPSand both enantiomers of CAMP-N(CH,),, have lower affinity for site 1 of the holoenzyrne than for the free regulatory subunit. This suggests that, unlike other analogs tested, these three analogs did not compete with cAMP for binding to the regulatory subunit. Furthermore, Rp CAMPS competed with cAMP for binding to the holoenzyme but was ineffective for protein kinase activation (294, 300, 305). O’Brian et al. (300) used Rp and Sp CAMPS to study the stereochemistry of cyclic nucleotide binding to and activation of the type I1 protein kinase. They reported that both enantiomers bind to and activate the kinase but the Sp conformer is much more potent for both of these actions than the Rp conformer. They also determined that the Sp conformer binds preferentially to site 2 while the Rp conformer binds preferentially to site 1. Botelho et al. have described a number of studies using Sp and Rp CAMPS in isolated hepatocytes (301, 302, 304, 306). Sp CAMPS is a full agonist that stimulates glucose production half-maximally and maximally at 0.8and 10 pM, respectively. Rp CAMPSappears to have no significant potency as an agonist of glucose production (301, 302), phosphorylase activation, or glycogen synthase inactivation (304). Instead, Rp CAMPS antagonizes these agonist-stimulated reactions. When 5 pM Rp CAMPSis present, 10-fold and 6-fold higher concentrations of Sp CAMPS and glucagon, respectively, are required for half-maximal glucose production. Similar increases in agonist concentrations are required for the activation of the CAMP-dependent protein kinase and phosphorylase, and inactivation of glycogen synthase. The putative antagonist (3 pM- 100 pM) produced a maximal inhibition of 50-74% when glucose production was stimulated by 1 nM glucagon, depending on the time of preincubation with Rp. Rp CAMPS appears to be an in vivo competitive protein kinase antagonist. It has been estimated that for Sp CAMPS-stimulated glucose production, a Rp CAMPS to Sp CAMPSmolar ratio of 3 and 30 are required for half-maximal and maximal inhibition, respectively. Further research using these protein kinase antagonists
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
85
and the development of others can provide useful and important tools to more completely define the role of protein kinase in the regulation of cell function. A potential complication of using cyclic nucleotide analogs in intact cells is a change in the intracellular cAMP concentration. For example, it is possible that analogs could serve as competitive substrates for phosphodiesterases and thereby increase the cAMP concentration. However, it has been shown that cAMP analog-stimulated hepatocytes have lower cAMP concentrations than unstimulated cells. The cAMP decrease appears to be mediated by a CAMP-dependent protein kinase mechanism (213). This suggests that through a feedback mechanism, such as phosphoidiesterase(s) stimulation and/or adenylate cyclase inhibition, the CAMP-dependent protein kinase can regulate its own activation state. The effects of insulin on cAMP analog-stimulated adipocyte lipolysis, hepatocyte glycogenolysis, and cardiac myocyte glycogenolysis and glycogenesis have been investigated (214, 307). In several mammalian tissues insulin is known to block most of the metabolic effects of hormones that elevate cAMP levels. If lowering of cAMP by phosphodiesterase activation is a necessary step in some of the effects of insulin, then this hormone may not work if the phosphodiesterase is prevented from catalyzing hydrolysis of cyclic nucleotides. This would be the case when cellular CAMP-dependent protein kinase is activated by phosphodiesterase-resistantcAMP analogs, instead of by either hormonal elevation of cAMP or by phosphodiesterase-sensitive cAMP analogs. Some, but not all, cAMP analogs are quite resistant to hydrolysis by phosphodiesterase (214). in cardiomyocytes insulin does not block the effects of the cAMP analogs tested on phosphorylase and glycogen synthase activity (307). In adipocytes and hepatocyges insulin blocks the metabolic effects of hormones that elevate CAMP, but when cAMP analogs are used, the results are different from those obtained in cardiomyocytes. Although insulin blocks the effects of some cAMP analogs it does not block the effects of analogs that are extremely resistant to hydrolysis by the low K,,,, hormone-sensitive phosphodiesterase (214). The results suggest that at least in adipocytes and hepatocytes insulin antagonism of the metabolic effects examined can be explained by phosphodiesterase activation.
E. THEROLE OF CYCLICAMP AND THE CYCLIC AMP-DEPENDENT PROTEIN KINASEISOZYMES I N THE CELL AND DIFFERENTIATION CYCLE,PROLIFERATION, The primary emphasis of this section is placed on cAMP and the CAMPdependent protein kinase since far more literature is available on this system as compared to cGMP and the cGMP-dependent protein kinase. Three levels of cyclic nucleotide involvement in the regulation of these developmental processes are discussed. The role of cAMP in these processes is only briefly reviewed here since this subject has been intensely studied over the years and has been the
86
STEPHEN J. BEEBE AND JACKIE D. CORBIN
target of several excellent reviews (308-318). The role of the CAMP-dependent protein kinase in these processes has been studied less frequently but has also been reviewed (239, 319, 320). The third level of involvement examines the possibility that specific cellular functions may be regulated by specific protein kinase isozymes. The literature in this field is inconclusive and often contradictory. It is difficult to arrive at definitive conclusions because methodological limitations require conservative interpretations (237, 312, 315, 318). Much of the early work was conducted without an appreciation for some of the pitfalls inherent in the experimental techniques. The events that regulate the cell cycle and determine if a cell will continue to proliferate or undergo differentiation are extremely complex. Research is being conducted against a background of incomplete and insufficient information. Several lines of evidence have accumulated to suggest a role for cAMP in the modulation of the cell cycle. One of the most fundamental observations supporting this is that the cAMP level in populations of synchronized cells oscillates during the cell cycle (311, 312, 314, 315, 317, 321-323). These cAMP fluctuations have a regular pattern and have been observed in a number of cell types, including normal and malignant cells, and using several different methods of cell synchronization. The most common finding is that the cAMP level is at a minimum during mitosis, gradually increases during G I , reaches a peak near the G , S border and declines again during the S phase. The G , phase is also often associated with a transient cAMP elevation. It is often seen that during the G I phase two peaks of cAMP are observed (311, 314, 318, 324-326). When two peaks occur, it appears to be the second peak that is required for DNA synthesis (318, 325, 327, 328). Although the cause of these cAMP surges is not known for certain, in general terms it is expected that a high ratio of adenylate cyclase to phosphodiesterase activities accounts for the elevation of cAMP and a low ratio of these enzyme activities accounts for the cAMP decrease (329). Although this seems reasonable, the hypothesis has not been rigorously tested. These relationships, however, have been observed in RPMI-8866 human lymphoid cells (330).In regenerating rat liver, an increase in the number of beta receptors on the hepatocyte membranes contributes to an increase in adenylate cyclase activity (331). In addition, a transient increase in the levels of calmodulin have been reported to coincide with the second cAMP increase seen in this tissue (318, 332). This could conceivably contribute to a stimulatory effect on adenylate cyclase and/or a stimulation of a phosphodiesterase (332, 333). Several investigators have demonstrated that cAMP elevation leads to an induction of phosphodiesterase (334339). Liu reported in 3T3-LI cells that treatment with dibutyryl-CAMP for 2-7 days leads to a 4- to 6-fold increase in the specificity activity of phosphodiesterase (337). Similar results were obtained in S-49 mouse lymphoma
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
87
cells (338) and mouse neuroblastoma cells (339). The observation that indomethacin, an inhibitor of prostaglandin synthesis, blocks the increase in cAMP and subsequent DNA synthesis in mouse lymphocytes suggests that prostaglandin, a known stimulator of adenyate cyclase, may be involved in the cAMP elevation (340). Rozengurt et al. (341)reported that prostaglandin E, causes an increase in intracellular cAMP and stimulates DNA synthesis in Swiss 3T3 cells when insulin is present. These investigators (342) have also demonstrated that partially purified porcine platelet-derived growth factor, a potent mitogen for untransformed fibroblastic cells, causes an increase in production of prostaglandins of the E series and a marked, indomethacin-sensitive elevation of cAMP in the presence of phosphodiesterase inhibitors. The origin of the signals that regulate these cAMP fluctuations are presently not known. There has been some speculation that signals that regulate the cell cycle are internal or intrinsic to the cells. There are examples of this type in nature. The intrinsic cardiac rhythmicity and electroencephalographic wave rhythms are of internal origin. Generation of cAMP may be one of these inherent signals of cAMP regulation superimposed on other inherent regulatory signals (317). In the intact organism, cells of a developing tissue do not function in isolation, and external signals, which act at cell surface or internal receptors, may affect cAMP levels. Hormones and growth factors are required for proliferation or differentiation. The cell cycle and these developmental processes may be regulated by both internal and external signals similar to circadian rhythms or other biological clock mechanisms. Rozengurt et al. have suggested (342),from their work and the work of others (343-343, that cells may secrete substances such as prostaglandins which then act on receptors of surrounding cells, as well as on their own. The original second-messenger hypothesis (3) presented a unifying theory describing the elevation of cAMP as an intracellular response generated by an external hormone signal. Therefore, cAMP is described as a “Director of Foreign Affairs” (3). That cAMP and the CAMP-dependent protein kinase are involved in cell development, which could be “internal affairs,” is not necessarily implicit in this theory (312). Although phosphorylation reactions are the only known mechanism of protein kinase action, it cannot necessarily be assumed that all the effects of cAMP are mediated by them. It should not be ruled out that the regulatory subunit or other unrecognized CAMP-binding proteins may play a role of their own (see Section IV,F.). Nevertheless, knowing the mechanism of activation of protein kinase by cAMP and the importance of this equilibrium reaction in the regulation of metabolism of cells in the quiescent, Go state, it is likely that protein kinase-mediated phosphorylation is involved in some aspects of regulation or modulation of cell cycle events. If cAMP andlor the protein kinase are involved in the regulation of developmental processes, an important question is at what site or sites do they act. Using
88
STEPHEN J. BEEBE AND JACKIE D.CORBIN
the role of cAMP in hormonal regulation as an analogy, it is likely that the CAMP-dependent protein kinase acts at transition phases; for example, it could act at sites between the end of one cell division and the DNA synthesis that precedes the next division. However, there is some controversy concerning the nature of events that comprise this transition (314, 317, 318). One hypothesis proposes that growth-arrested cells are in a distinct quiescent Go state which they must leave to reenter the GI phase (346-348). Friedman (317 ) has discussed the possible roles of cAMP at this point but whether or not protein kinase mediates these events, and if so, how, is not known. An alternative theory proposes that nonproliferating cells remain in the G, phase but have a very low probability of continuing into the S phase due to a number of factors related to requirements for DNA synthesis and mitosis (349). Pledger and co-workers (350) showed that quiescent BALB-c/3T3 cells must pass through at least two phases, which are separately regulated, before they can synthesize DNA. They suggested that these cells require a platelet-derived growth factor to become “competent,” that is to leave the Go phase and enter the cell cycle. Other factors are required for competent cells to progress through the cell cycle. These factors are present in platelet-poor plasma and are effective in competent but not in incompetent cells. This progression factor appears to be somatomedin C or other members of this family of growth factors and epidermal growth factor. Interestingly, simian virus 40 provides both competence and progression activity. Boynton and Whitfield (318) have reviewed this theory in detail and have suggested that there are at least four different types of prereplicative phases in eucaryotic cells. There has been considerable controversy concerning the role of cAMP in the cell cycle as a positive or negative regulator (314, 315, 317, 318). That cAMP is a negative regulator of proliferation is based on three general types of evidence. One is the observation that the levels of cAMP are often high in the quiescent state and then drop as the cells are stimulated to proliferate. The second is that the use of exogenous cyclic nucleotides or agents that elevate intracellular cAMP arrests many cells in the G, or G, phase of the cycle. A third type of evidence is derived from the use of cell varients that are deficient in the CAMP-dependent protein kinase (351-360). However, evidence is also available to support a stimulatory role for cAMP in the cell cycle. Although the addition of high concentrations of cAMP or cAMP analogs at critical points during the cell cycle inhibits cell proliferation in some cell types, at appropriate times cAMP or cAMP analogs stimulate proliferation in other cell types (314, 317, 318). Studies conducted by Wang et al. (340) using conconavalin A-stimulated mouse lymphocytes indicate that a rise and a fall in cAMP is required for the progression of these cells into the S phase of the cell cycle (318, 340, 361). When conconavalin A is used to stimulate lymphocytes to proliferate, RNA synthesis precedes and DNA synthesis follows the increase in CAMP. When indomethacin, which stimulates adenylate cyclase, is used to block synthesis of
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
89
prostaglandins, both the cAMP increase and DNA synthesis are blocked. This condition is reversed when indomethacin is removed. The addition of 8-bromocAMP or the phosphodiesterase inhibitor RO-20- 1724 after the cAMP rise, but before DNA synthesis, blocks the progression of concanavalin A-stimulated cells into the S phase. When the first peak of cAMP is prevented from falling in serum-starved human fibroblasts, DNA synthesis is not blocked (362). However, if the subsequent late GI phase cAMP surge is prevented from subsiding, DNA synthesis is arrested. Likewise, prevention of the natural rise and fall of cAMP in the late G , phase of human lymphoid cells prevents mitosis (363). It should be kept in mind that it is difficult to generalize the effects of cAMP on cell development, and the effects of the cyclic nucleotide may be tissue- and/or cell stagespecific (314, 315, 317). Other evidence not only supports a role in cell development for cAMP but also for the CAMP-dependent protein kinase isozymes (237, 31 7-320). The method generally used to quantitate the CAMP-dependent protein kinase isozymes is by the use of DEAE-cellulose chromatography. Although this technique can be used for reasonably accurate estimations of protein kinase isozymes, it is important to realize and avoid the potential pitfalls of the method. Specific antibodies for each isozyme have been used and provide a more accurate determination of isozyme levels (237). The levels of the CAMP-dependent protein kinase isozymes have been measured during the cell cycle in several studies. In these studies the levels of both isozymes are reported to oscillate during cell cycle traverse. While the oscillation of isozymes suggests that each may have a separate and specific function, there are little, if any, data to indicate what these functions might be. Costa et al. (364) observed in Chinese hamster ovary cells that the specific activity of CAMPdependent protein kinase first decreases about twofold and then increases I .5to 3.5-fold such that a maximum was reached at the G,-S border. As the cells proceed through the G , phase, the ratio of type I to type 11 protein kinase changes reciprocally. The increase in specific protein kinase activity is due to a selective elevation of the type I1 isozyme while the type 1 isozyme decreases. Haddox er al. (365) observed that as the Chinese hamster ovary cells traverse GI and approach the S phase, the type I1 isozyme increases as a function of time and cAMP concentration, but the specific activity of type I does not change throughout the cycle. However, if dibutyryl- or 8-bromo-CAMPis included in the growth medium after detachment, cell growth is arrested and a dramatic, cycloheximidesensitive increase in the type I isozyme occurs. The type 11 isozyme decreases by this treatment. Estimation of the half-lives of the isozymes indicates that the cyclic nucleotide treatment causes a selective turnover of the type I1 isozyme. Friedman and co-workers correlated the levels of cAMP with the levels and the activation state of the CAMP-dependent protein kinase in HeLa cells (366). Cells in the log phase of growth have nearly equal amounts of type I and type I1
90
STEPHEN J. BEEBE AND JACKIE D. CORBIN
isozymes but the enzyme activity ratio changes are relatively insensitive to high or changing levels of CAMP.This may be due to a higher KO for cAMP activation at high levels of protein kinase. However, during mitosis, the cAMP levels and the activity ratio decrease to their lowest levels. The protein kinase levels remain high during mitosis and then fall after mitosis. Although no separate and specific roles for the CAMP-dependent protein kinase isozymes have been clearly established, it has been suggested that the type I isozyme is a positive effector of growth and the type I1 isozyme relates more to tissue differentiation (319, 320). A number of different approaches have been used to study these phenomena. One approach has been to study the relative proportions of the CAMP-dependent protein kinase isozymes during whole-organ development. Lee et al. (367) demonstrated a rapid increase in rat testicular protein kinase activity during the first postnatal week which is correlated primarily with an increase in the type I isozyme. An increase in the type I1 isozyme occurs coincidently with the onset of complete spermatogenesis. Eppenberger et al. (368), studying postnatal uterine development, indicated that the ratio of type I to type I1 protein kinase decreases from about 0.55 on day 1 to about 0.1 on day 20, then increases to the day 1 level by day 40. These ratio changes are due to a decrease and then an increase in the type I isozyme with no change in the type 11 isozyme. Wittmaack et al. (369)used immunoprecipatation techniques in developing rat liver and malignant hepatic tissues. In developing liver, the total inhibitor-sensitive protein kinase activity steadily increases during normal liver development until the maximum levels are reached in the adult liver. The type Itype I1 ratio is about 1.2 in the fetus (4 days prepartum), 0.7 at birth, 1.8 on day 17 after birth, and 1.2 in the adult. Another approach to demonstrate a specific role for one of the isozymes in proliferation is to evaluate isozyme ratios in normal and malignant tissues from the same organ. Fossberg ef al. (370), comparing extracts of normal and carcinoma-involved human renal cortex, and Handschin and Eppenberger, studying normal and malignant human mammary tissue (371),found that the type I to type I1 ratio is approximately two times higher in extracts from malignant tissue, although the total protein kinase activity is the same in both normal and malignant tissue. Weber et al. (372) and Wittmaack et al. (369)suggest that a simple correlation of one isozyme with proliferation and the other with differentiation may not hold. They point out that in some of these systems changes in proliferation are also associated with changes in differentiation. Lymphocytes from normal patients and patients with chronic lymphocytic leukemia represent pure cell-types that show negligible proliferation and differ only in the state of differentiation (372). The tumor lymphocytes contain lower levels of CAMP, inhibitor-sensitive CAMP-dependent protein kinase activity and correspondingly lower levels of regulatory subunit. By using SDS-gel electrophoretic separation of 32P-labeled
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
91
8-azido-CAMPregulatory subunit and type 1- and type 11-specific immunotitration, differences in the regulatory subunit pattern are seen between the normal and leukemic lymphocytes. Approximately 60% of the total CAMP-binding sites are associated with the type I isozyme in both normal and leukemic cells. About 40% of the CAMP-binding sites are associated with the type I1 isozyme in leukemic lymphocytes, but in normal cells 20% of the sites are associated with the type I1 isozyme and about 20%are represented as low immunoreactive type I binding sites. Wittmaack et al. (369) have also demonstrated that the type I to type I1 ratio in rapidly proliferating AH- 130 hepatoma cells is higher than in the normal adult liver but does not change when the cells go into the stationary phase. In addition, the undifferentiated AH-1 30 hepatoma cells have a lower ratio than do the well-differentiated 9618-A cells. Consequently, these data do not support the type I-proliferation, type 11-differentiationhypothesis but suggest that the ratio of type I to type I1 relates more to the terminal differentiation of the organ than to the proliferation rates. Byus et al. (373) reported that proliferation of concanavalin A-stimulated human peripheral lymphocytes leads to a cAMP increase and a selective activation of the type I isozyme of the CAMP-dependent protein kinase, even though both isozymes are present. Incubation of lymphocytes with both concanavalin A and dibutyryl-CAMP causes an activation of both type I and type I1 isozymes and prevents both RNA and DNA synthesis. These data led them to conclude that the type 1 isozyme is a positive modulator of lymphocyte proliferation while activation of the type I1 isozyme, or activation of both isozymes, inhibits proliferation. The conclusion of Wang et al. (340),that there is a requirement for a rise and fall in CAMP, is not inconsistent with these data. The conconavalin A could allow the rise and fall in cAMP and subsequent cell division but the inclusion of dibutyryl-CAMP would not allow the fall in cyclic nucleotide, and proliferation could be prevented. Several lines of evidence indicate that the CAMP-dependent protein kinase isozyme ratio changes following viral or chemical transformation. Gharrett et al. (374)and Wehner et al. (375)characterized and compared the CAMP-dependent protein kinase isozymes in normal 3T3 cells with SV40-transformed (374, 375), spontaneously transformed ( 3 7 3 , and methylcholanthrene-transformed (375) cell counterparts. While normal cells contain only the type I1 isozyme, transformed cells contain an equivalent amount of kinase activity but these cells contain both type I and type I1 activities as determined by all three of these techniques. Ledinko and Chan (376) also observed that the type I isozyme is higher in rat 3Y 1 cells transformed by human adenovirus type 12 compared to untransformed 3Y1 cells. Little or no change occurs in the type I1 isozyme following transformation. However, Haddox et al. (365) determined that Rous sarcoma virus-transformed fibroblasts have a greater protein kinase specific activity and a lower ratio
92
STEPHEN J. BEEBE AND JACKIE D. CORBM
of type I to type I1 isozyme than do the normal cells (0.42 in the transformed cells and 0.85 in the normal cells). The higher amount of the type I1 isozyme in these transformed cells compared to normal cells is in contrast to the higher amount of the type I isozyme in the SV40-transformed 3T3 cells observed by Gharrett et al. (374) and Wehner et al. (375) and in the adenosine-transformed 3YI cells described by Ledinko and Chan (376). It is not clear if these differences are due to the cell type, the transforming virus, or both. Several laboratories have reported changes in CAMP-dependent protein kinase isozymes during cellular differentiation. Conti et al. (377) separated germ cells from mouse testes and determined the quantity of the two isozymes of protein kinase in preparations enriched (70-90%) in middle-late pachytene spermatocytes, round spermatids, and elongated spermatids by measuring CAMPdependent kinase activity using protamine as substrate and [3H]cAMP binding activity following DEAE-cellulose chromatography. Pachytene spermatocytes had a type I to type I1 isozyme ratio of about 2.0. Cells in later stages of spermatogenesis had lower amounts of the type 1 isozyme and increasing amounts of the type I1 isozyme. Round spermatids had a type I to type 11 isozyme ratio of about 1 .O while elongated spermatids contained almost exclusively the type 1 isozyme. Elongated spermatids appeared to contain lower total CAMPdependent protein kinase activity than do pachytene spermatocytes or rounded spermatids. Fakunding and Means (378) demonstrated similar isozyme changes during rat Sertoli cell maturation by measuring [3H]cAMP binding and inhibitor-sensitive, CAMP-dependent histone kinase activity after DEAE-cellulose chromatography. At 12-days of age, Sertoli cells contained 2.5-3.0 times more type I than type I1 isozyme. Further development was associated with a decrease in the type I to type I1 isozyme ratio such that after 20-days of age the ratio was approximately 0.8. Schwartz and Rubin (379) have used CAMP-dependent histone phosphorylation and [3H]cAMP binding following DEAE-cellulose chromatography in combination with type I and type I1 specific immunoprecipitation to study changes in the amounts of regulatory and catalytic subunits in Friend erythroleukemic cells before and after stimulation of differentiation with dimethylsulfoxide. During differentiation, the concentration of the type I1 regulatory subunit increased threefold and the type 1 regulatory subunit decreases to one-third of the control level, resulting in a change of the type I to type I1 regulatory subunit from 0.8 in the undifferentiated cells to 0.1 after induction of differentiation. Changes in the catalytic activity were proportional to changes in binding activity, indicating that the ratio of regulatory to catalytic subunit did not change. When the cells were treated with 8-bromo-CAMPand 3-isobutyl- 1-methylxanthine for two days, similar changes in the regulatory subunit occurred without proportional changes in the catalytic subunit, but differentiation did not appear.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
93
Liu (337) studied changes in the CAMP-dependent isozymes during differentiation of 3T3-Ll cells from fibroblasts to adipocytes. The regulatory subunit was determined by 8-azido-CAMP photoaffinity labeling and catalytic activity was determined by CAMP-dependent histone phosphorylation. In the undifferentiated fibroblasts, the type I1 isozyme was the predominant CAMP-dependent protein kinase. After promotion of differentiation with 3-isobutyl- 1-methylxanthine, dexamethasone, and insulin, an increase in the total CAMP-dependent protein kinase activity was attributed to a 3- to 6-fold increase in the type I isozyme. This was due to an increase in both the regulatory and the catalytic subunits. Similar results were obtained with spontaneously differentiating 3T3L1 cells, demonstrating that the selective increase in the type I isozyme appeared to be directly related to adipocyte differentiation rather than to the drug and hormone treatment used to promote differentiation. Furthermore, 3T3-C2 cells, which had a lower intrinsic ability to undergo differentiation, did not show the selective type I increase when stimulated in the same manner. How cAMP and protein kinases are involved in growth and development is poorly understood. It is likely that protein kinase is integrated with primary, intrinsic regulatory signals and other second messengers such as calcium and phosphoinositides. The consequences of this latter second messenger are only beginning to be unraveled but it is pertinent to ask how it may be involved in cell development (380, 381). Calcium is particularly interesting since it appears to play a central role in many regulatory processes (380, 381). For example, both phospholipase A,, which generates prostaglandin-like precursors (382), and phospholipase C , which generates phosphoinositides and diacylglycerol (380, 381), are calcium-sensitive enzymes. Furthermore, calcium can also regulate cAMP metabolism via regulation of adenylate cyclase and phosphodiesterase (383).A circular and more complicated, but potentially tightly regulated picture, emerges when it is considered that prostaglandins activate adenylate cyclase, phosphoinositides release intracellular calcium, and diacylglycerol activates protein kinase C, a calcium-sensitive enzyme. Cyclic AMP, via protein kinase, is known to regulate calcium levels. It will be interesting to follow future developments involving the interactions of CAMP, Ca2 +,and phosphoinositides in the regulation of growth, development, and metabolism in general. F.
VARIATIONS IN THE REGULATORY SUBUNIT-CATALYTIC SUBUNIT RATIO
The ratio of regulatory to catalytic subunit in terminally differentiated tissues has been reported to be approximately 1 .O. This has been demonstrated in several species of heart (216), in several tissues from adult rabbits (90). and in the postnatal developing rat liver (369) and rat brain (384). This suggests that the two subunits are coordinately regulated. Uno et al. (385), analyzing yeast mu-
94
STEPHEN J . BEEBE AND JACKIE D. CORBIN
tants altered in cAMP metabolism, have determined that the subunits of protein kinase are not coded by the same gene locus, suggesting the possibility that the levels of regulatory and catalytic subunits could be independently regulated. There are several reports in the literature indicating that, at least under certain circumstances in some cells, there are greater amounts of regulatory subunit than catalytic subunit. Richards and Rolfes (386)studied ovarian granulosa cells from immature, hypophysectomized rats treated with estrogen and human folliclestimulating hormones. Under the influence of these hormones, granulosa cells luteinize and produce steroids. These investigators reported that the type I1 regulatory subunit is induced 10- to 20-fold in treated animals, with little if any corresponding increase in catalytic activity. Darbon et al. (387)reported a similar finding. Segaloff et al. (281) have shown that porcine granulosa cells in primary culture respond to treatment with cholera toxin, follicle-stimulating hormone, and cAMP analogs by an increased specific activity of the type 11, but not of the type I regulatory subunit. A 5 - to 10-fold increase in the regulatory subunit determined [3H]cAMP binding and densitometric scans of autoradiograms from specific 8-azido["H]cAMP photoaffinity labeling of the regulatory subunit, is correlated with a 2- to 4-fold increase in the specific catalytic subunit activity, measured by heptapeptide phosphorylation. Walter et al. (388) and Lohmann et al. (389) studied the potential role of protein kinase in the dibutyryl-CAMP-stimulated differentiation of neuroblastoma-glioma hybrid cells. Treatment of hybrid cells with dibutyryl-CAMP or addition of agents that elevate intracellular cAMP results in a selective increase in the type I regulatory subunit with no change in the catalytic subunit or type I1 regulatory subunit. The type I regulatory subunit is detected by 8-azi~ o [ ~ ~ P ] c Aphotoaffinity MP labeling (388)and by an enzyme-linked immunosorbent assay and radioimmunolabeling followed by transfer from SDS-gels to nitrocellulose (389).These experiments indicate that the hybrid cells separately regulate the levels of regulatory and catalytic subunit and also suggest that the free type I regulatory subunit could possibly be involved with the expression of some differentiating function(s). Furthermore, Morrison et al. (390)have demonstrated that there are increases in the levels of mRNA coding for the regulatory subunit. It has been suggested that this altered regulatory subunit, termed R', may be elevated due to increased synthesis and decreased degradation. It is interesting that most of the known examples of tissues that appear to show an elevation of regulatory subunit, but not of catalytic subunit, are of nervous or reproductive origin or from a mutant cell line (386,394). It will be interesting to see if this is a unique characteristic of these tissues or if other tissues also show this phenomenon. Although it appears in all of these studies that the type I1 regulatory subunit is present in excess over the catalytic subunit, it has not been ruled out that some inhibitor(s) of protein kinase, other than the regulatory subunit, is also increased
3. CYCLIC NUCLEOTIDE-DEPENDENTPROTEIN KINASES
95
by the same treatment. The presence of a heat-stable protein kinase inhibitor in various tissues has been known for some time (32).Beale e t a / . (395)and Tash et al. (396) reported that a low-molecular-weight heat-stable protein kinase inhibitor is increased in the Sertoli cells of rat testes after follicle-stimulating hormone treatment. Because of potential errors in determining the levels of the protein kinase catalytic activity (389), specific antibody techniques or cDNA clones for the catalytic subunit may help resolve these uncertainties. If the regulatory subunit is present in excess compared to the catalytic subunit, the mechanism that maintains these subunits in equal proportions in normal, differentiated tissues is apparently disrupted. Although the levels of many proteins are regulated at the level of transcription, regulation can also occur at the level of translation and/or degradation of messenger RNA, and at the level of protein degradation (see Section V,G). It is therefore possible that the two subunits are regulated coordinately at one level (e.g., transcription) but regulated differently at another level (e.g., translation or degradation). These two subunits may be generally maintained in stoichiometric amounts by proteolysis of either subunit that is present in excess regardless of the mechanism of regulation of individual subunit levels. For example, the free regulatory subunit is known to be much more sensitive to proteases than is the regulatory subunit which is bound to the catalytic subunit (10). The nature of the events that determine the protein kinase subunit levels has not been determined. However, the experiments outlined in this section suggest that cAMP may be important in determining these levels. Recent results by Ratoosh et al. (397) indicate that FSH, via CAMP, may increase synthesis of rabbit granulosa cell type 11 regulatory subunit by altering the levels of mRNA for this protein. If it is assumed that the mechanism of cAMP action is through the CAMP-dependent protein kinase, it is possible that this enzyme regulates its own levels. Although either the type 1 or type I1 regulatory subunit may be bound to the particulate fraction (see Section V,B.), there may be an additional function for this subunit. Evidence has appeared to suggest such a role. The regulatory subunit may participate in the transient inhibition of phosphoprotein phosphatase(s) that dephosphoryiates various protein kinase substrates. In 1977, Gergely and Bot (398) reported that the CAMP-dependent protein kinase, in the presence of CAMP, inhibited the phosphoprotein phosphatase-catalyzed dephosphorylation of phosphorylase a, but not a 32P-labeled tetradecapeptide, suggesting a substrate-mediated effect. Khatra et a/. (399) have demonstrated that homogeneous preparations of type I1 regulatory subunits, or homogeneous type I1 CAMP-dependent protein kinase in the presence of CAMP, inhibits a highmolecular-weight phosphoprotein phosphatase from rabbit skeletal muscle. This inhibition of dephosphorylation occurs when phosphorylase, glycogen synthase (phosphorylated at sites 2 and 3) or histone is used as substrate, suggesting an
96
STEPHEN J. BEEBE AND JACKIE D. CORBIN
enzyme-directed inhibition. This inhibition occurs in vitro at concentrations of regulatory subunit that occur in vivo. Through the decrease in dephosphorylation rate, the regulatory subunit of protein kinase could possibly magnify the increases in phosphate content of proteins brought about by activation of the catalytic subunit. Thus, when tissue cAMP is elevated, the phosphoprotein phosphatase is inhibited, and when cAMP declines, as occurs in some tissues by insulin action, this enzyme is activated. It remains to be proved if this mechanism has importance in the physiological regulation of phosphoprotein phosphatase, but, if so, it suggests the possibility of a multifunctional regulatory ) in the presence of subunit. It has been reported by Constantinou et al. ( 3 9 9 ~that cAMP the phosphorylated form of the rat liver type I1 regulatory subunit possesses topoisomerase activity. There are indications to suggest that this regulatory subunit can form DNA-phospho-regulatory subunit-CAMP complexes and relax superhelixes of DNA. If this report can be confirmed and extended, a new concept in the transcriptional action of the CAMP-dependent protein kinase may emerge. Further experimentation will be required to elucidate the mechanisms that regulate the levels of protein kinase and to determine if the free regulatory subunit has a role(s) other than regulating protein kinase catalytic activity. If the regulatory subunit does have another function, the nomenclature of this enzyme as a protein kinase, which specifies a phosphorylation reaction, will be appropriate only for the phosphotransferase function. Although it has not been conclusively established that the regulatory subunit has a catalytic function, it may serve as a regulatory protein in capacities other than for protein kinase activity. Since it has some sequence homologies with the catabolite activator protein (CAP) of E . coli (156), it is tempting to speculate that it may serve as a regulator of gene transcription in mammalian cells. However, there is presently no direct evidence to support this idea, and it is known that the regulatory subunit does not contain the corresponding DNA binding domain found in CAP.
G. REGULATION OF THE AMOUNT OF CERTAIN PROTEINS BY CYCLICAMP-DEPENDENT PROTEINKINASES The postsynthetic modification of some preexisting enzymes by CAMP-dependent phosphorylation is known to alter the activities of these enzymes and thereby modify various short-term cellular functions. In recent years it has become clearer that cAMP is also involved in more long-term regulation of cellular functions through the regulation of the amounts of specific proteins. Since protein phosphorylation is a well-established mechanism of CAMPdependent protein kinase action, this mechanism may be involved in the phosphorylation of nuclear proteins, which could regulate gene transcription or other nuclear events. Although both histone and nonhistone nuclear proteins are known to be phosphorylated by the CAMP-dependent protein kinase in vitro, the
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
97
most convincing evidence for in vivo CAMP-mediated nuclear protein phosphorylation is for histone H I . Langan demonstrated an in vivo increase in [32P]phosphate incorporation of histone HI in the liver of rats injected with glucagon or dibutyryl-CAMP (31). To rule out artifactual phosphorylation during the extraction procedure, Wicks et al. (400) extracted histone HI with sulfuric acid and suggested a role for the CAMP-dependent protein kinase in the induction of tyrosine aminotransferase in Reuber H35 hepatoma cells. Harrison et al. (401) observed complex changes in the [32P]phosphate content of histone H1 subspecies in rat C6 glioma cells. Isoproternol elicited both increases and decreases in [32P]phosphatelevels at several phosphorylation sites. Although CAMP-independent phosphorylation apparently occurs, CAMP-dependent phosphorylation at seine-37 of the amino terminus of histone H1-1 and H1-2 in vitro correlated with increased 32Pcontent at these sites in vivo following treatment of these cells with isoproterenol. Dibutyryl-CAMP also caused complex changes in histone H 1 phosphorylation but these are different from those for isoproterenol. The physiological significance of histone phosphorylation is still not clear and has recently been reviewed by Johnson (402). Briefly, histone H1 is believed to be involved in the formation of higher-order chromatin structures and it has been suggested that phosphorylation of this protein alters the circular dichroism of histone-DNA complexes and the template activity of chromatin. Phosphorylation of serine-38 of histone HI reduces histone binding to DNA and may function to unwind tightly coiled chromatin to expose regions for RNA polymerase binding and transcription. Langan (31) has determined that more liver histone is phosphorylated at serine-38 than would be required to actively transcribe specific sequences in response to hormones or CAMP. This and other data suggest that specific base sequence recognition due to histone H1 phosphorylation is unlikely. Alternatively, Harrison et al. (401) calculated that only a very small number of glioma cell histone H 1 molecules are phosphorylated and suggest that these may occur at selected gene loci to alter chromatin function. Several reports have appeared documenting the in vitro CAMP-dependent and CAMP-independent protein kinase phosphorylation of RNA polymerase 11, the enzyme that catalyzes the transcription of genes coding for messenger RNA. Some investigators report that phosphorylation is correlated with increases in polymerase activity (403-406) while others are unable to support this finding (407-409). Kranias et al. (405) reported that nuclear c AMP-dependent protein kinase leads to incorporation of 0.5 mol [32P]phosphate/mol enzyme into the 25,000-dalton subunit of calf thymus RNA polymerase 11 with a concomitant 3fold increase in enzyme activity. Dephosphorylation by E . coli phosphatase results in a loss of 32P label and a corresponding decrease in enzyme activity. The in vivo, isoproterenol-stimulatedphosphorylation of rat C6 glioma cell RNA polymerase I1 has been reported by Lee et al. (410). Stimulation of cells results in 32P incorporation into serine residues of all six polymerase subunits with a total incorporation of 0.5-2.0 mol phosphate/mol enzyme. Propranolol inhibits
98
STEPHEN J . BEEBE AND JACKIE D. CORBIN
and dibutyryl-CAMP mimics the isoproterenol effects. The phosphorylation of RNA polymerase I, which catalyzes the transcription of ribosomal genes, and RNA polymerase 111, which transcribes genes coding for 5 S ribosomal RNA, have also been reported [see Ref. (40211. If the CAMP-stimulated induction of specific proteins requires phosphorylation event(s), the presence of the CAMP-dependent protein kinase or its catalytic subunit in the nucleus or a translocation to the nucleus would be important. Since cAMP is known to be synthesized at the plasma membrane, it seems probable that some mechanism may be required to translocate either cAMP and/or protein kinase to the nucleus. There is, however, some evidence to indicate that CAMPdependent protein kinases are in the nucleus and translocation of protein kinase to the nucleus may also occur (see Section V,B.). Agents that elevate the intracellular cAMP concentration have been shown to result in an apparent translocation of protein kinase activity from the cytoplasm to the nucleus in several tissues [see Refs. (36, 237,402, 404) for reviews]. It has been suggested that some of these earlier studies may be subject to artifacts due to enzyme redistribution and nonspecific ionic interaction of the catalytic subunit of protein kinase with subcellular binding sites when homogenization is carried out in lowionic-strength buffers (234). A number of other potential pitfalls of translocation studies have been reviewed, including cytoplasmic contamination and CAMPindependent protein kinases other than the catalytic subunit of protein kinase (10). However, nonaqueous procedures are now generally used to minimize redistribution and nonspecific binding during nuclei isolation (411). Cho-Chung (412, 413) proposed that tumor regression is dependent on translocation of a CAMP-protein kinase type I1 holoenzyme ternary complex from the cytoplasm to the nucleus. Although these studies and others (36, 237, 402, 404) suggest a translocation of protein kinase activity to the nucleus, they are not in agreement on whether it is the holoenzyme or free catalytic subunit that is translocated. Histochemical or immunocytochemical techniques have also been used to address the question of protein kinase translocation. This technique complements the purely biochemical approaches, and provides a sensitive technique to visually localize protein kinases which may be present at low concentrations in some cells or cell compartments. This approach avoids certain potential artifacts of in vitro biochemical methods and allows a more definite assignment of the presence of protein kinases in the nucleus (also see Section V,B.). Although it cannot be totally ruled out that the appearance of immunoreactive protein kinase in the nucleus is due to “uncovering” enzyme already present in the nucleus, the data are consistent with biochemical data suggesting translocation of protein kinase from the cytoplasm to the nucleus. Early experiments concerning the CAMP-stimulated induction of tyrosine aminotransferase and phosphoenolpyruvate carboxykinase suggested that regulation occurs at a posttranscriptional level, most likely involving an enhancement in the
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
99
rate of translation of preexisting mRNAs (414. 415). This conclusion was based on studies using inhibitors of protein synthesis and comparing the kinetics of CAMP- and glucocorticoid-stimulated protein induction. While these earlier studies determined protein induction by measuring enzyme activities, later studies quantitated specific mRNA levels by indirect in v i m translation assays and in some cases more directly by measuring mRNA levels and/or specific gene transcription, using specific cDNA probes. Results from these later studies suggested regulation at a pretranslational step and emphasized the need to reevaluate the cAMP mechanism for the specific induction of enzymes in eucaryotes. Using indirect quantitation of specific mRNA levels by in vitro translation, it has been determined that cAMP regulates the functional levels of mRNA or mRNA translational efficiency for phosphoenolpyruvate carboxykinase (416418), tyrosine aminotransferase (419, 420), lactate dehydrogenase A subunit (421), and alkaline phosphatase (422). The proportional changes in the specific mRNAs and the enzymes for which they code indicate that translation is not the primary site of regulation for these proteins. Since this approach measures translationally active mRNAs, it is not possible to determine if cAMP affects transcription, posttranscriptional modification of primary gene transcripts, increases in translatability of mRNAs, or decreased breakdown or stability of mRNAs. Experiments using specific cDNA probes indicate that cAMP regulates the abundance of mRNA for albumin in mouse hepatoma cells (423), phosphoenolpyruvate carboxykinase in rat liver (424-426), and lactate dehydrogenase A subunit in rat glioma cells (427). Evidence for transcriptional action by cAMP on induction of pituitary prolactin (428),phosphoenolpyruvate carboxykinase (429-433), lactate dehydrogenase A subunit ( 4 3 4 , and tyrosine aminotransferase (435,436) have also been reported. The CAMP-stimulation of phosphoenolpyruvate carboxykinase gene transcription has been shown to be via the CAMP-dependent protein kinase (280).The use of cAMP analog combinations to specifically cause a synergistic increase in mRNAPEPCKand gene transcription clearly indicate that these effects occur following protein kinase activation. The type 11 isozyme is the predominant isozyme and it is primarily responsible for mediating the response (see Section V,C.). Since the catalytic subunit is common to both isozymes and determines the substrate specificity, and because all known CAMP-dependent protein kinase effects are due to phosphorylation, it is likely that PEPCK gene transcription is mediated by a phosphorylation event. Results obtained from fusion of hepatoma cells with red cell ghosts loaded with either catalytic subunit or protein kinase inhibitor indicate that the catalytic subunit and not the regulatory subunit is responsible for regulation of tyrosine aminotransferase gene transcription (210). However, the finding by Constantinou et al. (399a) that a complex of phosphotype I1 regulatory subunit-CAMP may be a topoisomerase implicates the regulatory subunit in the regulation of transcription.
100
STEPHEN J. BEEBE AND JACKIE D. CORBIN
In summary, these studies generally indicate that CAMPregulates the levels of some proteins by some mechanism that involves an enhanced transcription of specific genes coding for the regulated proteins. In the case of PEPCK and tyrosine aminotransferase, the CAMP-dependent protein kinase appears to be the mediator of the transcription of these genes but the putative phosphorylated proteins responsible have not been identified. It has been reported that chromosome-associated proteins such as histones and high-mobility group proteins are phosphorylated but demonstration of associated functional alterations of these proteins has been difficult. It is reasonable to consider that phosphorylation of these proteins may play some role in gene transcription, but since specificity is in question, this may serve a general function which may facilitate another mechanism mediating specific gene transcription. A specific mechanism could possibly involve phosphorylation and activation of mRNA polymerase 11. However, to clearly demonstrate the physiological significance of this, a rigorous analysis of these reactions is required. It also remains to be clearly demonstrated whether or not the regulatory subunit plays a role in the regulation of gene transcription. ACKNOWLEDGMENTS The authors are grateful to Dr. D. Friedman, Dr. D. Granner, and Dr. R. Uhing for helpful discussions during the course of this work. We would also like to thank the many scientists who provided us with published and unpublished data during the preparation of this text. We are also very appreciative of Mrs. Penny Stelling, who spent many hours typing and editing this manuscript.
REFERENCES 1. Burnett, G., and Kennedy, E. P. (1954). JBC 211, 969. 2. Rabinowitz, M. (1962). ”The Enzymes,” 2nd ed., Vol. 6, p. 119. 3. Robinson, G. A., Butcher, R. W., and Sutherland, E. W. (1971). “Cyclic AMP.” Academic
Press, New York. 4. Sutherland, E. W. (1972). Science 177, 401. 5. Krebs, E. G. (1972). Curr. Top. Cell. Regul. 5 , 99. 6. Corbin, J. D., Sugden, P. H., West, L., Flockhart, D. A,, Lincoln, T. M., and McCarthy, D. (1978). JBC 253, 3997. 7. Corbin, J. D., Keely, S. L., and Park, C. R. (1975). JBC 250, 218. 8. Weber, W., and Hilz, H. (1979). BBRC 90, 1073. 9. Granot, J., Mildvan, A. S., Hiyama, K., Kondo, H., and Kaiser, E. T. (1980). JBC 255, 4569. 10. Flockhart, D. A;, and Corbin, J. D. (1982). CRC Crit. Rev. Biochem. 12, 133. 11. Beavo, J. A., and Mumby, M. C. (1982). Handb. Exp. Pharmakol. 581, Part I , 363. 12. D@skeland,S. O., and Qgreid, D. (1981). Int. J. Biochem. 13, 1. 13. Krebs, E. G., and Beavo, J. A. (1978). Annu. Rev. Biochem. 48, 923. 14. Nimmo, H. G., and Cohen, P. (1977). Adv. Cyclic Nucleoride Res. 8, 146. 15. Beavo, J. A., Bechtel, P. J., and Krebs, E. G. (1975). Adv. Cyclic Nucleozide Res. 5 , 241. 16. Chock, P. B., and Stadtman, E. R. (1977). PNAS 74, 2766.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASES
101
17. Goldbeter, A,, and Koshland, D. E., Jr. (1981). PNAS 78, 6840. 18. Laporte, D. C., and Koshland, D. E., Jr. (1983). Nature (London) 305, 286. 19. Koshland, D. E., Goldbeter, A., and Stock, J. B. (1982). Science 217, 220. 20. Shacter, E., Chock, P. B., and Stadtman, E. R. (1984). JBC 259, 12252. 20a. Meinke, M. H., Bishop, J. S., and Edstrom, R. D. (1986). PNAS (in press). 21. Corbin, J. D., and Deskeland, S. 0. (1983). JBC 258, 11391. 22. Gill, G. N . , Holdy, K. E., Walton, G. M., and Kanstein, C. B. (1976). PNAS 73, 3918. 23. Lincoln, T. M., and Corbin, J. D. (1977). PNAS 8, 3239. 24. MacKenzie, C. W., 111 (1982). JBC 257, 5589. 25. Lincoln, T. M., and Corbin, J. D. (1983). Adv. Cyclic Nucleotide Res. 15, 139. 26. Gill, G. N., and McCune, R. W. (1979). Curr. Top. Regul. 15, I . 27. Corbin, J. D., and Lincoln, T. M. (1978). Adv. Cyclic Nucleoride Res. 9, 159. 28. Lincoln, T. M., and Corbin, J. D. J. Cyclic Nucleoride Res. 4, 3. 29. Gill, G. N. (1977). J. Cyclic Nucleotide Res. 3, 153. 30. Walsh, D. A . , and Krebs, E. G. (1973). Enzymes 8, 555. 31. Langan, T. A. (1973). Adv. Cyclic Nucleotide Res. 3, 99. 32. Walsh, D. A., and Ashby, C. D. (1973). Recent Prog. Horm. Res. 29, 329. 33. Rubin, C. S . , and Rosen, 0. M. (1975). Annu. Rev. Biochem. 44, 831. 34. Rosen, 0. W., Erlichman, J., and Rubin, C. S. (1975). Adv. Cyclic Nucleoride Res. 5, 253. 35. Corbin, J. D., Keely, S. L., Soderling, T. R., and Park, C. R. (1 975). Adv. Cyclic Nucleoride Res. 5, 265. 36. Jungmann, R. A., and Russell, D. H. (1977). Life Sci. 20, 1787. 37. Cohen, P. (1978). Curr. Top. Cell. Regul. 14, 118. 38. Carlson, G. M., Bechtel, P. J., and Graves, D. J. (1979). Adv. Enzymol. 50, 41. 39. Glass, D. B., and Krebs, E. G. (1980). Annu. Rev. Pharmacol. Toxicol. 20, 363. 40. Robinson-Steiner, A., and Corbin, J. D. (1986). In “Handbook of Cardiology” (in press). 41. Rosen, 0. M., and Krebs, E. G . (1981). Cold Spring Harbor Conf. Cell Proliferation 8. 42. Ramsyer, J . , Kaslow, H. R., and Gill, G. N. (1974). BBRC 59, 813. 43. Dills, W. L., Beavo, J. A., Bechtel, P. J., and Krebs, E. G. (1975). Adv. Cyclic Nucleoride Res. 5, 829. 44. Dills, W. L., Beavo, J. A., Bechtel, P. J., and Krebs, E. G. (1975). BBRC 62, 70. 45. Rieke, E., Pauitz, N., Eigel, A,, and Wagner, K. G. (1975). Hoppe-Seyler’s Z. Physiol. Chem. 356, 1177. 46. Rannels, S. R., and Corbin, J. D. (1983). “Methods in Enzymology,” Vol. 99, p. 55. 47. Corbin, J. D., and Rannels, S. R. (1981). JBC 256,. 11671. 48. Goodwin, C. D., Beavo, J. A,, Dills, W. L., and Krebs, E. G. (1977). FP 36, 728. 49. Seville, M., and Holbrook, J. J. (1984). Anal. Biochem. 137, 330. 50. Reimann, E. M., and Beham, R. A. (1983). “Methods in Enzymology,” Vol. 99, p. 51. 51. Stralfors, P., and Belfrage, P. (1982). BBA 721, 434. 52. Muniyappa, K., Leibach, F. H., and Mendicino, J. (1983). Mol. Cell. Biochem. 50, 157. 53. Beavo, J. A,, Bechtel, P. J., and Krebs, E. G. (1974). “Methods in Enzymology,” Vol. 38C, p. 299. 54. Bechtel, P. J., Beavo, J. A., and Krebs, E. G. (1977). JBC 252, 2691. 5 5 . Sugden, P. H., Holladay, L. A , , Reimann, E. M., and Corbin, J. D. (1976). BJ 159, 409. 56. Walsh, D. A., Perkins, J. P., and Krebs, E. G. (1968). JBC 243, 3763. 57. Hofmann, F., Beavo, J. A., Bechtel, P. J., and Krebs, E. G. (1975). JBC 250, 7795. 58. Hoppe, F., and Wagner, K. G. (1977). FEES Len. 74, 95. 59. Deskeland, S. 0. (1978). BBRC 83, 542. 60. Taylor, S. S., Lee, C., Swain, L., and Stafford, P. H. (1976). Anal. Biochem. 76, 45. 61. Taylor, S. S . , and Stafford, P. H. (1978). JBC 253, 2284.
102
STEPHEN J . BEEBE AND JACKIE D. CORBIN
62. Rubin, C. S., Erlichman, J., and Rosen, 0. M. (1972). JBC 247, 36. 63. Rubin, C. S., Erlichman, J . , and Rosen, 0. M. (1974). “Methods in Enzymology,” Vol. 38, p. 308. 64. Cobb, C., and Corbin, J . D. (1987). “Methods in Enzymology” (in press). 64a. Cobb, C. E., Beth, A. H., and Corbin, J. D. (1986). F.P. 45, 1800. 65. Rosen, 0. M., Rangel-Aldao, R., and Erlichman, J. (1977). Curr. Top. Cell. Regul. 12, 39. 66. Lincoln, T. M . , Dills, W. L., and Corbin, J . D. (1977). JBC 252, 4269. 67. Flockerzi, V., Speichermann, N., and Hofmann, F. (1978). JBC 253, 3395. 68. de Jonge, H. R. (1981). Adv. Cyclic Nucleoride Res. 14, 315. 69. Nakazawa, K., and Sano, M. (1975). JBC 250, 7415. 70. de Jonge, H. R., and Rosen, 0. M. (1977). JBC 252, 2780. 71. Gerzer, R., Hofmann, F., and Schultz, G. (1981). EJB 116, 479. 72. Dills, W. L., Goodwin, C. D., Lincoln, T. M., Beavo, J. A,, Bechtel, P. J., Corbin, J. D . , and Krebs, E. G. (1979). Adv. Cyclic Nucleoride Res. 10, 199. 73. Chen, L. J . , and Walsh, D. A. (1971). Biochemistry 10, 3614. 74. Yamamura, H., Inoue, Y., Shimomura, R., and Nishizuka, Y. (1972). BBRC 46, 589. 75. Kumon, A., Nishiyama, K., Yamamura, H., and Nishizuka, Y. (1972). JBC 247, 3726. 76. Yamamura, H., Nishiyama, K., Shimomura, R., and Nishizuka, Y. (1973). Biochemistry 12, 856. 77. Peters, K. A,, Demaille, J. G., and Fischer, E. H. (1977). Biochemistry 16, 5691. 78. Kubler, D., Gagelman, M., Pyerin, W., and Kinzel, V. (1979). Hoppe-Seyler’s Z. Physiol. Chem. 360, 1421. 78a. Uhler, M. D., Carmichael, D. F., Lee, D. C. Chriva, J . C., Krebs, E. G., andMcKnight, G. S. (1986). PNAS 83, 1300. 78b. Reed, J., Gagelmann, M., and Kinzel, V. (1983). ABB 222, 276. 79. Shoji, S., Ericsson. L. H., Walsh, K. A,, Fischer, E. H., and Titani, K. (1983). Biochemistry 22, 3702. 79a. Jahnsen, T., Hedin, L., Kidd, V. J., Schulz, T. 2.. and Richards, J. S. (1987). “Methods in Enzymology” (in press). 80. Titani, K., Sasagawa, T., Ericsson, L. H., Kumar, S., Smith, S. B., Krebs, E. G., and Walsh, K. A. (1984). Biochemistry 23, 4193. 81. Takio, K., Smith, S. B., Krebs, E. G., Walsh, K. A , , and Titani, K. (1982). PNAS 79,2544. 82. Erlichman, I . , Rubin, C. S., and Rosen, 0. M. (1973). JBC 248, 7607. 83. Connelly, P. A,, Hastings, T. G., and Reimann. E. M. (1986). JBC 261, 2325. 84. Hedrick, J. L., and Smith, A. J. (1968). ABB 126, 155. 85. Robinson-Steiner, A. M. Beebe, S. J., Rannels, S. R., and Corbin, J. D. (1984). JBC 259, 10596. 86. Rannels, S. R., and Corbin, J. D. (1980). J. Cyclic Nucleotide Res. 6, 203. 87. Uno, I . , Udea, T., and Greengard, P. (1977). JBC 252, 5164. 88. Nesterova, M. V., Sashchenco, L. P., Vasiliev, V. Y.,and Severin, E. S. (1975). BBA 377, 271. 89. Fleischer, N., Rosen, 0. M., and Reichlin, M. (1976). PNAS 73, 54. 90. Hofmann, F., Bechtel, P. J., and Krebs, E. G . (1977). JBC 252, 1441. 91. Rubin, C. S., Rangel-Aldao, A., Sarkar, D., Erlichman, J., and Fleischer, N. (1979). JBC 254, 5797. 92. Rapoor, C. L., Beavo, J. A , , and Steiner, A. L. (1979). JBC 254, 12427. 93. Zoller, M. J . , Kerlavage, A. R., and Taylor, S. S. (1979). JBC 254, 2408. 94. Weldon, S. L., Mumby, M. C., Beavo, J. A., and Taylor, S. S. (1983). JBC 258, 1129. 95. Corbin, J. D., Soderling, T. R., and Park, C. R. (1973). JBC 248, 1813. 96. Huang, T. S., Feramisco, J. R., Glass, D. B., and Krebs, E. G. (1979). Miami Winrer Symp. 16, 449.
3. CYCLIC NUCLEOTIDE-DEPENDENT PROTElN KINASES
103
Rangel-Aldao, R., and Rosen, 0. M. (1976). JEC 251, 3375. Rangel-Aldao, R., and Rosen, 0. M. (1977). JEC 252, 7140. Rangel-Aldao, R., Kupiec, J. W., and Rosen, 0. M. (1979). JEC 254, 2499. Scott, C. W., and Mumby, M. C. (1985). JEC 260, 2274. Hemmings, B. A., Aiten, A,, Cohen, P., Rymond, M., and Hofmann, F. (1982). EJE. 127, 473. 102. Carmichael, D. F., Geahlen, R. L., Allen, S. M., and Krebs, E. G. (1982). JEC 257, 10440. 103. Yagura, T. S . , and Miller, J. P. (1981). Biochemistry 20, 879. 103a. Goodman, M. (1981). Prog. Eiophys. Mol. Eiol. 37, 105. 104. 0greid, D., Ekanger, R., Suva, R. H., Miller, J. P., Sturm, P., Corbin, J. D., and Deskeland, S. 0. (1985). EJE 150, 219. 105. Rannels, S. R., and Corbin, J. D. (1980). JEC 255, 7085. 106. Bgreid, D., and Deskeland, S . 0. (1980). FEES Lett. 121, 340. 107. Corbin, J. D., Rannels, S. R., Flockhart, D. A,, Robinson-Steiner, A. M., Tigani, M. C., Deskeland, S. O., Suva, R., and Miller, J. P. (1982). EJB 125, 259. 108. Corbin, J. D., agreid, D., Miller, J. P., Suva, R. H., Jastorff, B., and Deskeland, S. 0. (1986). JBC 261, 12081. 109. Rannels, S. R., and Corbin, J. D. (1981). JEC 256, 7871. 110. Robinson-Steiner, A. M., and Corbin, J. D. (1982). JEC 257, 5482. 111. Robinson-Steiner, A. M., and Corbin, J. D. (1983). JEC 258, 1032. 112. Beebe, S. J . , and Corbin, J. D. (1984). Mol. Cell. Endocrinol. 36, 67. 113. Beebe, S. J . , Holloway, R., Rannels, S. R., and Corbin, J. D. (1984). JBC 259, 3539. 114. Beebe, S. J., Blackmore, P. F., Chrisman, T. D., and Corbin, J. D. (1987). “Methods in Enzymology” (in press). 114a. Beebe, S. J., Blackmore, P. F., Segaloff, D. L., Koch, S. R., Burks, D., Limbird, L. E., Granner, D. K., and Corbin, J. D. (1986). Eur. Symp. Horm. Cell Reg. loth, 1986 (in press). 115. Malkinson, A. M., Beer, D. S., Wehner, J. M., and Sheppard, J. R. (1983). EBRC 12, 214. 116. Tom-Delbauffe